Methods for transduction and cell processing
The rigid centrifugal chamber method enhances large-scale cell processing efficiency and reproducibility by automating transduction and selection steps, addressing inefficiencies in existing methods and reducing handling requirements.
Patent Information
- Application Number
- JP2024137490
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-03-05
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-08
AI Technical Summary
Existing cell processing methods, particularly for large-scale transduction and selection in adoptive cell therapy, are inefficient, costly, and lack reproducibility, requiring extensive user handling and biosafety equipment.
A method utilizing a rigid centrifugal chamber for cell processing, which includes transduction, selection, and formulation, performed under controlled centrifugal forces and automated conditions, reducing manual handling and enhancing efficiency and reproducibility.
The method achieves high transduction efficiency, reduced costs, and improved reproducibility in large-scale cell processing, enabling clinical-grade cell production without the need for separate sterile environments.
Smart Images

Figure 2024159813000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority from U.S. Provisional Application No. 62 / 075,801, entitled "Methods for Transduction and Cell Processing," filed November 05, 2014, and U.S. Provisional Application No. 62 / 129,023, entitled "Methods for Transduction and Cell Processing," filed March 05, 2015, the contents of which are incorporated by reference in their entireties.
[0002] Field The present disclosure relates to cell processing for use in therapy (e.g., adoptive cell therapy). The methods provided generally include transduction methods, in which cells and viral vector particles are incubated under conditions that result in the transduction of cells by the viral vector. The incubation may be performed within the internal cavity of a generally rigid centrifuge chamber (e.g., a cylindrical chamber made of hard plastic). The methods include other processing steps, including those performed within such chambers, including washing, selection, isolation, culture, and formulation. In particular, the present disclosure relates to methods that offer advantages over available processing methods (e.g., methods available for large-scale processing). Such advantages include, for example, lower costs, streamlining, improved efficacy, improved safety, and improved reproducibility among different subjects and disease states. [Background technology]
[0003] background Several methods are available for cell processing, including large-scale methods and methods for use in preparing cells for adoptive cell therapy. For example, methods are available for viral vector introduction (e.g., transduction), selection, isolation, stimulation, culture, washing, and formulation. The available methods have not been completely satisfactory. For example, improved methods are needed for large-scale processing (e.g., transduction) of cells for adoptive cell therapy. For example, methods are needed that improve efficiency and reproducibility, and reduce time, cost, handling, complexity, and / or other parameters associated with such production. Among the embodiments provided are methods, systems, and kits that address such needs. Summary of the Invention
[0004] overview Methods for cell processing are provided, for example, for the introduction of viral vectors and / or the selection of cells based on immune affinity. In some embodiments, the cells are for use in cell therapy, for example, primary cells prepared for autologous or allogeneic transfer (e.g., in adoptive cell therapy). The methods can include additional cell processing steps, such as washing, isolating, separating cells.
[0005] In some embodiments, the method is carried out by incubating a composition (considered as an input composition) containing cells and viral vector particles containing a recombinant viral vector in a container, e.g., an internal cavity of a centrifuge chamber, thereby generating an output composition containing a plurality of cells transduced with the viral vector. The centrifuge chamber is typically rotatable about an axis of rotation. In some embodiments, the axis of rotation is vertical. The chamber typically includes an end wall, a side wall (e.g., a substantially rigid side wall) extending from the end wall, and at least one opening (e.g., an inlet / outlet or an inlet and an outlet). At least a portion of the side wall generally surrounds an internal cavity. The at least one opening (e.g., an inlet / outlet or an inlet and an outlet) can allow for the introduction of liquid into the internal cavity and the expulsion of liquid from the cavity. The at least one opening is coaxial with the chamber in some embodiments, and is in an end wall of the chamber in some embodiments. The side wall may be curvilinear (e.g., cylindrical or generally cylindrical).
[0006] In some embodiments, the method includes incubating an input composition containing cells and viral particles containing the recombinant viral vector in an internal cavity of a centrifuge chamber, the centrifuge chamber being rotatable about an axis of rotation and including an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding an internal cavity, and the at least one opening capable of allowing introduction of liquid into and expulsion of liquid from the internal cavity, the centrifuge chamber rotating about the axis of rotation during at least a portion of the incubation, and the method producing an output composition containing a plurality of cells transduced with the viral vector.
[0007] In some embodiments, the centrifuge chamber further includes a movable member (e.g., a piston). In such embodiments, the internal cavity is generally of variable volume, e.g., a variable volume cavity defined by an end wall, a side wall, and a movable member (e.g., a piston), whereby the movable member can move within the chamber (e.g., axially within the chamber) to vary the internal volume of the cavity. Alternatively, in some embodiments, liquid is moved in and out of the chamber by a pump, syringe, and / or motor, or other device for introducing and expelling liquid or gas (e.g., drawing liquid from the cavity and / or pushing liquid into the cavity), while the volume of the cavity itself remains constant.
[0008] In some embodiments, the method includes incubating an input composition containing cells and viral particles containing a recombinant viral vector in an internal cavity of a centrifuge chamber, the centrifuge chamber being rotatable about an axis of rotation and including an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding an internal cavity, and the at least one opening being capable of allowing liquid to be introduced into and expelled from the internal cavity, the centrifuge chamber rotating about the axis of rotation during at least a portion of the incubation, a total liquid volume of the input composition present in the cavity during rotation of the centrifuge chamber is at most about 5 mL per square inch of internal surface area of the cavity, and the method produces an output composition comprising a plurality of cells transduced with the viral vector.
[0009] The chamber may include two end walls. In some such embodiments, one end wall defines an interior cavity along with other features, while the other is exterior to the cavity. In some embodiments, the cavity is bounded by both end walls.
[0010] The at least one opening may include an inlet and an outlet capable of allowing intake and exhaust, respectively, or may include a single port capable of allowing intake and exhaust.
[0011] Typically, the incubation is carried out at least in part under rotation of the chamber (e.g., under centrifugal force or acceleration). Thus, the method in some embodiments further comprises performing a rotation of the centrifuge chamber (e.g., rotation about the axis of rotation of the chamber) during at least a portion of the incubation.
[0012] In some of any such embodiments, the rotation comprises rotation at an interior surface of the sidewall of the cavity and / or a surface layer of cells at a relative centrifugal force (RCF) of greater than or about 200 g, greater than or about 300 g, or greater than or about 500 g. In some of any such embodiments, the rotation comprises rotation at a relative centrifugal force at the interior surface of the side walls of the cavity and / or at a surface layer of the cells that is at or about 1000 g, 1500 g, 2000 g, 2100 g, 2200 g, 2500 g, or 2500 g; or at or about 3000 g; or at least 1000 g, at least 1500 g, at least 2000 g, at least 2100 g, at least 2200 g, at least 2500 g, or at least 2500 g, or at least 3000 g.In some of any such embodiments, the rotation may be at or about 1000 g to 3600 or about 3600 g, at or about 1000 g to 3200 or about 3200 g, at or about 1000 g to 2800 or about 2800 g, at or about 1000 g to 2000 or about 2000 g, at or about 1000 g to 1600 or about 1600 g, at ... about 1600g to 3600 or about 3600g, 1600 or about 1600g to 3200 or about 3200g, 1600 or about 1600g to 2800 or about 2800g, 1600 or about 1600g to 2000 or about 2000g, 2000 or about 2000g to 3600 or about 3600g, 2000 or about 2000g to 3200 or about 3200g, 2000 or about 2000g to 2800 or about 2800g, 2800 or or about 2800g to 3600 or about 3600g, 2800 or about 2800g to 3200 or about 3200g, 3200 or about 3200g to 3600 or about 3600g (each including the boundary value); or at least 2000g or about 2000g, 2100g or about 2100g, 2200g or about 2200g, 2400g or about 2400g, 2600g or about 2600g, 2800g or about 2800g, 3000g or or about 3000g, 3200g, or 3600g; or about 2000g, 2100g, 2200g, 2400g, 2600g, 2800g, 3000g, 3200g, or 3600g.
[0013] In some of any such embodiments, at least a portion of the incubation during which the chamber is rotating is for a period of about or greater than 5 minutes, e.g., about or greater than 10 minutes, about or greater than 15 minutes, about or greater than 20 minutes, about or greater than 30 minutes, about or greater than 45 minutes, about or greater than 60 minutes, about or greater than 90 minutes, or about or greater than 120 minutes; or for a period of 5 or about 5 minutes to 60 or about 60 minutes, 10 or about 10 minutes to 60 or about 60 minutes, 15 or about 15 minutes to 60 or about 60 minutes, 15 or about 15 minutes to 45 or about 45 minutes, 30 or about 30 minutes to 60 or about 60 minutes, or 45 or about 45 minutes to 60 or about 60 minutes, inclusive.
[0014] In some embodiments, the input composition (or number of cells) in the cavity during incubation (e.g., at any one time throughout or during the entire incubation) and / or processed by the method is greater than or equal to 1×10 6 pcs or approx. 1×10 6 or at least about 1×10 6 pieces, 5×10 6 Pieces or about 5 x 10 6 or at least about 5×10 6 pieces, 1×10 7 pcs or approx. 1×10 7 or at least about 1×10 7 pieces, 5×10 7 Pieces or about 5 x 10 7 or at least about 5×10 7 pieces, 1×10 8 Or about 1 x 10 8 Or at least about 1 × 10 8 pcs, or 5×10 8 Or about 5 x 10 8 Or at least about 5×10 8 Contains cells.
[0015] In some of any such embodiments, the input composition in the cavity is at least 1×10 7 pcs or approx. 1×10 7 pieces, 2×10 7 pcs or approx. 2×10 7 pieces, 3×10 7 Pieces or about 3 x 10 7 pieces, 4×10 7 pcs or approx. 4 x 10 7 pieces, 5×10 7 Pieces or about 5 x 10 7 pieces, 6×10 7 pcs or approx. 6 x 10 7 pieces, 7×10 7 Pieces or about 7 x 10 7 pieces, 8×10 7 Pieces or about 8 x 10 7 pieces, 9×10 7 Pieces or about 9 x 10 7 pieces, 1×10 8 pcs or approx. 1×10 8 pieces, 2×10 8 pcs or approx. 2×10 8 pieces, 3×10 8 Pieces or about 3 x 10 8 pcs, or 4×10 8 pcs or approx. 4 x 10 8 Contains cells.
[0016] In some embodiments, the interior surface area of the cavity is at least 1×10 9 μm 2 Or at least about 1 × 10 9 μm 2 Or at least 1×10 10 μm 2 Or at least about 1 × 10 10 μm 2 and / or the length of the side wall in a direction extending from the end wall is at least about 5 cm and / or at least about 8 cm; and / or the internal cavity has a radius of at least about 2 cm in at least one cross-section.
[0017] In some embodiments, the input composition comprises at least 1 infectious unit (IU) or about 1 IU, at least 2 IU or at least about 2 IU, at least 3 IU or at least about 3 IU, at least 4 IU or at least about 4 IU, at least 5 IU or at least about 5 IU, at least 10 IU or at least about 10 IU, at least 20 IU or at least about 20 IU, at least 30 IU or at least about 30 IU, at least 40 IU or at least about 40 IU, at least 50 IU or at least about 50 IU, or at least 60 IU or at least about 60 IU per cell. In some embodiments, the input composition comprises 1 infectious unit (IU) or about 1 IU, 2 IU or about 2 IU, 3 IU or about 3 IU, 4 IU or about 4 IU, 5 IU or about 5 IU, 10 IU or about 10 IU, 20 IU or about 20 IU, 30 IU or about 30 IU, 40 IU or about 40 IU, 50 IU or about 50 IU, or 60 IU or about 60 IU per cell.
[0018] In some embodiments, the average or maximum liquid volume of the input composition, the composition with viral vector particles and cells, and / or any liquid composition present in the cavity during incubation is at most about 10, 5, or 2.5 milliliters (mL) per square inch of the internal surface area of the cavity during incubation. In some embodiments, the maximum total volume of such liquid compositions present in the cavity at any one time during incubation is at most 2 times, at most 10 times, at most 100 times, at most 500 times, or at most 1000 times the total volume of the cells. In some embodiments, the total volume of the cells is the total volume of the pellet of the cells. In some embodiments, the total volume of the cells is the volume of a monolayer of cells (e.g., a monolayer of cells present on the internal surface of the cavity during rotation of the centrifuge chamber).
[0019] In some embodiments, the liquid volume of the input composition occupies all or substantially all of the volume of the internal cavity during at least a portion of the incubation, while in other embodiments, the liquid volume of the input composition occupies only a portion of the volume of the internal cavity during at least a portion of the incubation, and the volume of the cavity during this at least a portion further comprises a gas, which gas is introduced into the cavity before or during the incubation, e.g., via at least one or the other of the openings.
[0020] In some of any such embodiments, the liquid volume of the input composition present in the cavity during rotation per square inch of internal surface area of the cavity (mL / sq.in.) is from 0.5 or about 0.5 mL / sq.in. to 5 or about 5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 1 or about 1 mL / sq.in., from 1 or about 1 mL / sq.in. to 5 or about 5 mL / sq.in., from 1 or about 1 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., or from 2.5 or about 2.5 mL / sq.in. to 5 or about 5 mL / sq.in.
[0021] In some of any such embodiments, the maximum total liquid volume of the input composition present in the cavity at any one time during incubation is at most 2 times, at most 10 times, or at most 100 times the total volume of the cells in the cavity, or the average volume of the input composition over the course of the incubation is at most 2, 10, or 100 times the total volume of the cells in the cavity.
[0022] In some of any such embodiments, the maximum volume of the input composition present in the cavity at any one time during incubation or the average volume over the course of the incubation is at most 2-fold, 10-fold, 25-fold, 50-fold, 100-fold, 500-fold, or 1000-fold the volume of the monolayer of cells formed on the interior surface of the cavity during rotation of the chamber at or about 2000 g force on the interior surface of the side wall.
[0023] In some of any such embodiments, the liquid volume of the input composition is at most 20 mL, at most 40 mL, at most 50 mL, at most 70 mL, at most 100 mL, at most 120 mL, at most 150 mL, or at most 200 mL.
[0024] In some of any such embodiments, during at least a portion of the incubation in the chamber or during rotation of the chamber, the liquid volume of the input composition occupies only a portion of the volume of the interior cavity of the chamber, and during at least a portion of said incubation or during said rotation, the volume of the cavity further comprises gas, which gas is introduced into the cavity via at least one opening before or during incubation.
[0025] In some embodiments, the centrifuge chamber includes a movable member, and introduction of gas into the centrifuge chamber causes movement of the movable member such that the volume of the interior cavity of the chamber increases, thereby decreasing the total liquid volume of the input composition present in the cavity per square inch of interior surface area of the cavity during rotation of the centrifuge chamber compared to when no gas is present in the chamber.
[0026] In some embodiments, the number of cells in the cavity during incubation is at or near a sufficient number of cells to form a monolayer on the interior surface of the cavity during rotation of the centrifuge chamber at a force of at or about 2000 g, and / or is at most 1.5 or 2 times such number of cells.
[0027] In some of any such embodiments, the number of cells in the input composition is at or near the number of cells sufficient to form a monolayer on the surface of the cavity during rotation of the centrifuge chamber at a force of at or about 2000 g on the inner surface of the sidewall; and / or the number of cells in the input composition is at most 1.5 or 2 times the number of cells sufficient to form a monolayer on the surface of the cavity during rotation of the centrifuge chamber at a force of at or about 2000 g on the inner surface of the sidewall.
[0028] In some embodiments, the duration of the centrifugation is from 120 to 7200 seconds, such as from 120 to 3600 seconds (including values within the range, such as values in minutes).
[0029] In some embodiments, the method comprises: (a) detecting at least 1×10 9 μm 2 Or at least about 1 × 10 9 μm 2 , or at least 1 × 10 10 μm 2 Or at least about 1 × 10 10 μm 2 (i) an input composition comprising cells and viral particles containing a recombinant viral vector in an internal cavity of a centrifuge chamber having an internal surface area of at least 1×10 7and the viral particles are present in the input composition at at least 1 infectious unit (IU) or at least about 1 IU per cell, and the input composition contains a liquid volume that is less than the maximum volume of the internal cavity of the centrifuge chamber; and (ii) a volume of gas that is at most the remainder of the maximum volume of the internal cavity of the centrifuge chamber; and (b) incubating the input composition, at least a portion of the incubation being performed within the internal cavity of the centrifuge chamber while rotating the centrifuge chamber, and the method produces an output composition containing a plurality of cells transduced with the viral vector.
[0030] In some embodiments, the number of cells is at least 50×10 6 or at least about 50×10 6 Pieces, at least 100 x 10 6 or at least about 100×10 6 pieces, or at least 200 x 10 6 or at least about 200×10 6 and / or the viral particles are present at at least 1.6 IU / cell, 1.8 IU / cell, 2.0 IU / cell, 2.4 IU / cell, 2.8 IU / cell, 3.2 IU / cell, or 3.6 IU / cell, 4.0 IU / cell, 5.0 IU / cell, 6.0 IU / cell, 7.0 IU / cell, 8.0 IU / cell, 9.0 IU / cell, or 10.0 IU / cell.
[0031] In some of any such embodiments, the liquid volume of the input composition is 200 mL or less, 100 mL or less, or 50 mL or less, or 20 mL or less. In some of any such embodiments, the gas volume is up to 200 mL, up to 180 mL, up to 140 mL, or up to 100 mL.
[0032] In some of any such embodiments, the rotation is at a relative centrifugal force of at least at or about 1000 g, 1500 g, 2000 g, 2400 g, 2600 g, 2800 g, 3000 g, 3200 g, or 3600 g on the interior surface of the side wall of the cavity or on the surface layer of the cells.
[0033] In some aspects, the method is a method for large scale processing.
[0034] In some embodiments, the composition in the cavity (e.g., input composition) is maintained at least partially during the incubation in a liquid volume of at least 50 mL, at least 100 mL, or at least 200 mL, and / or at least 1 cm of internal surface area of the cavity. 2 Each contains at least or about 1 million cells.
[0035] In some embodiments, the maximum liquid volume of the input composition present in the cavity at any one time during incubation is at most 2x or about 2x, 10x or about 10x, 25x or about 25x, 50x or about 50x, 100x or about 100x, 500x or about 500x, or 1000x or about 1000x the volume of the monolayer of cells formed on the interior surface of the cavity during rotation of the chamber at a force (e.g., effective force) of, e.g., at or about 2000g.
[0036] In some embodiments, the rotation of the chamber during at least a portion of the incubation is at a force of greater than or about 200 g, greater than or about 300 g, or greater than or about 500 g, e.g., greater than or about 1000 g, greater than or about 1500 g, greater than or about 2000 g, greater than or about 2500 g, greater than or about 3000 g, or greater than or about 3200 g, on the inner wall of the cavity of the centrifuge chamber and / or the layer of cells (e.g., the surface layer). In some embodiments, the force is at least 1000 g, 1500 g, 2000 g, 2500 g, 3000 g, or 3200 g. In some embodiments, the force is at least 2100 g, 2200 g, or 3000 g.
[0037] In some embodiments, the method includes incubating an input composition containing cells and viral particles containing the recombinant viral vector, where at least a portion of the incubating step is performed under rotating conditions, thereby generating an output composition containing a plurality of cells transduced with the viral vector, where the input composition contains a volume of about or greater than 20 mL, about or greater than 50 mL, at least 100 mL, or at least 150 mL, and / or the input composition contains at least 1×10 8 cells; and the spinning conditions comprise a relative centrifugal force at a surface layer of cells of greater than about 1500 g.
[0038] In some embodiments of the method, at least 25% or 50% of the cells in the output composition are transduced with the viral vector; and / or at least 25% or 50% of the cells in the output composition express the product of a heterologous nucleic acid contained within the viral vector.
[0039] In some of any such embodiments, the incubation occurs within a cavity of a centrifuge chamber, and the number of cells in the input composition is sufficient or close to the number of cells to form a monolayer or bilayer on the interior surface of the cavity during rotation.
[0040] In some embodiments, the centrifuge chamber includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding an internal cavity, and the at least one opening capable of allowing the introduction of liquid into and the expulsion of liquid from the internal cavity.
[0041] In some aspects, the centrifuge chamber further includes a movable member, and the internal cavity is a variable volume cavity defined by an end wall, a substantially rigid sidewall, and the movable member, the movable member capable of moving within the chamber to vary the internal volume of the cavity.
[0042] In some of any such embodiments, the input composition in the cavity has a liquid volume of at least 20 mL or 50 mL and an internal surface area of the cavity of at least 1 cm during at least a portion of the incubation. 2 Each contains at or about 1 million cells.
[0043] In some of any such embodiments, a further portion of the incubation occurs outside the centrifuge chamber and / or without rotation, said further portion occurring after at least a portion that occurs within the chamber and / or with rotation.
[0044] In some of any such embodiments, at least a portion of the incubation and / or a further portion of the incubation that takes place within the cavity of the centrifuge chamber is carried out at or about 37°C±2°C.
[0045] In some of any such embodiments, the incubation further comprises transferring at least a plurality of cells during the incubation to a container in which a further portion of the incubation is performed, hi some embodiments, the transferring is performed in a closed system, and the centrifuge chamber and the container are integrated into the closed system.
[0046] In some of any such embodiments, the incubation is carried out for 1 or about 1 hour to 96 or about 96 hours, 4 or about 4 hours to 72 or about 72 hours, 8 or about 8 hours to 48 or about 48 hours, 12 or about 12 hours to 36 or about 36 hours, 6 or about 6 hours to 24 or about 24 hours, 36 or about 36 hours to 96 or about 96 hours, inclusive; or a further portion of the incubation is carried out for 1 or about 1 hour to 96 or about 96 hours, 4 or about 4 hours to 72 or about 72 hours, 8 or about 8 hours to 48 or about 48 hours, 12 or about 12 hours to 36 or about 36 hours, 6 or about 6 hours to 24 or about 24 hours, 36 or about 36 hours to 96 or about 96 hours, inclusive.
[0047] In some of any such embodiments, the incubation, or a further portion of the incubation, occurs for up to 48 hours, up to 36 hours, or up to 24 hours; or the further portion of the incubation occurs for up to 48 hours, up to 36 hours, or up to 24 hours.
[0048] In some of any such embodiments, the incubation is performed in the presence of a stimulating agent; and / or a further portion of the incubation is performed in the presence of a stimulating agent.
[0049] In some of any such embodiments, the incubation occurs for up to 24 hours; the cells in the composition are not subjected to temperatures above 30° C. for more than 24 hours; and / or the incubation is not performed in the presence of a stimulant.
[0050] In some of any such embodiments, the stimulatory agent is an agent capable of inducing proliferation of T cells, CD4+ T cells, and / or CD8+ T cells.
[0051] In some of any such embodiments, the stimulatory agent is a cytokine selected from among IL-2, IL-15, and IL-7.
[0052] In some of any such embodiments, the output composition containing the transduced cells comprises at least 1×10 7 or at least 5 × 10 7 Contains cells.
[0053] In some of any such embodiments, the output composition containing the transduced cells comprises at least 1×10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8 pieces, 8×10 8 pcs or 1×10 9 Contains cells.
[0054] In some of any such embodiments, the cells are T cells. In some embodiments, the T cells are unfractionated T cells, isolated CD4+ T cells, and / or isolated CD8+ T cells.
[0055] In some of any such embodiments, the method results in integration of the viral vector into the host genome of one or more of at least a plurality of cells in the output composition, and / or into the host genome of at least or at least about 20%, or at least or at least about 30%, or at least or at least about 40% of the cells in the output composition.
[0056] In some of any such embodiments, at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the input composition are transduced with a viral vector by the method; and / or at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition are transduced with a viral vector; and / or at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition express a product of a heterologous nucleic acid contained within the viral vector.
[0057] Certain embodiments include a method of transduction performed by incubating an input composition comprising cells and viral vector particles under rotating conditions, wherein a plurality of cells are seeded for transduction with a viral vector, and the input composition comprises a total volume of more than 50 mL, e.g., at least 100 mL or at least 150 mL, and / or the input composition comprises at least 1×10 8cells; and the rotation conditions include a centrifugal force of more than about 1500 g. In some such embodiments, the incubation is performed in a cavity of a centrifuge chamber, and the number of cells in the input composition is sufficient or close to the number of cells that form a monolayer on the inner surface of the cavity during rotation. In some such embodiments, at least 25% or at least 50% of the cells are transduced with the viral vector.
[0058] In some embodiments, the method results in at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the input composition being transduced with the viral vector and / or producing an output composition in which at least 10%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells are transduced with the vector and / or express a recombinant product encoded by the vector. In some embodiments, the transduction efficiency is expressed for a particular input amount or relative amount of virus. For example, in some embodiments, such efficiency is achieved by the method for an input composition containing about 1 IU or about 2 IU of virus per cell.
[0059] In some embodiments, the average copy number of the recombinant viral vector in all cells in the output composition produced by the method is at most about 10, at most about 5, at most about 2.5, or at most about 1.5. In some embodiments, the average copy number of the vector in cells containing a recombinant viral vector in the output composition is at most about 5, at most about 2, at most about 1.5, or at most about 1.
[0060] In some of any such embodiments, the average copy number of the recombinant viral vector in all of the cells in the output composition that contain or have integrated the viral vector is at most about 10, at most about 5, at most about 2.5, or at most about 1.5; or the average copy number of the vector in the cells in the output composition is at most about 2, at most about 1.5, or at most about 1.
[0061] In some embodiments, the centrifuge chamber is incorporated into a closed system, for example, the closed system includes the chamber and at least one piping line operatively connected to at least one opening via at least one connector, so that in at least one configuration of the system, liquid and gas can move between the cavity and the at least one piping line. The at least one piping line typically includes a series of piping lines. The at least one connector typically includes multiple connectors. The closed system may further include at least one container operatively connected to the series of piping lines, so that the at least one connection allows liquid and / or gas to pass between the at least one container and the at least one opening via the series of piping lines.
[0062] The at least one connector may include one or more connectors selected from the group consisting of a valve, a luer port, and a spike, a rotary valve such as a stop cock or a multi-rotary port, and / or a sterile connector.
[0063] The at least one container may include one or more bags, vials, and / or syringes, and may include containers designated as a diluent container, a waste container, a product collection container, an output container, and / or an input container.
[0064] In some embodiments, the at least one vessel includes at least one input vessel containing virus and / or cells (which may be a single input vessel containing virus and cells, or two input vessels containing virus and cells, respectively), a waste vessel, a product vessel, and at least one vessel containing a diluent or wash solution, each connected to the cavity via a series of piping lines and at least one opening.
[0065] In some of any such embodiments, at least one of the containers further comprises a container containing a gas before and / or during at least a certain time during incubation, and / or the closed system further comprises a microbial filter capable of introducing a gas into the internal cavity of the centrifuge chamber, and / or the closed system contains a syringe port for effecting the introduction of the gas.
[0066] In some embodiments, the method further comprises performing an introduction of an input composition into the cavity before and / or during incubation. The introduction may include flow of liquid from at least one input receptacle into the cavity through at least one opening. The introduction may include introduction of virus from one input receptacle and input of cells from another to produce an input composition for incubation.
[0067] In some embodiments, the method includes providing or performing, under sterile conditions, introduction of gas into the cavity before and / or during incubation, by (a) inflow of gas from a container containing the gas, (b) inflow of gas from the environment external to the closed system through a microbial filter, or (c) inflow of gas from a syringe connected to the system at a syringe port.
[0068] In some embodiments, the step of effecting the introduction of a gas into the internal cavity of the centrifuge chamber is performed simultaneously or together with the step of effecting the introduction of an input composition into the internal cavity of the centrifuge chamber.
[0069] In some of any such embodiments, the input composition and gas are combined in a single container under sterile conditions outside the chamber prior to introduction of the input composition and gas into the interior cavity of the centrifuge chamber.
[0070] In some embodiments, the step of effecting the introduction of the gas is performed separately, either simultaneously or sequentially, from the step of effecting the introduction of the input composition into the cavity.
[0071] In some of any such embodiments, the introduction of gas is provided by allowing or causing the gas to flow in from a sterile sealed container containing the gas, from the external environment through a microbial filter, or from a syringe containing the gas.
[0072] In some of any such embodiments, the gas is air.
[0073] In some embodiments of the provided processing methods, the incubation is part of a continuous process, and the method further comprises performing a continuous intake of an input composition into the cavity during at least a portion of the incubation (typically while the chamber is rotating), and performing a continuous expulsion (i.e., removal) of liquid from the cavity through at least one opening during at least a portion of the incubation (typically while the chamber is rotating). The continuous intake and removal in some embodiments are performed simultaneously.
[0074] In some embodiments, the method includes performing a continuous introduction of gas into the cavity during rotation of the chamber during a portion of the incubation; and / or performing a continuous expulsion of gas from the cavity during a portion of the incubation.
[0075] In some embodiments, the method includes expressing a liquid and expressing a gas from the cavity, each of which is expressed simultaneously or sequentially into a different container.
[0076] In some of any such embodiments, at least a portion of the continuous intake and continuous output occurs simultaneously.
[0077] In some embodiments, incubation is part of a semi-continuous process, and in an exemplary process, the method further comprises the steps of: performing introduction of an input composition into the cavity through at least one opening; performing all or a portion of the incubation (e.g., centrifugation); and then expressing the liquid from the cavity; and then repeating the process, where another input composition is introduced into the cavity, followed by centrifugation, followed by expression. The process may be iterative and may include several more rounds of introduction, processing, and expression.
[0078] In some of any such embodiments, incubation is part of a semi-continuous process, and the method further comprises the steps of: prior to incubation, introducing an input composition and optionally a gas into the cavity through at least one opening; following incubation, expressing liquid and / or optionally a gas from the cavity; introducing another input composition comprising cells and viral particles containing a recombinant viral vector, and optionally a gas, into the internal cavity; and incubating the another input composition in the internal cavity, wherein the method produces another output composition containing a plurality of cells of the another input composition that have been transduced with the viral vector.
[0079] In some of any such embodiments, providing or introducing an input composition into the cavity includes introducing a single composition comprising the cells and viral particles containing the recombinant viral vector; or includes introducing a composition comprising the cells and a separate composition comprising viral particles containing the recombinant viral vector, where these compositions are mixed to effect introduction of the input composition.
[0080] The introduction can include introduction of a single composition containing the cells and the virus; or introduction of a composition containing the cells and a separate composition containing the virus, which are mixed to effect introduction of the input composition. In some embodiments of a continuous or semi-continuous process, a total of at least 1×10 8 pcs or 1×10 9 pcs or 1×10 10 The cells or more are processed over multiple rounds or sequential processes.
[0081] In some embodiments, the method includes rotating the centrifuge chamber before and / or during incubation and expressing liquid from the cavity into a waste container after incubation; expressing liquid from at least one diluent container into the cavity through at least one opening and mixing the contents of the cavity; and expressing liquid from the cavity into a product container, thereby transferring cells transduced with the viral vector into a product bag.
[0082] In some embodiments, the method further comprises performing other processing steps, or at least a portion of one or more other processing steps, in the same chamber and / or closed system. In some embodiments, the one or more processing steps may comprise a process in which the cells are isolated (e.g., separated or selected), stimulated, and formulated in the same chamber and / or closed system. In some cases, the one or more further processing steps may also comprise washing the cells, suspending the cells, and / or diluting or concentrating the cells, which may be performed before or after any one or more of the processing steps for isolating (e.g., separated or selected), stimulating, transducing, and / or formulating the cells. In some embodiments, the one or more other processing steps may be performed before, simultaneously, or after incubation of the cells with the viral vector particles in the transduction method. In some embodiments, one or more further processing steps, or a portion of one or more further processing steps, may be performed in a cavity of a centrifuge chamber that is the same as or different from the cavity of the centrifuge chamber employed in the incubation of the cells with the viral vector particles.
[0083] Among the processing methods provided, including isolation (eg, selection), stimulation, formulation, and other processing methods, are those performed according to any of the above embodiments.
[0084] For example, in some embodiments, the method includes (a) washing a cell-containing biological sample (e.g., a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product) in a cavity of a chamber prior to incubation to isolate (e.g., select) the cells and / or prior to incubation to incubate the cells with viral vector particles; (b) washing the cell-containing biological sample (e.g., a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product) in a cavity of a chamber prior to incubation to isolate (e.g., select) the cells and / or prior to incubation to incubate the cells with viral vector particles; and / or (c) isolating (e.g., selecting) cells from a sample (e.g., a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product) within the cavity prior to incubation of such cells with the viral vector particles; and / or (c) stimulating cells within the cavity prior to and / or during incubation of such cells with the viral vector particles, e.g., by exposing the cells to stimulatory conditions, thereby inducing proliferation of the cells of the input composition. In some embodiments, the isolating step comprises immunoaffinity-based selection.
[0085] In some of any such embodiments, the method includes (a) washing the biological sample containing the cells in the internal cavity of the centrifuge chamber prior to incubation; and / or (b) isolating the cells from the biological sample, where at least a portion of the isolating step is performed in the internal cavity of the centrifuge chamber prior to incubation; and / or (c) stimulating the cells before and / or during incubation, where the stimulating step comprises exposing the cells to stimulatory conditions, thereby inducing proliferation of the cells of the input composition, where at least a portion of the stimulating step is performed in the internal cavity of the centrifuge chamber.
[0086] In some embodiments, the method may further include isolating (e.g., selecting) cells in the chamber, e.g., by immunoaffinity-based selection. In some embodiments, the isolation (e.g., selecting) of cells occurs prior to incubation of cells with viral vector particles in the transduction method, whereby the isolated cells (e.g., selected cells) are cells that were present in the input composition and / or incubated with viral vector particles. In some embodiments, the isolation (e.g., selecting) includes incubation of cells with a selection reagent, such as an immunoaffinity reagent. In some embodiments, at least a portion of the isolation (e.g., selection) step, such as incubation of cells with a selection reagent (e.g., immunoaffinity reagent), occurs within the cavity of the chamber, which in some cases may include rotation of the chamber, e.g., for mixing of the reagent with the cells.
[0087] In some embodiments, the method may further include stimulating the cells before, during, and / or after incubation of the cells with the viral vector particles, and at least all or part of the stimulation may be performed in the cavity of the centrifuge chamber. In some embodiments, the stimulation condition may include incubation of the cells in the presence of an agent that can activate one or more intracellular signaling domains of one or more components of the TCR complex (e.g., a first agent that specifically binds to a member of the TCR complex (e.g., CD3)) and a second agent that specifically binds to a T cell costimulatory molecule (e.g., CD28, CD137 (4-1-BB), OX40, or ICOS) (including an antibody, e.g., an antibody present on the surface of a solid support (e.g., a bead)). In some embodiments, at least part of the stimulation, such as incubation of the cells in the presence of the stimulation condition, is performed in the cavity of the chamber, and in some cases, it may include rotation of the chamber, for example, to mix the reagent with the cells.
[0088] In some of any such embodiments, the method includes formulating cells, such as cells produced or generated according to the provided methods, including cells transduced by the method, in a pharma- ceutically acceptable buffer in the internal cavity of the centrifuge chamber, thereby producing a formulated composition. In some embodiments, the method further includes performing expression of the formulated composition into one or more containers. In some embodiments, the method includes performing expression of the formulated composition, which includes performing expression of a multiplicity of cells present in a single unit dose into one or each of the one or more containers.
[0089] In some of any such embodiments, each of the cavities of the centrifuge chamber is the same as or different from the centrifuge cavities employed in one or more of the other stages and / or in the process of incubating and / or spinning the input composition containing the cells and viral particles.
[0090] In some of any such embodiments, each of the centrifuge chambers is incorporated into a closed system including the chamber and at least one piping line operatively connected to at least one opening via at least one connector, and capable of transferring liquids and gases between the cavity and the at least one piping line in at least one configuration of the system.
[0091] The cells processed by the method are typically primary cells, e.g., cells obtained from a subject (typically a human). The cells may be derived from the subject to which therapy is to be administered, e.g., from a subject with a disease or condition targeted by a recombinant molecule (e.g., a recombinant antigen receptor, such as a chimeric antigen receptor or a transgenic TCR) expressed by a transduced vector. Alternatively, the cells may be derived from a different subject. Thus, the method includes processing for autologous and allogeneic transfer. The cells include suspension cells, e.g., leukocytes, e.g., isolated CD8 + T cells or isolated CD4 + These may include T cells, such as T cells, or a subset thereof, or NK cells.
[0092] In some embodiments, during incubation, the centrifuge chamber is associated with a sensor (e.g., a sensor that can monitor the position of the movable member) and control circuitry (e.g., circuitry that can receive and transmit information to and from the sensor and can cause movement of the movable member) and / or is further associated with a centrifuge, thus causing rotation of the chamber during incubation.
[0093] In some embodiments, the chamber contains a movable member and is located within the centrifuge during incubation and is associated with a sensor capable of monitoring the position of the movable member, and a control circuit capable of receiving and transmitting information from the sensor and causing movement of the movable member, the intake and expulsion of liquid into and out of the cavity via one or more piping lines, and the rotation of the chamber by the centrifuge.
[0094] In some embodiments, the chamber, control circuitry, centrifuge, and / or sensor are housed within a cabinet, e.g., during incubation.
[0095] In some embodiments of any of the viral transfer (e.g., transduction) methods, the recombinant viral vector encodes a recombinant receptor, which is expressed by the cells of the output composition. In some embodiments, the recombinant receptor is a recombinant antigen receptor, e.g., a functional non-T cell receptor, e.g., a chimeric antigen receptor (CAR), or a transgenic T cell receptor (TCR). In some embodiments, the recombinant receptor is a chimeric receptor that contains an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain.
[0096] In some of any such embodiments, the cells include primary human T cells obtained from a human subject, and prior to incubation with the viral vector particles and / or completion of transduction, and / or prior to formulation, if the method includes formulation, the primary human T cells have not been present outside the subject at a temperature greater than 30° C. for more than 1 hour, more than 6 hours, more than 24 hours, or more than 48 hours, or prior to incubation and / or completion of transduction, and / or prior to formulation, if the method includes formulation, the primary human T cells have not been incubated in the presence of an antibody specific for CD3 and / or an antibody specific for CD28 and / or a cytokine for more than 1 hour, more than 6 hours, more than 24 hours, or more than 48 hours.
[0097] Provided herein is a method for isolating (e.g., selecting) cells, comprising: (a) incubating primary cells with a selection reagent in an internal cavity of a centrifuge chamber under mixing conditions, thereby causing a plurality of primary cells to bind to the selection reagent; and (b) separating the plurality of primary cells from another one or more of the primary cells based on their binding to the selection reagent, thereby enriching the primary cells based on their binding to the selection reagent; wherein the centrifuge chamber is rotatable around a rotation axis, and the internal cavity has a maximum volume of at least 50 mL, at least 100 mL, or at least 200 mL. In some embodiments, the method for isolating (e.g., selecting) is carried out in a closed system. In some embodiments, before separating a plurality of cells, the cells incubated with the selection reagent are squeezed or transferred from the chamber, but are maintained in the closed system. In some embodiments, optionally after incubation with the selection reagent and prior to separating the cells, the method further comprises one or more washing steps, which in some cases may be performed within the cavity of the chamber according to the methods provided. In some embodiments, the step of separating the cells may be performed using a solid support such as an immunoaffinity column (including those for magnetic separation) that may be contained within a closed system.
[0098] Provided herein is a method for stimulating cells, comprising incubating a stimulating agent with primary cells under conditions where the stimulating agent binds to a molecule expressed by a plurality of primary cells to activate or stimulate the plurality of cells, at least a portion of the incubation being carried out under mixing conditions within an internal cavity of a centrifuge chamber, wherein the centrifuge chamber is rotatable about an axis of rotation and the internal cavity has a maximum volume of at least 50 mL, at least 100 mL, or at least 200 mL.
[0099] In some embodiments, the method of stimulation is carried out as part of a process that includes a step of transducing cells, so that all or part of such process is carried out in a centrifuge chamber and / or as part of the same closed system. In some embodiments, the primary cells stimulated with a stimulating agent include or are cells obtained after isolation (e.g., selection) of cells from a biological sample (e.g., by a method provided). In some embodiments, at least a part of the stimulation is carried out simultaneously with or during incubation of the cells with viral vector particles, so that the primary cells include or are cells present in the input composition and / or are cells where transduction is occurring or being initiated. In some embodiments, at least a part of the stimulation is carried out before incubation of the cells with viral vector particles, so that the cells incubated with the viral vector particles are stimulated cells, which in some cases include proliferating cells.
[0100] In some embodiments, at least a portion of one or more other processing steps of the method (including isolation (e.g., selection), stimulation, washing, and / or formulation) that are performed within the chamber include where the chamber comprises an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall enclosing an internal cavity, and the at least one opening is capable of allowing the introduction of liquid into the internal cavity and the expulsion of liquid from the cavity.
[0101] Provided herein is a composition containing transduced cells produced by the method of any of the above embodiments. In some of any such embodiments, the composition contains cells that are primary cells and / or human cells and / or include leukocytes, and / or T cells, and / or NK cells. In some of any such embodiments, the composition contains at least 5×10 7 pieces, 1×10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8pieces, 8×10 8 pcs or 1×10 9 In some of any such embodiments, the composition contains a therapeutically effective number of cells for use in adoptive T cell therapy. In some of any such embodiments, the cells are T cells, and after transduction, the cells in the composition are not subjected to cell proliferation in the presence of a stimulant, and / or the cells are not incubated at a temperature above 30° C. for more than 24 hours, or the composition does not contain a cytokine, or the composition does not contain a stimulant that specifically binds to CD3 or the TCR complex.
[0102] As used herein, at least 1×10 7 or at least 5 × 10 7 Compositions are provided that contain T cells, at least a plurality of the cells being transduced with a recombinant viral vector, and where after transduction the cells in the composition have not been subjected to cell expansion in the presence of a stimulant and / or the cells have not been incubated at a temperature above 30° C. for more than 24 hours, and / or at least 30, 40, 50, 60, 70, or 80% of the T cells in the composition contain high surface expression of CD69 or TGF-β-II. In some embodiments, the composition comprises at least 1×10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8 pieces, 8×10 8 pcs or 1×10 9 Contains cells.
[0103] In some of any such embodiments, the T cells are unfractionated T cells, isolated CD8+ T cells, or isolated CD4+ T cells.
[0104] In some of any such embodiments, at least 2.5%, 5%, 6%, 8%, 10%, 20%, 25%, 30%, 40%, 50%, or 75% of the cells in the composition are transduced with the viral vector.
[0105] In some of any such embodiments, the viral vector encodes a recombinant receptor, and the transduced cells in the composition express the recombinant receptor. In some embodiments, the recombinant receptor is a recombinant antigen receptor. In some embodiments, the recombinant antigen receptor is a functional non-T cell receptor. In some embodiments, the functional non-T cell receptor is a chimeric antigen receptor (CAR). In some embodiments, the recombinant receptor is a chimeric receptor that contains an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain. In some embodiments, the recombinant antigen receptor is a transgenic T cell receptor (TCR).
[0106] In some of any such embodiments, the average copy number of the recombinant viral vector in all cells in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2, or the average copy number of the vector in cells transduced with a recombinant viral vector in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2.
[0107] In some of any such embodiments, the composition contains a pharma- ceutically acceptable excipient.
[0108] Provided herein are methods of treatment comprising administering to a subject having a disease or condition a composition of any of the above embodiments. In some embodiments, the transduced T cells in the composition exhibit increased or longer proliferation and / or persistence in the subject than transduced T cells in a composition in which, after transduction, the cells in the composition have been subjected to cell expansion in the presence of a stimulant and / or the cells have been incubated at a temperature above 30° C. for more than 24 hours.
[0109] In some of any such embodiments, the recombinant receptor, chimeric antigen receptor, or transgenic TCR specifically binds to an antigen associated with a disease or condition. In some embodiments, the disease or condition is cancer, an autoimmune disease or disorder, or an infectious disease.
[0110] As used herein, at least 1×10 7 Compositions are provided that contain cells and at least 1 infectious unit (IU) or at least about 1 IU of viral particles containing the recombinant viral vector per cell. In some embodiments, the cells are at least 50×10 6 or at least about 50×10 6 Pieces, at least 100 x 10 6 or at least about 100×10 6 pieces, or at least 200 x 10 6 or at least about 200×10 6 cells and / or the viral particles are present in the composition in an amount that is at least 1.6 IU / cell, 1.8 IU / cell, 2.0 IU / cell, 2.4 IU / cell, 2.8 IU / cell, 3.2 IU / cell, 3.6 IU / cell, 4.0 IU / cell, 5.0 IU / cell, 6.0 IU / cell, 7.0 IU / cell, 8.0 IU / cell, 9.0 IU / cell, or 10.0 IU / cell.
[0111] In any of such embodiments, the liquid volume of the composition is 220 mL or less, 200 mL or less, 100 mL or less, 50 mL or less, or 20 mL or less.
[0112] In some of such embodiments, the cells are primary cells. In some of such embodiments, the cells are human cells. In some of such embodiments, the cells include suspension cells, the cells include leukocytes, and / or the cells include T cells or NK cells. In some of such embodiments, the cells are T cells, and the T cells are unfractionated T cells, isolated CD8+ T cells, or isolated CD4+ T cells.
[0113] In some of any such embodiments, the viral vector encodes a recombinant receptor. In some embodiments, the recombinant receptor is a recombinant antigen receptor. In some embodiments, the recombinant antigen receptor is a functional non-T cell receptor. In some embodiments, the functional non-T cell receptor is a chimeric antigen receptor (CAR). In some embodiments, the recombinant receptor is a chimeric receptor that contains an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain. In some embodiments, the recombinant antigen receptor is a transgenic T cell receptor (TCR).
[0114] Provided herein is a centrifuge chamber rotatable about an axis of rotation that includes an internal cavity containing a composition of any of the above aspects.
[0115] As used herein, (a) at least 5×10 7 and / or (b) a composition containing at least 5×10 primary T cells. 7 A centrifuge chamber rotatable about an axis of rotation is provided that contains an internal cavity containing a composition comprising the primary T cells and viral particles containing the recombinant viral vector.
[0116] In some of any such embodiments, the chamber further includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding an internal cavity, and the at least one opening capable of allowing the introduction of liquid into and the expulsion of liquid from the internal cavity.
[0117] In some of any such embodiments, the composition in the cavity is at least 1×10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8 pieces, 8×10 8 pcs or 1×10 9 Contains cells.
[0118] In some of any such embodiments, the T cells are unfractionated T cells, isolated CD8+ T cells, or isolated CD4+ T cells.
[0119] In some of any such embodiments for the chamber, at least 2.5%, 5%, 6%, 8%, 10%, 20%, 25%, 30%, 40%, 50%, or 75% of the cells in the composition are transduced with the viral vector.
[0120] In some of any such embodiments of the chamber, the viral vector encodes a recombinant receptor, and the cells in the composition express the recombinant receptor. In some embodiments, the recombinant receptor is a recombinant antigen receptor. In some embodiments, the recombinant antigen receptor is a functional non-T cell receptor. In some embodiments, the functional non-T cell receptor is a chimeric antigen receptor (CAR). In some embodiments, the recombinant receptor is a chimeric receptor that contains an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain. In some embodiments, the recombinant antigen receptor is a transgenic T cell receptor (TCR).
[0121] In some of any such embodiments for the chamber, the average copy number of the recombinant viral vector in all cells in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2, or the average copy number of the vector in cells transduced with the recombinant viral vector in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2.
[0122] Provided herein is a centrifuge chamber rotatable about a rotation axis, comprising an internal cavity containing the composition of any of the above aspects. In some embodiments, the chamber further contains a volume of gas up to the maximum volume of the internal cavity of the chamber. In some embodiments, the gas is air.
[0123] In some of any such embodiments of the chamber, the chamber is rotatable about an axis of rotation and includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding an internal cavity, and the at least one opening can allow for the introduction of liquid into the internal cavity and the expulsion of liquid from the cavity. In some embodiments, the side wall is curved. In some embodiments, the side wall is generally cylindrical.
[0124] In some of any such embodiments of the chamber, the at least one opening includes an inlet and an outlet that can allow intake and exhaust, respectively, or the at least one opening includes a single inlet and outlet that can allow intake and exhaust. In some of any such embodiments of the chamber, the at least one opening is coaxial with the chamber and located in an end wall.
[0125] In some of any such embodiments, the chamber further includes a movable member, and the internal cavity is a variable volume cavity defined by an end wall, a substantially rigid sidewall, and the movable member, which is movable within the chamber to vary the internal volume of the cavity. In some embodiments, the movable member is a piston, and / or the movable member is movable axially within the chamber to vary the internal volume of the cavity.
[0126] In some of any such embodiments, the interior surface area of the cavity is at least 1×10 9 μm 2 Or at least about 1 × 10 9 μm 2 and the internal surface area of the cavity is at least 1 × 10 10 μm 2 Or at least about 1 × 10 10 μm 2and the length of the rigid wall in a direction extending from the end wall is at least about 5 cm, the length of the rigid wall in a direction extending from the end wall is at least about 8 cm, and / or the cavity contains a radius of at least about 2 cm in at least one cross-section.
[0127] In some of any such embodiments for a chamber, the liquid volume of the composition present in the cavity per square inch of interior surface area of the cavity (mL / sq.in.) is from 0.5 or about 0.5 mL / sq.in. to 5 or about 5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 1 or about 1 mL / sq.in., from 1 or about 1 mL / sq.in. to 5 or about 5 mL / sq.in., from 1 or about 1 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., or from 2.5 or about 2.5 mL / sq.in. to 5 or about 5 mL / sq.in. In some of any such embodiments, the liquid volume of the composition present in the cavity is at least 0.5 mL / sq.in., 1 mL / sq.in., 2.5 mL / sq.in., or 5 mL / sq.in.
[0128] Provided herein is a closed system that contains the centrifuge chamber of any of the above-mentioned embodiments.In some of the embodiments of the closed system, the centrifuge chamber can rotate at a speed of up to 8000g, and the centrifuge chamber can withstand a force of 500, 1000, 1500, 2000, 2500, 3000, or 3200g without substantially denting, bending, breaking, or otherwise damaging the chamber, and / or while substantially maintaining a generally cylindrical shape under such force. [Brief description of the drawings]
[0129] [Figure 1A]FIG. 1A shows the transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the chimeric antigen receptor (CAR) encoded by the viral vector, after incubation under various conditions described in Example 1. [Figure 1B] FIG. 1B shows population doublings over a 6 day period during the transduction study described in Example 1. [Diagram 2] FIG. 2 shows transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the CAR encoded by the viral vector, after incubation under the indicated conditions described in Example 2. [Diagram 3] FIG. 3 shows the transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the CAR encoded by the viral vector, after incubation under various conditions described in Example 3. [Figure 4] FIG. 4 shows the average vector copy number (VCN) of viral vectors in the indicated cell populations after transduction under various conditions described in Example 4. [Diagram 5] Figure 5 provides a schematic diagram of an embodiment of a closed system (processing kit) for use in embodiments of the methods provided. The exemplary system shown includes a generally cylindrical centrifuge chamber (1) that is rotatable about an axis of rotation and includes an end wall (13), a rigid side wall (14), and a piston (2) that define an interior cavity of the chamber (7). The chamber further includes an inlet / outlet opening (6) that allows for the flow of liquids and gases into and out of the cavity in at least some configurations of the system. The opening (6) is operatively connected to a series of tubing lines (3), connectors (including stopcock valves (4)), and various additional containers. A clamp (5) is also shown. [Figure 6A] FIG. 6A shows population doublings over a 10 day period during the study described in Example 6. [Figure 6B]FIG. 6B shows the percent cell viability over a 10 day period during the study described in Example 6. [Figure 7] 7 provides a schematic diagram of an embodiment of a closed system (processing kit) for use in embodiments of the methods provided. The exemplary system shown includes a generally cylindrical centrifuge chamber (1) that is rotatable about an axis of rotation and includes an end wall (13), a rigid side wall (14), and a piston (2) that define an interior cavity of the chamber (7). The chamber further includes an inlet / outlet opening (6) that allows for the flow of liquids and gases into and out of the cavity in at least some configurations of the system. The opening (6) is operatively connected to a series of tubing lines (3), connectors (including stopcock valves (4)), various additional containers, and an air filter (15) that is connected to a removable cap (16). A clamp (5) is also shown. [Figure 8A] FIG. 8A shows transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the CAR encoded by the viral vector, after incubation under the indicated conditions described in Example 8A. [Figure 8B] Figure 8B shows transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the CAR encoded by the viral vector, after incubation under the indicated conditions described in Example 8B. [Figure 8C] FIG. 8C shows the average vector copy number (VCN) of viral vectors in the indicated cell populations after transduction under various conditions described in Example 8B. [Figure 9]Figure 9A shows transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the viral vector-encoded CAR, after incubation under the indicated conditions described in Example 9. Figure 9B shows the mean vector copy number (VCN) of the viral vector in the indicated cell populations after transduction under various conditions described in Example 9. [Figure 10] FIG. 10 shows transduction efficiency, calculated as the percentage of CD3+ T cells with surface expression of the CAR encoded by the viral vector, after incubation under the indicated conditions described in Example 10. [Figure 11] FIG. 11 provides a schematic diagram of an embodiment of a closed system (processing kit) for use in embodiments of the methods provided. The exemplary system shown includes a generally cylindrical centrifuge chamber (1) that is rotatable about an axis of rotation and includes an end wall (13), a rigid side wall (14), and a piston (2) that define an interior cavity of the chamber (7). The chamber further includes an inlet / outlet opening (6) that allows for the flow of liquids and gases into and out of the cavity in at least some configurations of the system. The opening (6) is operatively coupled to a series of tubing lines (3), connectors (including stopcock valves (4) and ports (18)), and various additional containers (including multiple output bags (17)). A clamp (5) is also shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0130] Detailed Description Unless otherwise defined, all terms, expressions, and other technical and scientific terms or terminology used herein are intended to have the same meaning as commonly understood by those skilled in the art to which the claimed subject matter pertains. In some cases, terms having commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial difference compared to commonly understood in the art.
[0131] All publications, including patent documents, scientific articles, and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. In the event that a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in a patent, application, published application, or other publication incorporated herein by reference, the definition set forth herein shall take precedence over the definition incorporated herein by reference.
[0132] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0133] I. Cell Processing Methods and Related Systems, Kits, and Devices Methods are provided for processing cells, for example, to generate a composition of cells for use in adoptive cell therapy. The methods include methods for introducing recombinant viral vectors into cells, such as by viral transduction. The viral vector generally encodes a recombinant molecule that is expressed in cells, for example, for use in cell therapy. The processing steps of the methods may also or alternatively include all or part of washing, diluting, selecting, isolating, separating, culturing, stimulating, packaging, and / or formulating cells. The methods generally allow for cell processing (e.g., selection or separation and / or transduction) on a large scale (e.g., in a composition with a volume of 50 or more than about 50 mL). One or more of the cell processing steps are generally performed in the internal cavity of a centrifuge chamber (e.g., a substantially rigid chamber) that is generally cylindrical in shape and can rotate around a rotation axis, which may provide certain advantages compared to other available methods. In some embodiments, all processing steps are performed in the same centrifuge chamber. In some embodiments, one or more processing steps are performed in different centrifuge chambers (eg, multiple centrifuge chambers of the same type).
[0134] The provided methods provide various advantages over available methods for cell processing (including transduction and selection), particularly available methods for large-scale cell processing. Certain available methods have not been entirely satisfactory, for example, due to suboptimal effectiveness, accuracy, reproducibility, cost and time consumption, risk of error, complexity, and the need for user handling and biosafety facilities. In some embodiments, the provided methods are suitable for large-scale and / or clinical-grade cell production, while still providing desirable attributes that are otherwise only available in small-scale production methods, and providing additional advantages not provided by available methods. For example, methods for cell transduction and / or affinity-based selection provide advantages over available methods that are carried out in flexible plastic bags or plastic multi-well plates.
[0135] In some embodiments, the centrifugation chamber and / or its internal cavity in which the cells are processed is at least partially surrounded or defined by a rigid or substantially rigid material. Incubation in a cavity bounded by such a material (e.g., hard plastic) allows for centrifugation under certain conditions (greater forces than can be used with bags used in other large-scale cell processing methods). For example, in some embodiments, the chambers and cavities withstand centrifugation at a force (e.g., relative centrifugal force) of at least or about 500 g, 1000 g, 1500 g, 2000 g, 2500 g, 3000 g, or 3200 g, e.g., as measured at an interior or exterior wall of the chamber or cavity or one or more cells (e.g., a layer of cells), without substantially denting, bending, breaking, or otherwise damaging the chamber or cavity holding the cells, such that the chamber and / or cavity substantially retains their shape under such forces.
[0136] Thus, the chamber and / or its internal cavity is typically surrounded by all or part of a rigid or semi-rigid sidewall (e.g., a hard plastic sidewall) that retains its shape under applied centrifugal force. The sidewall is generally curvilinear (e.g., cylindrical or generally cylindrical) and typically extends from one or two end walls of the chamber, the inner surface of one or both of which may also define the boundary of the internal cavity. The end walls may also be made of a rigid material in some embodiments, and may include a more flexible material in some embodiments. In some embodiments, although the wall is made of a rigid or substantially rigid material, it may nevertheless be lined and / or coated with a flexible material and / or contain a minor portion that is more flexible, so long as the cavity as a whole maintains its overall shape during the conditions of the method.
[0137] The centrifuge chamber is generally rotatable around a rotation axis, and the cavity is typically coaxial with the chamber. In some embodiments, the centrifuge chamber further comprises a movable member, such as a piston, which is generally capable of movement (e.g., axial movement) within the chamber, causing the volume of the cavity to vary. Thus, in certain embodiments, the internal cavity is bounded by the side and end walls of the chamber and the movable member, and has a variable volume that can be adjusted by moving the movable member. The movable member can be made of a rigid, substantially or nearly rigid, flexible material, or a combination thereof.
[0138] The chamber generally also includes one or more openings, such as one or more inlets, one or more outlets, and / or one or more ports, which can allow for the intake and pressure of liquid and / or gas into and out of the cavity. In some cases, the openings can be ports through which liquid and / or gas are both taken in and pressured out. In some cases, the inlets or inlets can be separate or different from the outlets or outlets. The opening or openings can be in one of the end walls. In some embodiments, liquid and / or gas can be taken into and / or pressured out of the cavity by movement of a movable member that increases and / or decreases the volume of the cavity. In other embodiments, liquid and / or gas can be taken into and / or pressured out of the cavity through piping lines or other channels that are connected or placed in connection with the openings, for example, by placing the lines or channels in connection and control with a pump, syringe, or other machine, which can be controlled in an automated manner.
[0139] In some embodiments, the chamber is part of a closed system (e.g., a sterile system) with various additional components (e.g., plumbing lines and connectors and caps) in which the processing steps are performed. Thus, in some embodiments, the provided methods and / or steps thereof are performed within a completely closed or semi-closed environment (e.g., a closed or semi-closed sterile system), facilitating production of cells for therapeutic administration to a subject without the need for a separate sterile environment (e.g., a biosafety cabinet or room). The methods in some embodiments are performed in an automated or partially automated manner.
[0140] In some embodiments, the chamber is associated with a centrifuge, which can cause the chamber to rotate (e.g., around the axis of rotation of the chamber). The rotation can occur before, during, and / or after incubation in one or more of the processing steps. Thus, in some embodiments, one or more of the various processing steps are performed under rotation (e.g., with a certain force). The chamber is typically capable of vertical or near-vertical rotation, so that during centrifugation, the chamber remains vertical, and the side walls and axis are vertical or near-vertical, and the end walls are horizontal or near-horizontal. One exemplary chamber is illustrated in the exemplary closed system illustrated in FIG. 5, FIG. 7, or FIG. 11.
[0141] The processing step of the method (e.g., steps performed in whole or in part in the chamber) may include any one or more of several cell processing steps, alone or in combination. In certain embodiments, the processing step includes transduction of cells with viral vector particles (e.g., encoding a recombinant product for expression in cells) containing retroviral vectors, and at least a portion of the incubation with the viral vector particles is performed in the chamber to initiate transduction. The method may further and / or alternatively include other processing steps, such as steps for isolating, separating, selecting, culturing (e.g., inducing cell proliferation and / or activation, e.g., stimulating cells), washing, suspending, diluting, concentrating, and / or formulating cells. In some embodiments, the method includes the following processing steps performed in the following order: first, isolating (e.g., selecting or separating) cells (e.g., primary cells) from a biological sample; stimulating the obtained isolated or selected cells in the presence of a stimulating reagent; incubating the stimulated cells with viral vector particles for transduction; and formulating the transduced cells into a composition. In some embodiments, stimulation is additionally or alternatively performed during at least a portion of the incubation with the viral vector particles. In some cases, stimulation is additionally or alternatively performed after incubation of the cells with the viral vector particles. In some cases, the method does not include a step of stimulating the cells. In some embodiments, the method may include one or more processing steps of washing, suspending, diluting, and / or concentrating the cells, which may be performed before, during, or simultaneously with one or more of the steps of isolating (e.g., separating or selecting), stimulating, transducing, and / or formulating. All or a portion of each of the processing steps may be performed in a closed system, such as in a centrifuge chamber.In aspects of the method, the processes need not be performed in the same closed system (e.g., in the same centrifuge chamber), but may be performed under different closed systems (e.g., in different centrifuge chambers); in some embodiments, such different centrifuge chambers are at respective locations in the method associated with the same system (e.g., associated with the same centrifuge). In some embodiments, all processing steps are performed in a closed system, in which all or part of each of one or more processing steps is performed in the same or different centrifuge chambers.
[0142] In some embodiments, the methods provide the ability to transduce cells with higher transduction efficiency compared to available methods, e.g., by performing all or part of the transduction at higher centrifugal forces / speeds and / or by allowing easy, automated, and / or independent control or adjustment of various parameters such as reagent volumes or amounts, speeds, and / or temperatures, etc. In some embodiments, the methods increase efficacy and / or reduce variability (improving reproducibility) by streamlining and / or reducing the number of user interaction and / or handling steps, e.g., by providing automated or semi-automated control of various steps.
[0143] In some embodiments, the provided methods allow for large-scale preparation of cells for clinical use without exposing the cells to non-sterile conditions and without the use of a separate sterile room or cabinet by performing one or more (e.g., all or a portion of all) of the processing steps in a closed system (e.g., a sterile closed system). In some embodiments, the cells are isolated, separated or selected, stimulated, transduced, washed, and formulated in a closed system, e.g., in an automated manner. In some embodiments, the methods are advantageous in that they are streamlined, e.g., require fewer steps, less user handling or intervention, e.g., by being performed in a single closed system and / or in an automated manner. For example, in some embodiments, the methods provide improvements over methods for processing cells for use in clinical applications that may require transduction in a bag or plate in a centrifuge, by mixing the viral vector particles and cells in the appropriate ratio in a biosafety cabinet, followed by transporting the plate or bag to a centrifuge for transduction or other processing steps, additional steps that may also require handling. In some embodiments, the methods provided are less manual and / or require less labor, and require a reduced degree or amount of handling and user interaction, as compared to such available methods.
[0144] In some embodiments, the method allows a greater degree of process control compared to available methods. For example, the method in some embodiments allows independent control of various parameters, for example in an automated manner. For example, the method can allow independent control of the volume, amount, and / or concentration of various components and reagents used in and processed with the method or various conditions used in one or more of the processes or methods. They generally allow control of the duration of one or more of the various steps of the method, and / or the ratio of cells in a particular incubation or composition, liquid volume, and / or surface area of the container used for processing, such as chamber or cavity. The ability to control such parameters independently, especially in an automated manner and independently of each other, can allow users to easily optimize and perform the method for individual conditions.
[0145] Also provided are systems, devices, and equipment for use with such methods, kits containing the same, and methods of using the compositions, and cells produced by the methods.For example, provided are methods of treatment, and the use of the cells and compositions produced by the methods in treatment (e.g., adoptive cell therapy).Also provided are pharmaceutical compositions and formulations for use in such treatments.
[0146] II. Centrifugal chambers and related systems and devices In some embodiments, all or part of one or more of the processing steps, e.g., incubation with virus to initiate or effect transduction, and / or incubation with beads for immunoaffinity-based separation, and / or one or more other processing steps described, are performed in a centrifuge chamber. In particular, such steps and incubations are generally performed within the internal cavity of such a chamber, which may be the same or different centrifuge chambers for each of the one or more processes.
[0147] The centrifuge chamber can generally be rotated, for example, by a centrifuge that can be associated with the chamber during incubation. In some embodiments, the centrifuge chamber can rotate around a rotation axis (e.g., a vertical or approximately vertical or substantially vertical rotation axis). In some embodiments, the centrifuge chamber includes an end wall and a side wall, at least a portion of which surrounds or encircles the internal cavity of the chamber. The centrifuge chamber also generally includes another end wall from which the side wall extends in the opposite direction.
[0148] The interior cavity is generally bounded on its exterior by the interior surfaces of all or a portion of the end wall, all or a portion of the side wall, and all or a portion of the other end wall of the chamber, or by another surface or object (e.g., a movable member (e.g., a piston) within the chamber). In some aspects, the cavity is hollow. In other aspects, a solid or hollow object, such as a tube or channel, is contained within a portion of the interior space of the cavity.
[0149] In some aspects, the cavity is volume-variable, meaning that the total available volume in the cavity that can be occupied, for example, by liquid or gas, can vary, for example, by movement of a movable member (e.g., a piston). In some embodiments, such movement is possible during various stages of the method, such as during incubation or selection that initiates or results in transduction, or subsequent and / or preceding stages. Movement in some embodiments can be performed in an automated manner, such as by the execution of a pre-specified program by the machine and circuitry associated with the chamber, such as sensors and motors that detect and control the position of the movable member and other aspects of the process, and circuitry for communicating between the sensor and one or more components.
[0150] The sidewall of the chamber or a portion thereof (and thus the shape of the cavity) that surrounds the internal cavity of the chamber is typically curved, e.g., cylindrical, substantially cylindrical, or generally cylindrical. The term cylindrical is generally understood by those skilled in the art to refer to a particular type of curved surface formed by a number of points at fixed distances from a given line segment that is considered the axis of the cylindrical shape. "Generally cylindrical" refers to a shape or surface that has a configuration that is roughly cylindrical in shape or structure, such as one that appears cylindrical or is approximately cylindrical to the eye, but allows for some variability. For example, the term encompasses shapes and surfaces that do not have all their points at the same distance from the axis, and allows for some degree of contouring and / or tapering, as long as the shape or surface appears cylindrical and / or has a predominantly cylindrical shape. It also encompasses configurations in which a majority of the outer wall of the centrifuge chamber is cylindrical or substantially cylindrical in shape, while a smaller portion thereof takes another configuration, such as when one or more ends of the wall are tapered or contoured or approaching therein, etc. In some embodiments, a portion of the side wall of the chamber surrounding the cavity may be cylindrical, while other portions of the wall are not.
[0151] In some embodiments, all or a portion of the chamber and / or cavity is rigid or substantially rigid. For example, all or a portion of the sidewall is rigid or substantially rigid, e.g., the chamber and cavity can be moved, e.g., at high speeds, e.g., at the inner surface of the sidewall of the cavity and / or at the surface layer of cells, at greater than or about 200g, greater than or about 300g, or greater than or about 500g, e.g., greater than or about 600g, greater than or about 800g, greater than or about 1100g, greater than or about 1000g, greater than or about 1500g, greater than or about 1600g, greater than or about 2000g, greater than or about 2 ... or greater than about 600 g, 800 g, 1000 g, 1100 g, 1500 g, 1600 g, or greater than about 600 g. g or about 1600 g, 2000 g or about 2000 g, 2200 g or about 2200 g, 2500 g or about 2500 g, 3000 g or about 3000 g, or 3200 g or about 3200 g, for example, 2100 g or about 2100 g, or 2200 g or about 2200 g (relative centrifugal force (RCF)).In some embodiments, the RCF at the interior surface of the sidewall of the cavity and / or the surface layer of the cells is greater than or about 1100g or is greater than or about 1100g, greater than or about 1200g or is greater than or about 1200g, greater than or about 1400g or is greater than or about 1400g, greater than or about 1600g or is greater than or about 1600g, greater than or about 1800g or is greater than or about 1800g, greater than or about 2000g or is greater than or about 2000g, greater than or about 2200g or is greater than or about 2200g. In contrast, available methods for processing cells on a large scale, for example in volumes of more than 50 mL or more than 100 mL, using flexible bags may only allow centrifugation at relative centrifugal forces of at most 200 g, 500 g, or 1000 g. Thus, the provided methods may provide greater efficiency compared to such methods.
[0152] The term "relative centrifugal force" or RCF is generally understood to be the effective force imparted to an object or substance (such as a cell, sample, or pellet, and / or a point within a rotating chamber or other container) relative to the Earth's gravity at a particular point in space relative to the axis of rotation. Its value can be determined using well-known formulas that take into account gravity, the speed of rotation, and the radius of rotation (the distance from the axis of rotation of the object, substance, or particle for which the RCF is being measured).
[0153] The object, particle, or location (or average value thereof) at which the RCF in a given case is expressed or determined may be specified. For example, the RCF value or approximate value or range in some contexts herein is given for a particular part or location in the centrifuge chamber used in such a method, for example, at any point or average radial distance along the inner surface of the sidewall of the cavity of the chamber in which the cells are processed, for example, the surface of the cylindrical sidewall of the cavity. Similarly, the RCF value may be given for a radial distance or average radial distance relative to the axis of rotation in another container (e.g., bag) in which the cells are processed. In other embodiments, the RCF is given for the location of the sample or composition as a whole during rotation, or for one or more specific cells or averages or layers thereof. For example, the value may be the RCF of a surface layer of cells in the chamber or other container during rotation, such as at the cell surface at the interface between the liquid in which the cells are spinning and the cells themselves.
[0154] Generally, RCF is calculated using the formula 1.119 × 10 -5 (rpm) 2 r (or 1.12×10-5×(rpm)2 *The RCF is calculated by: r = radius (i.e., the distance (cm) from the axis of rotation to a given particle, object, or substance); rpm = rotational motion per minute. For example, in some embodiments, the RCF at the inner surface of the sidewall of the inner processing cavity where cells are processed can be calculated using this formula, where r is the distance between a point on the inner surface of the sidewall and the axis of rotation. Alternatively, the RCF at the cell or surface layer of the cell (e.g., the interface between the rotating cell layer and the liquid) can be calculated using the formula, where r is the distance between the cell, surface layer, and / or interface, or an average value thereof. For example, in some embodiments, the radius (r) value for the RCF of the sidewall can be based on the maximum and minimum possible radius or the average of all possible radii along the length of the sidewall of the chamber. In some embodiments, the radius of an exemplary centrifuge chamber sold by Biosafe AG for use with the Sepax® system (e.g., A-200 / F) is 2.6 cm or about 2.6 cm, or 2.7 cm or about 2.7 cm. In such exemplary chambers, the radius for determining the RCF at the interface between the cell layer and the liquid during rotation in such chambers can be calculated by adding the exact or approximate radial distance between the inner sidewall of the cavity and the chamber occupied by the cells of the layer during rotation. Such a value can be calculated or estimated using known methods, for example, based on the diameter of one of the cells being processed, for example, and / or the average diameter among such cells during rotation of the chamber. Such a value can be based on the actual size of the cells, but typically takes into account the effect of the rotation or force itself on the relative volume occupied by each cell, generally speaking, such volume is reduced by the rotation or force. In some examples, the size (or average) of the nuclei of the cells is used to determine an approximation.
[0155] Thus, the RCF or average RCF during a particular spin in a particular chamber or device can be calculated for a given point or area based on the revolutions per minute (rpm) and the distance between the point and the axis of rotation using known methods. The revolutions per minute (rpm) can be determined for various devices and chambers using known methods, for example, using a tachometer suitable for the particular device, system, or chamber. For example, in some embodiments, in the case of a centrifuge, system, or device that has a window from the environment to the chamber or cavity (e.g., Sepax®) that is transparent or otherwise allows the passage of light between the tachometer and the chamber, a handheld phototachometer or laser tachometer can be used, for example, in combination with a reflective tape. For opaque systems, other tachometers can be used, such as a vibrating plate tachometer.
[0156] As will be understood by those skilled in the art, when used in the context of various containers, such as chambers, plates, tubes, and bags, and their materials used in cell processing and centrifugation, rigidity generally describes an object, part thereof, or material that substantially retains its shape and / or volume when placed in an environment, such as under some force, temperature, or other conditions that are normally expected to exist during the course of using the object.For example, rigid centrifuge chambers and tubes, such as those made from hard plastics, can be distinguished from flexible containers, such as cell processing and cell culture bags, such as bags made from soft plastics and rubbers, such as fluoroethylene propylene and similar materials, that change shape when pressure is applied by hand or by drawing in liquid or gas to expand the bag. Thus, in some embodiments, rigid materials include hard plastics, metals, carbon fiber, composites, ceramics, and glass, and / or are distinguished from flexible materials such as soft rubbers, silicones, and plastics used in making flexible bags, whose shape and volume are easily changed by normal pressure, such as hand pressure, or filling of the container with liquid at ambient temperature or under normal conditions.
[0157] For example, in some embodiments, a rigid centrifuge chamber and / or a part or material thereof, such as a rigid sidewall or a part thereof surrounding a central cavity, can retain its shape and / or volume under certain conditions and / or not burst or break so as to no longer contain liquid or gas. In some embodiments, such conditions include hand pressure, such as pressure that can be applied by a human hand. In some embodiments, such conditions include a specified centrifugal force, such as a force (RCF) at the inner surface of the sidewall of the cavity, such as an effective force, greater than or about 200g, greater than or about 300g, or greater than or about 500g, such as greater than or about 1000g, greater than or about 1500g, greater than or about 2000g, greater than or about 2500g, greater than or about 30 ... or at least about 1000g, at least about 1500g, at least about 2000g, at least about 2500g, at least about 3000g, or at least about 3200g, such as at least about 2100g or at least about 2100g. In some embodiments, the environment includes a particular condition, such as a temperature as low as at or about -80°C and / or up to a physiological temperature, or a temperature at which the cells remain viable, and / or a temperature between 18°C and 42°C, such as between 22°C and 39°C, or higher, such as at least 25°C±2°C or 37°C±2°C.
[0158] As is understood in the art, describing a substance as being rigid or substantially rigid does not exclude the possibility that any change in shape or volume of the substance or material may occur over time, e.g., under excessive or unexpected forces, e.g., under extreme forces or environmental conditions, such as those well outside those normally used in connection with the transduction methods described herein.
[0159] A chamber generally includes at least one opening, such as an inlet, an outlet, and / or a port, that allows a substance to pass between the cavity or other portion of the chamber and another space. For example, such an opening is generally included in at least one of the walls of the chamber. A chamber generally includes at least one inlet and at least one outlet, which in some embodiments may be the same opening (port), through which liquid and / or gas can be introduced into the cavity and pressed out of the cavity. The opening is generally associated with another environment via a channel (e.g., a piping line or a system of piping lines), in some embodiments, for example, via one or more connectors.
[0160] In some embodiments, the chamber is included as part of and / or integrated into a system (e.g., a closed or partially closed system) that further includes additional components (e.g., plumbing lines, connectors, and containers). In some embodiments, the chamber is pre-connected directly and / or indirectly to one or more of the additional components. Such a chamber may be provided as part of a pre-assembled kit (e.g., a kit packaged for a single sterile use in connection with the provided methods). In some embodiments, the various components are packaged separately, for example, to allow custom configurations where the user connects and arranges the components for a particular embodiment of the processing method.
[0161] The components typically include at least one piping line, and generally a set or system of piping lines, and at least one connector. Exemplary connectors include valves, ports, spikes, welds, seals, and hose clamps. The connectors and / or other components may be sterile, for example, to allow the entire process to be performed in a closed, sterile system, which may eliminate or reduce the need for clean rooms, sterile cabinets, and / or laminar flow systems.
[0162] In some embodiments, the at least one tubing line includes a series of tubing lines. The tubing can be made of plastic, such as polycarbonate, and can be of various sizes and / or volumes, and can generally be designed to allow the desired liquid / gas flow at an appropriate speed, as well as connection with the chamber and / or other components. The series of tubing lines generally allows the flow of liquid and gas between the chamber and / or one or more components of the system (e.g., other containers), which in some aspects is facilitated by connectors. In some embodiments, the system includes tubing lines connecting each of the various components to at least one other component, allowing liquid to flow between each container (e.g., bag) and the chamber, which can be enabled or disabled by the configuration of various connectors, such as valves and / or clamps.
[0163] In some aspects, the connectors may be arranged or intended for different configurations, each of which may block, allow, and / or direct the flow of fluids and gases (through various components, e.g., between various containers and through certain piping lines connecting various components), e.g., rotary and gated valves. In other embodiments, certain connectors and / or other components have a single configuration that allows, directs, or blocks the passage of liquids or gases, such as a seal, cap, and / or open port or channel. Various components in the system may include valves, ports, seals, and clamps. Valves may include rotary valves, e.g., stop cocks, rotary valves, and gated valves. Valves may be arranged in a manifold array or as a single multi-port rotary valve. Ports may include luer ports or spike ports. Seals may include O-rings, gaskets, adhesive seals, and couplings. Clamps may include pinch clamps.
[0164] Other components of the system include containers that can hold or store liquids and / or gases. Containers can include bags, vials, boxes, syringes, bulbs, tanks, bottles, beakers, buckets, flasks, and plumbing lines. Such components can hold compositions used in and produced by the methods, including by-products and intermediate products and waste liquids. Such compositions can include liquids, including buffers, growth media, transduction media, water, diluents, washes, and / or saline, and can also include cells, viruses, and / or other agents for use in processing steps, such as transduction. Containers can also include waste containers and containers that hold one or more output products, such as products containing cells selected and / or transduced by one or more processing steps of the methods herein.
[0165] In some embodiments of the system, multiple containers can be aseptically connected to one or more locations of the plumbing lines of the system. The containers can be connected simultaneously and / or sequentially during the cell processing method in the provided embodiments. In some embodiments, the containers can be disconnected or removed from the connectors, so that the containers can be removed from the system and / or replaced with another container at the same location for use with the system. In some embodiments, not all connector locations of the system are connected to containers, so that the system can contain empty connectors. In some such embodiments, the closed system is maintained by the operation of one or more stopcocks, valves, or clamps, either manually or automatically, to close the communication between the plumbing lines and the empty connectors (e.g., ports). In some embodiments, the closed system is maintained by sealing or disconnecting the empty connectors (e.g., ports).
[0166] In some embodiments of the system, such as the exemplary systems illustrated in FIG. 5, FIG. 7, or FIG. 11, containers may be operatively connected to plumbing lines, e.g., through connectors, at locations corresponding to an input bag location, a diluent bag 1 location, a diluent bag 2 location, a waste bag location, and / or an output bag location. With respect to the figures, the designations of these locations are merely for illustrative purposes and are not intended to limit the particular types of containers or container contents that may be connected to a location. Also, in embodiments of the methods provided, not all locations of the system, such as those illustrated in the figures, need be utilized in performing the processing steps of the methods provided. In some such embodiments, plumbing lines that make available empty connectors (e.g., ports) may be released or closed by operation of a stop cock or valve. In some embodiments, the empty connectors may be sealed or removed.
[0167] In some embodiments, the system (e.g., a closed system) is a sterile system. In some embodiments, all connections of the components of the system (e.g., connections between tubing lines and containers via connectors) are made under sterile conditions. In some embodiments, the connections are made under laminar flow. In some embodiments, the connections are made using a sterile connection device that creates a sterile connection (e.g., sterile welding) between the tubing and container. In some embodiments, the sterile connection device provides the connection under thermal conditions (e.g., a temperature of at least 200°C, e.g., at least 260°C or 300°C) that are high enough to maintain sterility.
[0168] In some embodiments, the system can be disposable, for example, a single-use kit.In some embodiments, the single-use kit can be used in multiple cycles of one or more processes, for example, at least 2, 3, 4, 5 or more times, for example, in a process that is carried out in a continuous or semi-continuous manner.In some embodiments, the system, such as a single-use kit, is employed in the processing of cells from a single patient.
[0169] Exemplary centrifuge chambers include those produced and sold by Biosafe SA, including those for use with the Sepax® and Sepax® 2 systems, including the A-200 / F and A-200 centrifuge chambers, as well as various kits for use with such systems. Exemplary chambers, systems, and processing instruments and cabinets are described, for example, in U.S. Patent No. 6,123,655, U.S. Patent No. 6,733,433, and published U.S. Patent Application Publication No. US 2008 / 0171951, and published International Patent Application Publication No. WO 00 / 38762, the contents of each of which are incorporated herein by reference in their entirety. Depending on the particular process (e.g., dilution, washing, transduction, formulation), it is within the level of ordinary skill in the art to select a particular kit that is appropriate for the process. Exemplary kits for use with such systems include, but are not limited to, single-use kits sold by BioSafe SA under the product names CS-430.1, CS-490.1, CS-600.1, or CS-900.2.
[0170] In some embodiments, the system includes a series of containers (e.g., bags), tubing, stop cocks, clamps, connectors, and centrifuge chambers. In some embodiments, the containers (e.g., bags) include one or more containers (e.g., bags) that contain the cells to be transduced and the viral vector particles in the same or separate containers (e.g., the same or separate bags). In some embodiments, the system further includes one or more containers (e.g., bags) that contain media (e.g., diluents and / or wash solutions) that are drawn into the chambers and / or other components to dilute, resuspend, and / or wash components and / or compositions during the method. The containers can be connected at one or more locations within the system, e.g., locations that correspond to input lines, diluent lines, wash lines, waste lines, and / or output lines.
[0171] Exemplary systems for use in embodiments of the provided methods for performing one or more or all parts of the process are illustrated in Figures 5, 7, and 11. In one exemplary embodiment illustrated in Figure 5, the centrifuge chamber (1) is at least generally cylindrical and rotatable about an axis of rotation. The chamber includes an end wall (13) and a rigid side wall (14), and a movable member (2) that is a piston. The inner surface of the end wall (13), the rigid side wall (14), and the piston (2) collectively define the boundary of an internal cavity (7) of the chamber. The cavity (7) is of variable volume and is coaxial with the chamber, and is designed to contain the liquid and / or gas contained within the chamber during a processing step. The piston (2) is axially movable within the chamber (1) to vary the volume of the internal cavity (7). The chamber further includes an inlet / outlet opening (6) that allows for the flow of liquids and gases into and out of the cavity in at least some configurations of the system. The opening (6) is operatively connected to a series of tubing lines (3) and connectors, including stopcock valves (4), that can control the movement of fluids and / or gases between various components of the system. The series of tubing lines (3) are further connected to various additional containers, including bags labeled input bag, diluent bags 1 and 2, waste bag, and output bag in the illustrated configuration. Clamps (5) can be opened and closed to allow and block the movement of fluids through the indicated portions of the series of tubing lines (3), allowing flow between various components of the system. In some embodiments, each container is operatively connected to the tubing lines via a port, such as a luer port or spike port. By way of example, with respect to FIG. 5, at each point where a container is shown, in some aspects the container is indirectly connected via a port.
[0172] Although Figure 5 shows the connection of a container at each position or line, in alternative embodiments, in some aspects, a container is not connected at each position or line of the system. In some embodiments of the system provided, a port can be used for connection at each position or line, and a container is connected to all positions or lines, or less than all positions or lines. In some embodiments, not all connector positions of the system are connected to a container, so the system can contain empty connectors at each position or line.
[0173] In some embodiments, a system such as that shown in FIG. 5 may include a sterile or microbial filter. An exemplary such system is shown in FIG. 7, which illustrates a filter (15). In some embodiments, the filter includes a filtration membrane having a pore size that blocks the passage of microorganisms such as bacteria or viruses. In some embodiments, the pore size is between 0.1 μm and 0.45 μm, such as between 0.1 μm and 0.22 μm, such as about 0.20 or 0.20 μm. In some embodiments, the membrane is composed of nitrocellulose (cellulose nitrate), cellulose acetate, regenerated cellulose, polyamide, polytetrafluoroethylene (PTFE), or polyethersulfone (PES). In some embodiments, the filter includes a cap (16) that closes or seals the membrane of the filter from exposure to the environment outside the closed system. In some embodiments, the cap is closed or unvented. In some embodiments, the cap is removable. In some embodiments, the cap is fitted to the filter by a luer lock fitting. As described in more detail below, in some embodiments, filters may be used to effect the passage of gas (e.g., air) into and out of the chambers of the system, and in some such embodiments, the passage of air is maintained under sterile or microbial-free conditions.
[0174] In one embodiment, the input bag contains cells for processing by the provided method, such as transduction. In one embodiment, the diluent bag 1 contains viral vector particles containing the vector used to transduce the cells. Thus, in some embodiments, an input composition containing viral vector particles and cells is generated by taking fluid from the input bag and taking fluid from the diluent bag 1. In some embodiments, the diluent bag 2 contains a wash solution. The output bag is generally designed to take cells after one or more processing steps, for example by transferring the output composition from the cavity of the chamber to the output bag after incubation with viral vector particles. Thus, in some embodiments, the output bag contains transferred cells that have been transduced with viral vector particles and / or in which transduction by viral vector particles has been initiated. In some embodiments, the processing includes transduction of cells by viral vectors.
[0175] In some embodiments, a multi-way manifold (17) can be used to operatively connect one or more vessels to the system via multiple ports (18) connected to the manifold of piping lines. The multi-way manifold can contain a series of piping lines feeding into the inlets and outlets of the chambers to allow flow between the chambers and the connected vessel or vessels. In some such embodiments, the manifold connects multiple vessels (e.g., at least 2, 3, 4, 5, 6, 7, 8, or more vessels) at the same location or line on the system. In some embodiments, all ports of the multi-way manifold (17) are connected to vessels (e.g., bags). In some embodiments, less than all ports of the multi-way manifold (17) are connected to vessels (e.g., bags), such that vessels are connected at fewer than the total number of port locations, e.g., less than 8, 7, 6, 5, 4, 3, or 2 vessels (e.g., bags). In some embodiments, the plumbing lines associated with the manifold may contain clamps or stop cocks that can be opened or closed to control movement through the lines into the vessels as needed. The multi-way manifold (17) may be connected to any of the available locations or lines on the system, for example, locations or lines designated for input lines, diluent lines, wash lines, waste lines, and / or output lines.
[0176] In some embodiments, an exemplary multi-way manifold (17) for coupling one or more containers is shown in FIG. 11 for connecting one or more containers (e.g., one or more bags, e.g., one or more output bags). As shown, in some embodiments, the multi-way manifold (17) can be connected to one output location or line, which includes a series of manifold piping lines, each terminating in a connector (e.g., port (18)) for functional connection to a container (e.g., bag). One or more of the ports (e.g., all or less than all of the ports) can be connected to a container. In one embodiment illustrated in FIG. 11, up to three containers can be connected to each piping line of the manifold via ports. In other embodiments, up to 1, 2, 3, 4, 5, 6, 7, or 8 containers (e.g., output bags) can be connected in the output line. In some embodiments, one or more clamps (5) associated with a piping line, such as a manifold piping line, can be opened or closed to allow or control the movement of liquid to one or more of a plurality of output bags. In some embodiments, a single clamp may control the movement of liquid into all of the output bags simultaneously. In some embodiments, the movement of liquid into each of the multiple bags may be separately regulated by a clamp operatively connected to a tubing line associated with only one respective container, such that the movement of liquid into each container may be made separate from the movement of liquid into all other containers. In some embodiments, the movement of liquid into each container (e.g., each bag, e.g., each output bag) may be made sequential.
[0177] In some embodiments, the system is included in and / or associated with other equipment, including equipment that operates, automates, controls, and / or monitors aspects of the various processing steps performed within the system, which in some embodiments are contained within a cabinet.
[0178] In some embodiments, the apparatus includes a cabinet including a housing containing control circuitry, a centrifuge, a cover, a motor, a pump, a sensor, a display, and a user interface. Exemplary devices are described in U.S. Patent No. 6,123,655, U.S. Patent No. 6,733,433, and US 2008 / 0171951.
[0179] The control circuitry in some aspects monitors and communicates information and instructions to and from various components of the other instruments and systems. In some embodiments, the cabinet contains a user interface device including a display and an input device (e.g., keyboard, mouse, or touch screen). The user interface presents information from the control circuitry and allows the user to stop and start processes or steps, such as performing a transduction protocol. The interface may also prompt the user to input settings for variables used by the control circuitry during processing steps, such as a transduction protocol. Such variables may include volumes of various solutions added to and / or removed from various containers and / or chamber cavities, times / durations of centrifugation, centrifugation, stirring, mixing, and / or other processing steps, rotational forces, piston movements, and / or program selections.
[0180] The device generally further comprises a centrifuge in which the centrifuge chamber is placed to effect rotation of the chamber. In some embodiments, the centrifuge chamber is coupled to a rotation drive unit of the centrifuge device, which allows the chamber to rotate around a rotation axis. In some embodiments, a cover closes at the top of the centrifuge chamber and holds the chamber in place. In some embodiments, the cover includes two semicircular disks that can rotate on a hinge. Exemplary centrifuges and covers are described in U.S. Patent No. 6,123,655 or U.S. Patent No. 6,733,433. The centrifuge locks the centrifuge chamber in place and rotates the centrifuge chamber by contact with the side or end of the chamber.
[0181] In some embodiments, a sensor or array of sensors in the centrifuge can measure the rotation speed of the centrifuge chamber, the position of the movable member, or the volume contained in the internal cavity. Sensors on the outside of the centrifuge can detect the color and flow rate of the liquid and gas flowing to and from the centrifuge chamber. The sensor can also detect an empty tubing or centrifuge chamber. Sensors include optical sensors, such as those described in U.S. Pat. No. 6,123,655, U.S. Pat. No. 6,733,433, and US 2008 / 0171951. In some embodiments, information from one or more sensors can be received by a control circuit. Based on the transmitted information, the control circuit can, in some embodiments, effect changes in one or more of the following: the rotation speed of the centrifuge chamber, the position of the movable member, the volume contained in the cavity, the orientation of one or more valves, ports, seals, or clamps, and other processes of the centrifuge, chamber, or system.
[0182] In some embodiments, the cabinet contains a motor or an array of motors. The motors can communicate information to control circuitry that can operate or regulate the motors.
[0183] In some embodiments, a motor or an array of motors can rotate a centrifuge chamber within the centrifuge. The control circuitry can start, stop, or adjust the speed of the motor that rotates the centrifuge chamber within the centrifuge.
[0184] In some embodiments, a motor or an array of motors can move a movable member within the centrifuge chamber, the movement of the movable member varying the volume of the internal cavity and causing the intake or expulsion of liquid or gas into or out of the internal cavity.
[0185] In some embodiments, a motor or an array of motors can operate the valves, ports, seals, and clamps described herein. Control circuitry can cause the motors to open or close a vessel or centrifuge chamber, or direct fluid through a series of tubing from a vessel to a centrifuge chamber or from a centrifuge chamber to a vessel.
[0186] In some embodiments, the one or more motors are electric motors, pneumatic motors, or hydraulic motors. In some embodiments, the cabinet includes an electric motor for operating some aspects and a pneumatic motor for operating other aspects. In some embodiments, the cabinet includes an electric motor for centrifugation and a pneumatic motor for controlling the movement of the movable member.
[0187] III. Introduction of viral nucleic acid into cells, e.g., by transduction In some embodiments, the processing step of the method includes for the introduction of a viral particle into a cell, such as a viral vector that encodes a recombinant product that is expressed in the cell. A viral vector particle generally includes a genome that contains a recombinant nucleic acid, such as a transgene, that encodes such a product. In some embodiments, the viral vector particle encodes a recombinant receptor, such as a chimeric antigen receptor (CAR), whereby transduction of the cell can generate a cell that expresses the recombinant receptor (e.g., CAR). Introduction of nucleic acid from a viral vector into a cell can use any of a number of known methods. The introduction is typically by transduction. Alternative methods for introducing a viral vector into a cell include transposons and / or electroporation. Such processing steps can be performed in a centrifuge chamber according to embodiments of the provided method. In some embodiments, the centrifuge chamber is incorporated into a closed system, and such processing steps are performed in the closed system.
[0188] The introduction is generally carried out by transduction. Methods for viral introduction (e.g., transduction) generally involve at least initiating the transduction by incubating an input composition comprising cells to be transduced and viral vector particles containing the vector in a centrifuge chamber under conditions in which the cells are transduced or in which transduction is initiated in at least a portion of the cells in the input composition, and the method produces an output composition comprising the transduced cells.
[0189] In some embodiments, the cells for transduction and / or the transduced cells contain immune cells, such as T cells, for use in adoptive immunotherapy. In some embodiments, the cells for transduction are obtained by a method that includes an isolation step, such as selecting a specific subset of cells present in a biological sample, before incubation of the cells with viral vector particles. Methods related to the isolation and selection of cells for transduction, and the resulting cells, are described below. In some embodiments, the T cells are activated before the start of the process for transduction, such as by culturing and stimulating as described below. In some embodiments, one or more of all or part of the steps related to isolation (e.g., selection) and activation can also be performed in the cavity of the centrifuge chamber according to the embodiments provided below.
[0190] In some embodiments, the viral vector particle used in the transduction method aspect is any suitable for transducing cells (e.g., immune cells, e.g., T cells). In some embodiments, the viral vector particle is a retroviral vector particle, such as a lentiviral vector particle or a gamma retroviral vector particle. In some such embodiments, the viral vector particle contains a recombinant nucleic acid, i.e., a genome that comprises a recombinant viral vector. Exemplary such viral vector particles are described below.
[0191] The input composition (the composition containing the viral vector particles and cells during the transduction step) may further include one or more additional agents, such as those that promote transduction efficiency, such as polycations, including protamine (e.g., protamine sulfate), hexadimethrine bromide (POLYBRENE®, Abbott Laboratories Corp), and CH-296 (RETRONECTIN®, Clontech). In some embodiments, the polycation may be present in the input composition at a final concentration of 1 μg / mL to 100 μg / mL, such as 5 μg / mL to 50 μg / mL. The composition may also include media, including cell culture media, including media designed for culture of the cell type to be processed, such as hematopoietic stem cell media, e.g., serum-free media.
[0192] In the provided methods, all or part of the processing steps for transduction of cells can be performed in a centrifuge chamber, e.g., under centrifugation or rotation. In some such embodiments, an input composition containing cells and viral vector particles is provided or introduced into the inner cavity of the centrifuge chamber. In some embodiments, the input composition is incubated under conditions that include rotation of the centrifuge chamber. In some embodiments, the rotation can be performed at a relative centrifugal force greater than can be achieved using a flexible plastic bag or a plastic multi-well plate.
[0193] Greater transduction efficiency is achieved in some embodiments, in part, by the ability of the method to perform transduction at higher relative centrifugal forces (RCF) compared to other methods for processing cells on a large scale. For example, certain available methods for processing cells on a large scale, e.g., above 50 or 100 mL volumes, using flexible bags, may only allow centrifugation at a maximum relative centrifugal force of 200, 500, or 1000 g. At greater accelerations or relative forces, for example, at or about 1000 g or at least 1000 g, at or about 1000 g, at or about 1500 g or at least 1500 g, at or about 1500 g or at least 1500 g, at or about 2000 g or at least 2000 g, at or about 2100 g or at or about 2100 g, at or about 2200 g or at or about 2200 g, at or about 2500 g or at least By allowing centrifugation at or about 2500g, 3000g or at least about 2500g, 3000g or at least about 3000g, 3200g or at least about 3200g, or 3600g or at least about 3600g, the provided methods may improve or allow for co-centrifugation of virus and cells in the composition during transduction, improving the rate of virus and cell interaction, thereby improving transduction.
[0194] The method generally allows for large-scale transduction, and therefore the input composition and / or the output composition incubated during transduction may contain at least a certain volume and / or number of cells. In some embodiments, the liquid volume of the input composition, or the liquid volume during at least one point during incubation, is at least or greater than about 10 mL, at least or greater than about 20 mL, at least or greater than about 30 mL, at least or greater than about 40 mL, at least or greater than about 50 mL, at least or greater than about 100 mL, at least or greater than about 150 mL, at least or greater than about 200 mL, at least or greater than about 250 mL, at least or greater than about 300 mL, at least or greater than about 350 mL, at least or greater than about 400 mL, at least or greater than about 450 mL, or at least or greater than about 500 mL. In some embodiments, the input composition, the transduced composition, and / or the total cells transduced by the method are at least 1×10 5 or at least about 1×10 5 Pieces, at least 1 × 10 6 or at least about 1×10 6 Pieces, at least 1 × 10 7 or at least about 1×10 7 Pieces, at least 1 × 10 8 or at least about 1×10 8 Pieces, at least 1 × 10 9 or at least about 1×10 9 pieces, or at least 1×10 10 or at least about 1×10 10 In some embodiments, for at least a portion of the incubation, the vessel in which the cells are transduced, e.g., the centrifuge chamber or cavity thereof, contains at least 1×10 cells. 5 or at least about 1×105 Pieces, at least 1 × 10 6 or at least about 1×10 6 Pieces, at least 1 × 10 7 or at least about 1×10 7 Pieces, at least 1 × 10 8 or at least about 1×10 8 Pieces, at least 1 × 10 9 or at least about 1×10 9 pieces, or at least 1×10 10 or at least about 1×10 10 Such numbers and volumes may also apply to other processing steps that take place within the system, e.g., within the cavity of a chamber, such as cell separation and / or washing steps.
[0195] In some embodiments, when describing various processing steps in the cavity of the centrifuge chamber, including the process for transduction (e.g., preparation of input composition), or other processes described in subsequent sections, any reference to volume is a target volume. In some embodiments, the exact volume utilized in various steps (e.g., washing, dilution, or formulation) may vary from the desired target volume in some aspects due to dead volumes in the tubing lines, priming of the lines, sensor sensitivity, user control, and other factors related to maintaining or monitoring the volume. The method may allow for precise control of the volume in some aspects, for example, by including a sensor as part of the circuitry associated with the system. In some embodiments, the volume varies by at most 10%, e.g., at most 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the desired target volume. In some embodiments, the volume is within 2 mL or 3 mL of the target volume and / or varies by at most 2 mL or 3 mL of the target volume.
[0196] In some embodiments, the processing step is carried out by mixing cells and viral vector particles to produce an input composition. In an aspect of the method, the composition of cells and viral vector particles is prepared in such a way that the resulting mixed input composition has a low ratio of total liquid volume to the internal surface area of the cavity of the centrifuge chamber. In some embodiments, the total liquid volume is sufficient to cover or just exceed the mass of cells that exists as a monolayer on the internal surface of the cavity after rotation of the centrifuge chamber, while the thickness of the liquid covering the cells is minimized. In some embodiments, by reducing the thickness of the liquid, the centrifugation time required to contact the viral vector particles with the cells can be shortened, because the viral vector particles travel less distance and / or are less subject to resistance from the viscous medium.
[0197] In some aspects, advantages such as improved transduction efficiency are due, at least in part, to the ability to use a relatively lower volume of liquid per volume of cells, cell number, or cell pellet size during the transduction process (e.g., during spinning), as compared to other methods, particularly for large-scale production.
[0198] In some embodiments, the liquid volume of the input composition (containing the cells and viral vector particles) present in the vessel (e.g., cavity) during rotation is at most about 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 milliliters (mL) per square inch of the internal surface area of the cavity or the maximum internal surface area of the cavity during rotation.
[0199] In certain embodiments, the average liquid volume of the input composition present in the vessel (e.g., cavity) in which transduction is initiated, such as the average liquid volume of all processes performed in a cycle of the method, is at most about 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 milliliters (mL) per square inch of the internal surface area of the cavity or the maximum internal surface area of the cavity during incubation. In some embodiments, the maximum liquid volume of the input composition (containing cells and viral vector particles) present in the vessel (e.g., cavity) in which transduction is initiated, such as the maximum liquid volume of all processes performed in a cycle of the method, is at most about 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 milliliters (mL) per square inch of the internal surface area of the cavity of the centrifuge chamber. In some embodiments, the liquid volume (e.g., liquid volume of the input composition) present in the container (e.g., cavity) during rotation is at most 50%, e.g., at most 40%, at most 30%, at most 20%, or at most 10% of the internal surface area of the cavity during rotation or the maximum internal surface area of the cavity. In some embodiments, the remainder of the volume can be gas (e.g., air).
[0200] In some embodiments, the total liquid volume of the input composition (containing cells and viral vector particles) in the centrifuge chamber during incubation (e.g., spinning) is at least 5 mL or at least 10 mL, but at most 220 mL, e.g., at most 200 mL. In some embodiments, the liquid volume of the input composition during incubation (e.g., spinning) is at most 100 mL, 90 mL, 80 mL, 70 mL, 60 mL, 50 mL, 40 mL, 30 mL, or 20 mL. In aspects of the provided methods, the input composition is prepared in a total volume to achieve a desired concentration, amount, and / or ratio of cells and viral vector particles, such as those described below.
[0201] In some embodiments, the method allows the user to control the ratio of cells to the cavity surface, for example by varying the cavity volume and / or the number of cells added. In some embodiments, this allows for a reduction in the layer of cells (e.g., cell pellet) on the cavity surface compared to other methods, such as those performed in centrifuge bags, particularly those available for large-scale transduction under centrifugal force. In some embodiments, the ability to control the thickness of the layer of cells in the cavity of the centrifuge chamber during transduction can lead to an increase in transduction efficiency under otherwise comparable conditions and / or a lack of increase in copy number associated with increased viral transduction efficiency.
[0202] In some embodiments, the cells in the provided method are present in the cavity in a single or nearly single monolayer, or at most 1.5 times or about 1.5 times or at most 2 times or about 2 times thicker than a single monolayer, or not substantially thicker than a monolayer, during incubation for transduction under centrifugal force.This reduction during centrifugation can facilitate and improve the interaction between virus and cells, and can avoid the increase in virus copy number (VCN) that can occur, especially when the relative virus or infectious unit (IU) is high (e.g., when the outer or upper layer of cells is preferentially transduced).
[0203] In some embodiments, the input composition is aliquoted to at least 1 cm2 of the internal surface area of the cavity during at least a portion of the incubation of the input composition in the centrifuge chamber (e.g., during rotation). 2 In some embodiments, the input composition contains at least 1 million cells per cm of the internal surface area of the cavity during at least a portion of the incubation of the input composition in the centrifuge chamber (e.g., during rotation). 2 In some embodiments, the cavity contains at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or 20 million cells per cavity. In some embodiments, the interior surface area of the cavity during at least a portion of the incubation (e.g., during rotation) is at least 1×10 9 μm2 Or at least about 1 × 10 9 μm 2 or at least 1 × 10 10 μm 2 Or at least about 1 × 10 10 μm 2 It is.
[0204] In some embodiments, the total number of cells in the input composition during at least a portion of the incubation of the input composition in the centrifuge chamber (e.g., during rotation) is at least 10×10 6 pieces, 20×10 6 pieces, 30×10 6 pieces, 40×10 6 pieces, 50×10 6 pieces, 60×10 6 pieces, 70×10 6 pieces, 80×10 6 pieces, 100×10 6 pieces, 200×10 6 pieces, 300×10 6 pcs, or 400 x 10 6 There are 10 pieces.
[0205] In some aspects, a processing step in the closed cavity of the centrifuge system can also be used to process cells, such as activated cells, prior to transduction. In some aspects, processing can include dilution or concentration of cells to a desired concentration or number. In some aspects, processing can include volume reduction, thereby increasing the concentration of cells as desired. In some aspects, processing includes exchange of media to a media acceptable or desired for transduction.
[0206] In some embodiments, the input composition comprises a certain ratio of copies of viral vector particles or infectious units (IU) per total number of cells in the input composition (IU / cell) or per total number of cells to be transduced. For example, in some embodiments, the input composition comprises 1 IU or about 1 IU or at least 1 IU or at least about 1 IU, 2 IU or about 2 IU or at least 2 IU or at least about 2 IU, 3 IU or about 3 IU or at least 3 IU or at least about 3 IU, 4 IU or about 4 IU or at least 4 IU or at least about 4 IU, 5 IU or about 5 IU or at least 5 IU or at least about 5 IU, 10 IU or about 10 IU or at least 10 IU or at least about 10 IU, 15 IU, or about 15 IU or at least 15 IU, 20 IU or about 20 IU or at least 20 IU, 30 IU or about 30 IU or at least 30 IU, 40 IU or about 40 IU or at least 40 IU, 50 IU or about 50 IU or at least 50 IU, or 60 IU or about 60 IU or at least 60 IU of viral vector particles.
[0207] In certain embodiments, the ability to use higher IU in the present method provides an advantage over other methods. Under otherwise identical conditions, using a higher IU / cell ratio generally leads to higher transduction efficiency, or similarly up to a certain higher level of IU / cell where the corresponding improvement in efficiency may reach a plateau. Nevertheless, for certain available methods, an increase in IU / cell, and thus an improvement in transduction efficiency, also leads to an increase in vector copy number (VCN), which may present a safety risk and may not meet regulatory standards.
[0208] In some embodiments, for the methods provided, the average VCN in the transduced cells (e.g., cells containing a viral vector or expressing a molecule encoded by a viral vector) in the output composition does not increase with increasing IU / cell in the input composition. In some embodiments, in the methods provided, the average VCN in the transduced cells decreases with increasing ratio of IU / cell in the input composition.
[0209] In some embodiments, the titer of the viral vector particles is greater than or equal to 1×10 6 IU / mL or approximately 1 × 10 6 IU / mL ~ 1×10 8 IU / mL or approximately 1 × 10 8 IU / mL, e.g., 5×10 6 IU / mL or approximately 5 × 10 6 IU / mL ~ 5 × 10 7 IU / mL or approximately 5 × 10 7 IU / mL, e.g., at least 6 × 10 6 IU / mL, 7×10 6 IU / mL, 8×10 6 IU / mL, 9×10 6 IU / mL, 1×10 7 IU / mL, 2×10 7 IU / mL, 3×10 7 IU / mL, 4×10 7 IU / mL, or 5 × 10 7 IU / mL.
[0210] In some embodiments, the input composition contains viral vector particles at a concentration having a particular value for the ratio of copy number or infectious units (IU) of viral vector particles per total number of cells in the input composition or total number of cells to be transduced per total liquid volume of the input composition present during at least a portion of the incubation (e.g., during rotation) of the input composition in the centrifuge chamber. In some embodiments, the input composition contains at least 0.01 IU, 0.05 IU, 0.1 IU, 0.5 IU, or 0.1 IU of viral vector particles per cell per mL of liquid volume of the input composition during at least a portion of the incubation (e.g., during rotation).
[0211] In some embodiments, the step of creating input composition (cells and viral vector particles) can be carried out in the centrifuge chamber. In some embodiments, the step of creating input composition is carried out outside the centrifuge chamber. Thus, the term "input composition" is not intended to imply that the entire composition is taken into each container (e.g., tube, bag, or cavity) at once, or to exclude drawing in a portion of the composition from a different container or line. Input composition can include those formed by drawing in two different compositions into the cavity of the chamber and mixing the two (thereby creating the input composition).
[0212] The input composition can be introduced or otherwise transferred from the same vessel or from multiple separate vessels into the vessel in which incubation (e.g., rotation) takes place. For example, the input composition can be introduced into the chamber by drawing in a composition containing cells and another composition containing viral vector particles, which can be done sequentially or simultaneously. Alternatively, an input composition containing viral vector particles and cells is introduced into the cavity or other vessel in which transduction takes place.
[0213] In some embodiments, when transduction is performed in the internal cavity of the centrifuge chamber, this is achieved by containing the liquid input composition only in a certain part of the cavity. This can be achieved, for example, by drawing air or gas into a part of the cavity and / or by containing one or more solid objects in a space within the cavity, such as the internal space. In some embodiments, this can minimize or reduce the total liquid volume of the input composition present in the cavity of the centrifuge chamber during incubation (e.g., during rotation) per square inch of the internal surface area of the cavity, compared to when there is no gas in the cavity and / or no one or more solid objects in the space of the cavity. In this way, the provided method can be advantageous compared to other methods in which the effectiveness of transduction can be limited by the diffusion of viruses through a large volume of liquid compared to the volume of cells. Thus, in some embodiments, the input composition occupies all or substantially all of the volume of the internal cavity during at least a portion of the incubation, while in some embodiments, during at least a portion of the incubation, the input composition occupies only a portion of the volume of the internal cavity during said incubation.
[0214] In some such embodiments, the volume of the cavity during at least this portion of the incubation may further include gas that is introduced into the cavity, e.g., by one or more openings (e.g., inlets) in the cavity before or during the incubation. In some embodiments of the method, the air is sterilized or aseptic air. In some embodiments, the air is free or substantially free of microbial contamination or other potential pathogens.
[0215] In some embodiments, the gas (e.g., air) supplying or intake step can be performed in any manner that allows the passage of air into the internal cavity of the centrifuge chamber, such as without compromising the sterility of the closed system in some aspects. In some embodiments, the gas (e.g., air) can be added to the container under sterile conditions, and the container can be aseptically connected to a location on the system for transfer into the chamber. In some embodiments, the gas (e.g., air) addition to the container (e.g., bag) is performed under laminar flow conditions, for example, in a biological safety cabinet or hood. In some such embodiments, the gas (e.g., air) is added to the container together with a liquid volume, such as a liquid volume containing a composition of cells and / or a liquid volume containing a composition of viral vector particles. Thus, in some embodiments, the gas (e.g., air) supplying or intake step into the internal cavity of the chamber is performed together with or simultaneously with the supply or intake of one or both of the cells or viral vector particles that make up the input composition.
[0216] In some embodiments, the step of supplying or drawing gas (e.g., air) into the chamber is accomplished by using a syringe that can be attached to any luer lock associated with the system and is operatively connected to the internal cavity of the centrifuge chamber. In some embodiments, the air is transferred into the syringe under sterile conditions, such as under laminar flow. In some embodiments, the syringe is a sterile syringe, e.g., a syringe that contains a movable plunger that, in some aspects, is not exposed to the surrounding non-sterile environment. In some embodiments, the syringe contains a filter at its end that provides for the sterile transfer of gas (e.g., air) into the internal cavity of the chamber.
[0217] In some embodiments, the step of supplying or drawing gas (e.g., air) into the internal cavity of the chamber is accomplished by using a filter operatively connected to the internal cavity of the chamber via a sterile tubing line. In some such embodiments, the filter is a sterile filter or a microbial filter as described with respect to the exemplary system, such as the filter illustrated in FIG. 7 in some aspects. In some such embodiments, a device is connected to the filter, such as via a luer lock connection, to transfer the air. In some such embodiments, the device is a syringe, pump, or other injection device. In some embodiments, the gas is air, and the drawing of air through the filter is direct drawing from the surrounding environment. In some embodiments, the filter contains a cap, such as a non-vented cap, that can be removed or disengaged and controls the transfer of air into the filter as desired.
[0218] Thus, in some embodiments, the method includes supplying or taking a liquid input composition and a volume of gas (e.g., air) into the internal cavity of the chamber. The volume of gas (e.g., air) supplied or taken is related to the volume of the composition containing cells and the composition containing viral vector particles that make up the input composition. In some embodiments, the volume of gas is the difference between the total volume of the internal cavity and the liquid volume of the input composition. In some embodiments, the total volume of gas and liquid is at most 200 mL, and therefore the volume of gas supplied or taken into the internal cavity is the difference between 200 mL and the liquid volume of the input composition (cells and viral vector particles).
[0219] In an exemplary aspect of the provided method, the method of transduction comprises the step of: 9 μm 2 Or at least about 1 × 10 9 μm 2 Or at least 1×10 10 μm 2 Or at least about 1 × 1010 μm 2 100 mL, in a volume of at most 100 mL. 6 or at least about 50×10 6 In some embodiments, the cell composition includes providing a composition containing at least 100×10 cells in a volume that is at most 50 mL, 40 mL, 30 mL, 20 mL, 10 mL, or 5 mL. 6 or at least about 100×10 6 cells or at least 200 x 10 6 or at least about 200×10 6 In some embodiments, the composition of cells is diluted or concentrated to a volume of at most 100 mL, for example at most 50 mL, 40 mL, 30 mL, 20 mL, 10 mL, or 5 mL, before providing the cells to the internal cavity. In addition to the cell composition, the method also includes providing a composition containing viral vector particles in an amount of at least 1 IU / cell in a volume, such that the total liquid volume, including the liquid volume from the composition containing cells, is less than the maximum volume of the internal cavity of the centrifuge chamber, such as at most 200 mL, thereby generating an input composition. In some embodiments, the composition containing viral vector particles is provided in an amount of at least 1.6 IU / cell, 1.8 IU / cell, 2.0 IU / cell, 2.4 IU / cell, 2.8 IU / cell, 3.2 IU / cell, or 3.6 IU / cell. In some embodiments, the total liquid volume of the input composition is less than 100 mL, less than 90 mL, less than 80 mL, less than 60 mL, less than 40 mL, less than 20 mL. Optionally, the method can also include providing a gas (e.g., air) up to the total volume of the internal cavity, e.g., such that the total volume occupied within the internal cavity of the centrifuge chamber is at or about 200 mL.
[0220] In some embodiments, the composition containing cells, the composition containing viral vector particles, and optionally air can be mixed or blended together before feeding the composition into the cavity. In some embodiments, the composition containing cells, the composition containing viral vector particles, and optionally air are fed separately and mixed and blended in the cavity. In some embodiments, the composition containing cells, the composition containing viral vector particles, and optionally air can be fed into the internal cavity in any order. In any of such some embodiments, the composition containing cells and viral vector particles is an input composition that is mixed or blended together once, regardless of whether the composition is mixed or blended inside or outside the centrifuge chamber and / or whether the cells and viral vector particles are fed into the centrifuge chamber together or separately (e.g., simultaneously or sequentially).
[0221] In some embodiments, the introduction of a volume of gas (e.g., air) occurs prior to incubation (e.g., rotation) in the transduction method. In some embodiments, the introduction of a volume of gas (e.g., air) occurs during incubation (e.g., rotation) in the transduction method.
[0222] In some embodiments, the liquid volume of cells or viral vector particles, and optionally the volume of air, that make up the input composition can be a predetermined volume, which can be programmed into and / or controlled by circuitry associated with the system.
[0223] In some embodiments, the intake of the input composition, and optionally the gas (e.g., air), is controlled manually, semi-automatically, and / or automatically until a desired or predetermined volume is taken into the internal cavity of the chamber. In some embodiments, a sensor associated with the system can detect the liquid and / or gas flowing into and out of the centrifuge chamber, such as by its color, flow rate, and / or density, and can communicate with associated circuitry to stop or continue the intake as necessary until such a desired or predetermined volume is achieved. In some aspects, a sensor that is programmed or capable of detecting only the liquid in the system and not the gas (e.g., air) can be made to allow the gas (e.g., air) to pass into the system without stopping the intake. In some such embodiments, an opaque section of tubing can be placed in the line near the sensor while the intake of the gas (e.g., air) is desired. In some embodiments, the intake of the gas (e.g., air) can be controlled manually.
[0224] In aspects of the methods provided, the internal cavity of the centrifuge chamber is subjected to high speed rotation. In some embodiments, the rotation is performed before, simultaneously with, after, or intermittently with the introduction of the liquid input composition and optionally air. In some embodiments, the rotation is performed after the introduction of the liquid input composition and optionally air. In some embodiments, the rotation provides a lateral flow rate of at least about 800 g, at or about 800 g, at or about 800 g, at or about 800 g, at or about 1000 g, at or about 1000 g, at or about 1000 g, at or about 1100 g, at or about 1100 g, at or about 1100 g, at or about 1500 g, at or about 1500 g, at or about 1500 g, at or about 1600 g, at or about 1600 g, at or about 1600 g, at or about 18 ... by centrifugation of the centrifuge chamber at a relative centrifugal force of 1800g, 2000g or about 2000g or at least 2000g or at least about 2000g, 2200g or about 2200g or at least 2200g or at least about 2200g, 2500g or about 2500g or at least 2500g or at least about 2500g, 3000g or about 3000g or at least 3000g or at least about 3000g, 3500g or about 3500g or at least 3500g or at least about 3500g, or 4000g or about 4000g or at least 4000g or at least about 4000g. In some embodiments, the rotation is by centrifugation at a force of about or greater than 1100 g, e.g., about or greater than 1200 g, about or greater than 1400 g, about or greater than 1600 g, about or greater than 1800 g, about or greater than 2000 g, about or greater than 2400 g, about or greater than 2800 g, about or greater than 3000 g, or about or greater than 3200 g.
[0225] In some embodiments, the transduction method comprises rotating or centrifuging the input composition and optionally air in a centrifuge chamber for about or more than 5 minutes, e.g., about or more than 10 minutes, about or more than 15 minutes, about or more than 20 minutes, about or more than 30 minutes, about or more than 45 minutes, about or more than 60 minutes, about or more than 90 minutes, or about or more than 120 minutes. In some embodiments, the input composition and optionally air are rotated or centrifuged in the centrifuge chamber for more than 5 minutes, but not longer than 60 minutes, 45 minutes, 30 minutes, or 15 minutes.
[0226] In some embodiments, the method of transduction comprises at least 1000 g or greater than 1000 g, at least 1100 g or greater than 1100 g, at least 1200 g or greater than 1200 g, at least 1400 g or greater than 1400 g, at least 1500 g or greater than 1500 g, at least 1600 g or greater than 1600 g, at least 1700 g or greater than 1700 g, at least 1800 g or greater than 1800 g, at least 1900 g or greater than 1900 g, at least 2000 g or greater than 2000 g, at least 2100 g or greater than 2100 g, at least 2200 g or greater than 2200 g, at least 2300 g or greater than 2300 g, at least 2400 g or greater than 2400 g, at least 2500 g or greater than 2500 g, at least 2600 g or greater than 2600 g, at least 2700 g or greater than 2700 g The method includes rotating or centrifuging the input composition and optionally air in a centrifuge chamber at a relative centrifugal force of at least about 100g, at least about 1500g, at least about 1600g, at least about 1800g, at least about 2000g, at least about 2200g, at least about 2400g, at least about 2800g, at least about 3200g, or at least about 3600g.
[0227] In some embodiments, the method includes performing an expression of an output composition from an internal cavity of the centrifuge chamber, the output composition being a composition resulting from incubation of cells with viral vector particles under conditions including rotation or centrifugation in the centrifuge chamber in any of the above described embodiments. In aspects of the method, the output composition includes cells transduced with a viral vector or cells initiated for transduction by a viral vector. In some embodiments, the expression of the output composition is into an output bag that is operatively linked as part of a closed system with the centrifuge chamber. In some embodiments, the expression of the output composition is after the rotation or centrifugation. In some embodiments, the expression of the output composition is simultaneous or partially simultaneous with the rotation or centrifugation, such as in a semi-continuous or continuous process.
[0228] In some embodiments, the gas (e.g., air) in the cavity of the chamber is released from the chamber. In some embodiments, the gas (e.g., air) is released into a container that is operatively connected as part of a closed system with the centrifuge chamber. In some embodiments, the container is empty, i.e., an empty container. In some embodiments, the air, such as the gas in the cavity of the chamber, is released through a filter that is operatively connected to the internal cavity of the chamber via a sterile tubing line. In some embodiments, the air is released using a manual, semi-automated, or automated process. In some embodiments, the air is released from the chamber before, simultaneously, intermittently, or after the step of expressing the output composition containing the incubated cells (e.g., cells that have been initiated with transduction by a viral vector or cells that have been transduced with a viral vector) and the viral vector particles.
[0229] In some embodiments, transduction and / or other incubations are performed as or part of a continuous or semi-continuous process. In some embodiments, a continuous process involves continuous intake of cells and viral vector particles, e.g., continuous intake of an input composition (either as a single pre-existing composition or by continuously drawing portions thereof into the same container (e.g., cavity) and thereby mixing the portions) during at least a portion of the incubation (e.g., during centrifugation), and / or continuous expelling or expelling of liquid from the container, and optionally releasing gas (e.g., air). In some embodiments, the continuous intake and continuous expelling are performed at least in part simultaneously. In some embodiments, the continuous intake is performed during a portion of the incubation, e.g., during a portion of the centrifugation, and the continuous expelling is performed during a different portion of the incubation. The two may alternate. Thus, continuous intake and expelling while incubation allows for a larger overall volume of sample to be processed (e.g., transduced).
[0230] In some embodiments, incubation is part of a continuous process, and the method includes performing a continuous intake of an input composition into the cavity during rotation of the chamber during at least a portion of the incubation, and performing a continuous expulsion of liquid from the cavity through at least one opening, and optionally expulsion of gas (e.g., air) from the cavity, during rotation of the chamber and during a portion of the incubation.
[0231] In some embodiments, the semi-continuous incubation is performed by alternating between taking a composition into the cavity, incubating, squeezing liquid from the cavity into an output container or the like, and optionally releasing gas (e.g., air) from the cavity, and then taking a subsequent (e.g., second, third, etc.) composition containing more cells and other reagents for processing, such as viral vector particles, and repeating the process. For example, in some embodiments, the incubation is part of a semi-continuous process, and the method includes taking an input composition into the cavity through at least one opening before incubation, and squeezing fluid out of the cavity after incubation; taking another input composition containing cells and viral vector particles into the internal cavity; and incubating the other input composition in the internal cavity under conditions in which the cells in the other input composition are transduced with the vector. The process can be continued in an iterative manner for several additional rounds. In this regard, semi-continuous or continuous methods may allow for the production of even greater volumes and / or numbers of cells.
[0232] In some embodiments, a portion of the transduction incubation is performed in a centrifuge chamber, which is performed under conditions that include rotation or centrifugation.
[0233] In some embodiments, the method includes a further part of incubation of the cells with the viral vector particles without rotation or centrifugation, which generally occurs after at least a part of the incubation including rotation or centrifugation of the chamber. In some such embodiments, the further incubation is performed under conditions that result in the integration of the viral vector into the host genome of one or more cells. It is within the level of ordinary skill in the art to assess or determine whether the incubation has resulted in the integration of the viral vector particles into the host genome, and therefore to empirically determine the conditions for further incubation. In some embodiments, the integration of the viral vector into the host genome can be evaluated by measuring the level of expression of a recombinant protein, such as a heterologous protein, encoded by a nucleic acid contained in the genome of the viral vector particle after incubation. Several well-known methods for evaluating the expression level of a recombinant molecule can be used, for example, for cell surface proteins, for example, detection by affinity-based methods (e.g., immunoaffinity-based methods), such as detection by flow cytometry. In some examples, expression is measured by detection of a transduction marker and / or a reporter construct. In some embodiments, the nucleic acid encoding the truncated surface protein is included in a vector and used as a marker for expression and / or its enhancement.
[0234] In some embodiments, the further incubation is carried out in the centrifuge chamber, but without rotation. In some embodiments, the further incubation is carried out outside the centrifuge chamber. In some embodiments, the further incubation is carried out at a temperature above room temperature, for example, above or about 25°C, for example, about or about 32°C, about or about 35°C, or about or about 37°C. In some embodiments, the further incubation is carried out at a temperature of 37°C±2°C or about 37°C±2°C, for example, 37°C or about 37°C. In some embodiments, the period of further incubation is from 1 or about 1 hour to 48 or about 48 hours, 4 or about 4 hours to 36 or about 36 hours, 8 or about 8 hours to 30 or about 30 hours, or 12 or about 12 hours to 24 or about 24 hours, inclusive.
[0235] In some embodiments, the further incubation is performed in a closed system. In some embodiments, after expression of the output composition from the chamber into a container (e.g., a bag), the container containing the output composition is incubated for an additional portion of time. In some embodiments, the container (e.g., a bag) is incubated for 1 or about 1 hour to 48 or about 48 hours, 4 or about 4 hours to 36 or about 36 hours, 8 or about 8 hours to 30 or about 30 hours, or 12 or about 12 hours to 24 or about 24 hours, inclusive, at a temperature of 37°C ± 2°C or about 37°C ± 2°C.
[0236] In some embodiments, the method results in the transduction of a certain number or percentage (%) of cells in the input composition and / or the (transduced) output composition or a subset thereof. For example, in some embodiments, at least 2.5%, 5%, 6%, 8%, 10%, 20%, 25%, 30%, 40%, 50%, or 75% of the total cells (or of a particular target cell type, such as T cells) in the input composition and / or the (e.g., transduced) output composition are transduced with the viral vector and / or express a recombinant gene product encoded thereby. In some embodiments, the transduction method results in an output composition in which at least 2.5%, 5%, 6%, 8%, 10%, 20%, 25%, 30%, 40%, 50%, or 75% of the total cells, such as T cells, in the composition are transduced with the viral vector and / or express a recombinant gene product encoded thereby.
[0237] In some embodiments, the method may achieve such at least a particular transduction efficiency under certain conditions. For example, in some embodiments, when the input composition comprises virus and cells at a ratio of 1 infectious unit (IU) or about 1 IU to 10 IU or about 10 IU per cell, e.g., 1 infectious unit (IU) or about 1 IU, or 2 IU or about 2 IU, 5 IU or about 5 IU, or 10 IU or about 10 IU per cell, the method may produce a transduced composition in which at least 10%, 25%, 30%, 40%, 50%, or 75% of the cells in the transduced composition produced by the method comprise a recombinant viral vector, e.g., are transduced with a recombinant viral vector. Transduction of a cell may be detected by detecting the presence in the cell of a recombinant nucleic acid (e.g., a transgene) or a product thereof contained within the vector. In some embodiments, the product is detected at the surface of the cell, indicating that the cell has been successfully transduced. In some embodiments, detection of transduction involves detection of a transduction marker (e.g., another transgene or product included for the purpose of generating a transduced cell) and / or other selectable marker.
[0238] In some embodiments, the output composition resulting from the transduction method contains a particular average copy number (vector copy number (VCN)) of the transduced vector per cell. VCN may be expressed in terms of the number of copies in a single cell. Alternatively, it may be expressed as an average number across an entire cell population or composition, such as an output or transduced composition (which may contain some non-transduced cells in the composition, which will not contain any copy number of the vector). Alternatively, VCN may be expressed in terms of the average copy number in only the transduced cells. In some embodiments, the average VCN in all the transduced cells in the composition produced by the method or in the output composition is at most 10 or about 10, 5 or about 5, 4 or about 4, 2.5 or about 2.5, 1.5 or about 1.5, or 1 or about 1. In some embodiments, the average VCN in transduced cells containing the recombinant viral vector or expressing the recombinant gene product in the composition or output composition is at most 4 or about 4, 3 or about 3, 2 or about 3, 2.5 or about 2.5, 1.5 or about 1.5, or 1 or about 1.
[0239] Compositions produced by any of the above methods are also provided. In some embodiments, the compositions comprise at least 1×10 7 cells or 5 x 10 7 pieces, e.g., at least 1 x 10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8 pieces, 8×10 8 pcs or 1×10 9 In some embodiments, the cell comprises a T cell, wherein at least a plurality of the cells are transduced with a recombinant viral vector.
[0240] In some embodiments, practice of the methods provided herein allows for the production of output compositions containing multiple transduced cells in large numbers, such as numbers that can achieve a therapeutically effective dosage of T cells for use in adoptive immunotherapy, in some aspects, this is not only due to the ability to transduce cells on a large scale, but can also be achieved in some aspects by repeating the process in a continuous or semi-continuous manner.
[0241] In contrast, existing methods in the art, where transduction is performed on a smaller scale, such as in plates, require extensive expansion of cells after transduction to achieve the number of cells required to obtain a therapeutically effective dosage. Expansion of cells, such as T cells, with one or more stimulatory agents can activate cells and / or alter the phenotype of the cells, such as by producing effector cells with exhausted T cell phenotypes. For example, activation or stimulation of T cells can result in changes in the differentiation or activation state of T cells, which can result in and / or lead to reduced persistence in vivo when genetically engineered cells are administered to a subject. Some of the changes in differentiation state that can occur include, in some cases, loss of naive phenotype, loss of memory T cell phenotype, and / or production of effector cells with exhausted T cell phenotypes. Exhaustion of T cells can lead to the progressive loss of T cell function and / or exhaustion of the cells (Yi et al. (2010) Immunology, 129:474-481). T cell exhaustion and / or lack of T cell persistence are impediments to the efficacy and therapeutic outcome of adoptive cell therapy; clinical trials have revealed a correlation between greater and / or longer exposure to antigen receptor (e.g., CAR)-expressing cells and therapeutic outcome.
[0242] In some embodiments, in the methods provided herein, it is not necessary to stimulate and / or activate the cells after transduction to the same extent as required in other known methods in the art. In some embodiments, after transduction, the cells in the composition are not subjected to growth in the presence of a stimulatory agent (e.g., a cytokine such as IL-2) and / or are not subjected to incubation at about or above 30° C. or about or above 37° C. for more than 24 hours. In some embodiments, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the T cells in the composition and / or the transduced T cells in the output composition comprise high surface expression of CD69 or TGF-β-II. In some embodiments, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the T cells or transduced T cells in the composition do not comprise surface expression of CD62L and / or comprise high expression of CD25, ICAM, GM-CSF, IL-8, and / or IL-2.
[0243] In some embodiments, engineered cells, such as cells transduced with a viral vector encoding an intracellularly expressed recombinant product of an output composition produced by the methods described above, or by a method that includes further processing steps, such as to generate a formulated composition, exhibit increased persistence when administered to a subject in vivo. In some embodiments, the persistence of the provided cells (e.g., cells expressing a receptor (e.g., a CAR)) in the subject upon administration is greater than that achieved by another transduction method, such as one that involves administration of cells engineered by a method involving smaller scale transduction in which T cells are activated and / or stimulated to expand before and / or after transduction to achieve a number of cells that is a therapeutically effective dose. For example, in some aspects, the persistence of the provided cells (e.g., cells produced by the provided methods) is greater than that achieved by administration of a population of cells expressing an engineered recombinant receptor (e.g., a CAR), at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of which have lower levels of expression of CD69 or TGF-βII. In some embodiments, the persistence of the provided cells (e.g., cells produced by the provided methods) is greater than that achieved by administration of a population of cells expressing an engineered recombinant receptor (e.g., a CAR), at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of which exhibit surface expression of CD62L and / or include low surface expression of CD25, ICAM, GM-CSF, IL-8, and / or IL-2.
[0244] In some embodiments, persistence is improved by at least or about 1.5-fold, 2-fold or about 2-fold, 3-fold or about 3-fold, 4-fold or about 4-fold, 5-fold or about 5-fold, 6-fold or about 6-fold, 7-fold or about 7-fold, 8-fold or about 8-fold, 9-fold or about 9-fold, 10-fold or about 10-fold, 20-fold or about 20-fold, 30-fold or about 30-fold, 50-fold or about 50-fold, 60-fold or about 60-fold, 70-fold or about 70-fold, 80-fold or about 80-fold, 90-fold or about 90-fold, 100-fold or about 100-fold, or more.
[0245] In some embodiments, the degree or extent of persistence of administered cells can be detected or quantified after administration to a subject.For example, in some aspects, quantitative PCR (qPCR) is used to evaluate the quantity of cells expressing recombinant receptors (e.g., CAR-expressing cells) in the subject's blood or serum or organ or tissue (e.g., disease site).In some aspects, persistence is quantified as the number of copies of DNA or plasmid encoding the receptor (e.g., CAR) per μg of DNA, or the number of cells expressing the receptor (e.g., CAR) per μl of sample (e.g., blood or serum), or per total number of peripheral blood mononuclear cells (PBMCs) or white blood cells or T cells in μl of sample.In some embodiments, flow cytometry assays can also be performed, generally using receptor-specific antibodies to detect receptor-expressing cells. Cell-based assays can also be used to detect the number or percentage of functional cells, e.g., cells capable of binding to, neutralizing, and / or inducing a response (e.g., a cytotoxic response) against disease or pathological cells, or cells capable of expressing an antigen recognized by a receptor. In any of such embodiments, the degree or level of expression of another marker that interacts with the recombinant receptor (e.g., CAR-expressing cells) can be used to distinguish between the administered cells and endogenous cells in the subject.
[0246] In some embodiments, by minimizing T cell activation and / or stimulation, the provided embodiments may result in engineered T cells that are more potent for use in adoptive immunotherapy methods, in some aspects due to increased persistence. In some embodiments, the increased potency and / or increased persistence of the provided cells (e.g., cells produced by any of the provided methods) allows for methods of administering cells at lower dosages. Such methods may minimize toxicity that may result from adoptive immunotherapy methods.
[0247] Other cellular processing events In some embodiments, the processing methods of the provided methods include other processing steps and methods in addition to and / or instead of the transduction step, such as for isolating, separating, selecting, culturing (e.g., stimulating the cells to induce their proliferation and / or activation), washing, suspending, diluting, concentrating, and / or formulating the cells. In some embodiments, at least a portion of the one or more other processing steps and / or at least a portion of the steps are performed in whole or in part within the cavity of a centrifuge chamber, such as the same or a different centrifuge chamber used in the transduction method. In some embodiments, all or a portion of such one or more other processing steps are performed in a closed system containing the centrifuge chamber, such as in a sterile closed system.
[0248] In some embodiments, the method includes one or more of the following steps: (a) washing a cell-containing biological sample (e.g., a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product) within the cavity of the chamber; (b) isolating (e.g., selecting) a desired subset or population of cells (e.g., CD4+ or CD8+ T cells) from the sample within the cavity of the chamber, e.g., by incubation of the cells with a selection reagent or immunoaffinity reagent for immunoaffinity-based separation; (c) incubating the isolated cells (e.g., selected cells) with viral vector particles, such as according to the methods described above; and (d) formulating the transduced cells in a pharma- ceutically acceptable buffer, cryopreservative, or other suitable medium, etc. In some embodiments, the method may further include (e) stimulating the cells in the cavity of the chamber by exposing the cells to a stimulating condition, thereby inducing cell proliferation. In some embodiments, stimulating the cells is performed before, during, and / or after incubation of the cells with the viral vector particles. In some embodiments, one or more additional washing or suspension steps may also be performed before or after any of the above steps, for example, for diluting, concentrating, and / or buffer exchange of the cells.
[0249] Thus, in some embodiments, the method performs one, multiple, or all steps in preparing cells for clinical use, for example in adoptive cell therapy, without exposing the cells to non-sterile conditions and without the need to use a sterile room or cabinet. In some embodiments of such processes, cells are isolated, separated or selected, stimulated, transduced, washed, and formulated, all within a closed system. In some embodiments, the method is performed in an automated manner. In some embodiments, one or more of the steps are performed away from the centrifuge chamber system.
[0250] sample In some embodiments, the processing step includes the isolation of cells or compositions thereof from a biological sample (e.g., a sample obtained or derived from a subject, such as one having a particular disease or condition, or in need of, or to be administered cell therapy). In some aspects, the subject is a human, e.g., a patient in need of a particular therapeutic intervention (e.g., adoptive cell therapy, for which cells are isolated, processed, and / or genetically engineered). Thus, the cells in some embodiments are primary cells, e.g., primary human cells. Samples include tissues, fluids, and other samples (obtained directly from a subject), as well as samples resulting from one or more processing steps, such as separation, centrifugation, genetic engineering (e.g., transduction with a viral vector), washing, and / or incubation. Biological samples can be samples obtained directly from a biological source or samples that have been processed. Biological samples include processed samples derived therefrom, including, but not limited to, bodily fluids such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, tissue, and organ samples.
[0251] In some aspects, the sample is blood or blood-derived sample, or is or is derived from apheresis product or leukapheresis product.Exemplary samples include whole blood, peripheral blood mononuclear cells (PBMC), white blood cells, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut-associated lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissue, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testis, ovary, tonsil, or other organ, and / or cells derived therefrom.In the context of cell therapy (e.g., adoptive cell therapy), samples include samples from autologous and allogeneic sources.
[0252] In some embodiments, the isolation of a cell or population includes one or more preparation steps and / or cell separation steps that are not based on affinity. In some examples, the cells are washed, centrifuged, and / or incubated in the presence of one or more reagents, for example, to remove unwanted components, to enrich for desired components, to lyse or remove cells that show sensitivity to a particular reagent. In some examples, the cells are separated based on one or more characteristics, such as density, adhesive properties, size, sensitivity and / or resistance to a particular component. In some examples, cells from the circulating blood of a subject are obtained, for example, by apheresis or leukapheresis. The sample may contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and / or platelets.
[0253] In some embodiments, the provided methods include, in whole or in part, processing one or more of the samples in a closed system, such as in a centrifuge chamber. In some embodiments, the processing step may involve washing the sample from the subject, such as a blood cell-containing sample, for example to remove the plasma fraction, and / or replacing the cells in a suitable buffer or medium for a subsequent processing step, and / or performing a density-based cell separation method, such as in preparing white blood cells from peripheral blood by lysis of red blood cells and centrifugation through a Percoll or Ficoll gradient. Exemplary such processing steps may be performed using a centrifuge chamber in conjunction with one or more systems associated with a cell processing system, such as the centrifuge chambers produced and sold by Biosafe SA, including those for use with the Sepax® or Sepax 2® cell processing systems.
[0254] Affinity-based selection The processing step (e.g., performed in the centrifuge chamber) may include isolation of cells from a mixed population and / or composition, such as by using one of a variety of selection steps, including density-based or other physical property-based separation methods and affinity-based selection. In some embodiments, the method includes selection, in which all or part of the selection is performed in the internal cavity of the centrifuge chamber, e.g., under centrifugal rotation. In some embodiments, incubation of the cells with a selection reagent, such as an immunoaffinity-based selection reagent, is performed in the centrifuge chamber. Such methods may confer certain advantages compared to other available selection methods.
[0255] For example, immunoaffinity-based selection may rely on favorable energetic interactions between the cells to be separated and molecules (e.g., antibodies) or other binding partners on solid surfaces (e.g., particles) that specifically bind to markers on the cells. In certain available methods for affinity-based separation using particles (e.g., beads), the particles and cells are incubated in a container such as a tube or bag with shaking or mixing at a certain cell density-to-particle (e.g., bead) ratio that helps promote energetically favorable interactions. Such approaches may not be ideal for use with large-scale production, for example, in that they may require the use of large volumes to maintain optimal or desired cell-to-particle ratios while maintaining the desired cell number. Thus, such approaches may require processing in a batch manner or format, which may require increased time, number of steps, and handling, increasing costs and the risk of user error.
[0256] In some embodiments, by performing such a selection step or part thereof (e.g., incubation with antibody-coated particles (e.g., magnetic beads)) in the cavity of the centrifuge chamber, the user can control certain parameters, such as the volume of various solutions, the addition of solutions during processing, and their timing, which may provide advantages compared to other available methods. For example, the ability to reduce the liquid volume in the cavity during incubation can increase the concentration of the particles (e.g., bead reagents) used in the selection, and therefore the chemical potential of the solution, without affecting the total number of cells in the cavity. This, in turn, can enhance pairwise interactions between the cells being processed and the particles used in the selection. In some embodiments, for example, when the chamber is associated with the systems, circuits, and controls described herein, performing the incubation step in the chamber allows the user to perform agitation of the solution at desired times during incubation, which may also improve interactions.
[0257] In some embodiments, at least a portion of the selection step is carried out in a centrifuge chamber, which includes incubation of cells with selection reagents. In some aspects of such processes, a volume of cells is mixed with a much smaller amount of selection reagents based on the desired affinity than would normally be used when performing a similar selection in a tube or container for the selection of the same number and / or volume of cells according to the manufacturer's instructions. In some embodiments, in a tube or container-based incubation for the same number and / or volume of cells according to the manufacturer's instructions, an amount of one or more selection reagents is used that is at most 5%, at most 10%, at most 15%, at most 20%, at most 25%, at most 50%, at most 60%, at most 70%, or at most 80% of the amount of the same selection reagent used for the selection of cells.
[0258] Incubation with one or more selection reagents, for example as part of a selection method that may be performed in the chamber cavity, includes using one or more selection reagents for the selection of one or more different cell types based on the expression or presence of one or more specific molecules (e.g., surface markers (e.g., surface proteins), intracellular markers, or nucleic acids) in or on the cells. In some embodiments, any known method using one or more selection reagents for such marker-based separation may be used. In some embodiments, the one or more selection reagents result in a separation that is an affinity or immunoaffinity-based separation. For example, selection in some aspects includes incubation with one or more selection reagents for the separation of cells and cell populations based on the cellular expression or expression level of one or more markers, typically cell surface markers, for example by incubation with an antibody or binding partner that specifically binds to such marker, typically followed by a washing step and separation of cells that are bound to the antibody or binding partner from those cells that are not bound to the antibody or binding partner.
[0259] In some embodiments, for cell selection, e.g., immunoaffinity-based selection, the cells are incubated in the cavity of the centrifuge chamber in a composition that also contains a selection buffer along with a selection reagent, such as a molecule, such as an antibody, that specifically binds to a surface marker on the cells desired to be enriched and / or depleted but not on other cells in the composition, and optionally linked to a scaffold, such as a polymer or surface (e.g., beads, e.g., magnetic beads, such as magnetic beads linked to monoclonal antibodies specific for CD4 and CD8). In some embodiments, the selection reagent is added to the cells in the cavity of the chamber in an amount that is substantially less (e.g., at most 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% of the amount) than would typically be used or required to achieve the same or similar efficiency for selection of the same number of cells or the same volume of cells when selection is performed in a tube with shaking or rotation, as described.In some embodiments, incubation is performed by addition of a selection buffer to the cells and selection reagent to obtain between 10 mL and 200 mL of reagent, e.g., at least 10 mL or at least about 10 mL, at least 20 mL or at least about 20 mL, at least 30 mL or at least about 30 mL, at least 40 mL or at least about 40 mL, at least 50 mL or at least about 50 mL, at least 60 mL or at least about 60 mL or The target volume is achieved by incubation of about 60 mL, at least 70 mL, at least 80 mL, at least 90 mL, at least 100 mL, at least 150 mL, or at least 200 mL. In some embodiments, the selection buffer and the selection reagent are premixed before addition to the cells. In some embodiments, the selection buffer and the selection reagent are added to the cells separately. In some embodiments, the selection incubation is performed using periodic gentle mixing conditions that may help promote energetically favorable interactions, thereby allowing the use of less overall selection reagent while achieving high selection efficiency.
[0260] In some embodiments, the total duration of incubation with the selection reagent is from or about 5 minutes to or about 6 hours, e.g., from 30 minutes to 3 hours, e.g., at least or about 30 minutes, 60 minutes or about 60 minutes, 120 minutes or about 120 minutes, or 180 minutes or about 180 minutes.
[0261] In some embodiments, incubation is generally under mixing conditions, e.g., generally at relatively low forces or speeds, e.g., speeds lower than those used to pellet the cells, e.g., at or about 600 rpm to 1700 or about 1700 rpm (e.g., 600 rpm or about 600 rpm or at least 600 rpm, 1000 rpm or about 1000 rpm or at least 1000 rpm, or 1500 rpm or about 1500 rpm or at least 1500 rpm, or 1700 rpm). At or about 1700 rpm, for example, in the presence of a spin at an RCF of 80 g or about 80 g to 100 g or about 100 g (e.g., 80 g or about 80 g or at least 80 g, 85 g or about 85 g or at least 85 g, 90 g or about 90 g or at least 90 g, 95 g or about 95 g or at least 95 g, or 100 g or about 100 g or at least 100 g) on the sample or wall of a chamber or other container. In some embodiments, spinning is performed by sequentially repeating periods of spinning at such low speeds followed by rest periods (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 seconds of spin and / or rest, e.g., about 1 or 2 seconds of spin followed by about 5, 6, 7, or 8 seconds of rest).
[0262] In some embodiments, such processes are performed within a completely closed system that the chamber is built into. In some embodiments, the process (and in some aspects one or more additional steps, such as a prior washing step to wash a cell-containing sample, such as an apheresis sample) is performed in an automated manner, such that an automated program is used to complete the washing and binding steps within a single closed system, such that cells, reagents, and other components are brought into and pushed out of the chamber and centrifugation is performed at the appropriate times.
[0263] In some embodiments, after incubation and / or mixing of cells and one and / or multiple selection reagents, the incubated cells are subjected to a separation that selects cells based on the presence or absence of a specific one or more reagents. In some embodiments, further selection is performed outside the centrifuge chamber. In some embodiments, separation is performed in the same closed system in which the centrifuge chamber is present and in which the incubation of cells with the selection reagent is performed. In some embodiments, after incubation with the selection reagent, the incubated cells, including the cells to which the selection reagent is bound, are squeezed out of the centrifuge chamber, such as transferred from the centrifuge chamber into a system for immunoaffinity-based cell separation. In some embodiments, the system for immunoaffinity-based separation is or contains a magnetic separation column. In some embodiments, one or more other processing steps, such as washing, can be performed in the chamber before separation.
[0264] Such a separation step can be based on positive selection, where cells that bind to a reagent (e.g., an antibody or binding partner) are retained for further use, and / or negative selection, where cells that do not bind to a reagent (e.g., an antibody or binding partner) are retained. In some cases, both fractions are retained for further use. In some aspects, negative selection can be particularly useful when an antibody that specifically identifies a cell type is not available in a heterogeneous population, in which case separation is best performed based on markers expressed by cells other than the desired population.
[0265] Separation does not necessarily result in the enrichment or removal of 100% of a particular cell population or cells expressing a particular marker. For example, positive selection or enrichment for a particular type of cell, such as one expressing a marker, refers to increasing the number or percentage (%) of such cells, but does not necessarily result in the complete absence of cells that do not express the marker. Similarly, negative selection, removal, or depletion of a particular type of cell, such as one expressing a marker, refers to decreasing the number or percentage (%) of such cells, but does not necessarily result in the complete removal of all such cells.
[0266] In some cases, multiple rounds of separation steps are performed when the positively or negatively selected fraction from one step is subjected to another separation step, such as a subsequent positive or negative selection. In some cases, a single separation step can deplete cells expressing multiple markers simultaneously, such as by incubating cells with multiple antibodies or binding partners, each specific to a marker targeted for negative selection. In the same way, multiple cell types can be positively selected simultaneously by incubating cells with multiple antibodies or binding partners expressed on various cell types. In any of such cases, at least a portion of the further selection or selection step is performed in a centrifuge chamber, which includes the incubation of cells with a selection reagent as described above.
[0267] For example, in some aspects, a particular subpopulation of T cells, e.g., cells that are positive for or express high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+ T cells), is isolated by positive or negative selection techniques. In some embodiments, such cells are selected by incubation with one or more antibodies or binding partners that specifically bind to such markers. In some embodiments, the antibodies or binding partners can be conjugated (e.g., directly or indirectly) to a solid support or matrix (e.g., magnetic or paramagnetic beads) to perform the selection. For example, CD3+, CD28+ T cells can be positively selected using CD3 / CD28-conjugated magnetic beads (e.g., DYNABEADS® M-450 CD3 / CD28 T Cell Expander, and / or ExpACT® beads).
[0268] In some embodiments, the processing step further comprises negative and / or positive selection of the incubated cells, such as with a system or device capable of performing affinity-based selection. In some embodiments, the isolation is performed by enrichment of a particular cell population by positive selection, or depletion of a particular cell population by negative selection. In some embodiments, the positive or negative selection is achieved by incubating the cells with one or more antibodies or other binding agents that specifically bind to one or more surface markers that are expressed (marker+) or expressed at relatively higher levels (markerhigh) on the positively or negatively selected cells, respectively.
[0269] In some embodiments, T cells are separated from PBMC samples by negative selection for markers expressed on non-T cells, such as B cells, monocytes, or other white blood cells, e.g., CD14. In some aspects, a CD4+ or CD8+ selection step is used to separate CD4+ helper T cells and CD8+ cytotoxic T cells. Such CD4+ and CD8+ populations can be further sorted into subpopulations by positive or negative selection for markers expressed or expressed to a relatively higher extent on one or more naive, memory, and / or effector T cell subpopulations.
[0270] In some embodiments, CD8+ cells are further enriched or depleted for naive, central memory, effector memory, and / or central memory stem cells, such as by positive or negative selection based on surface antigens associated with each subpopulation. In some embodiments, enrichment of central memory T (TCM) cells is performed to improve efficacy, e.g., long-term survival, proliferation, and / or engraftment after administration, which in some aspects is particularly strong for such subpopulations. See Terakura et al. (2012) Blood.1:72-82;Wang et al. (2012) J Immunother. 35(9):689-701. In some embodiments, efficacy is further enhanced by combining TCM-enriched CD8+ T cells and CD4+ T cells.
[0271] In some embodiments, memory T cells are present in both the CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes. PBMCs can be enriched or depleted for the CD62L-CD8+ and / or CD62L+CD8+ fractions, such as with anti-CD8 and anti-CD62L antibodies.
[0272] In some embodiments, enrichment of central memory T (TCM) cells is based on positive or high surface expression of CD45RO, CD62L, CCR7, CD28, CD3, and / or CD127; in some aspects, based on negative selection for cells expressing or highly expressing CD45RA and / or granzyme B. In some aspects, isolation of a CD8+ population enriched for TCM cells is performed by depletion of cells expressing CD4, CD14, CD45RA, and positive selection or enrichment of cells expressing CD62L. In one aspect, enrichment of central memory T (TCM) cells is performed starting with a negative fraction of cells selected on the basis of CD4 expression, which fraction is subjected to negative selection on the basis of expression of CD14 and CD45RA, and positive selection on the basis of CD62L. Such selections are performed simultaneously in some aspects and sequentially in other aspects, in either order. In some aspects, the same CD4 expression-based selection step used in preparing the CD8+ cell population or subpopulation is also used to generate the CD4+ cell population or subpopulation, such that both the positive and negative fractions from the CD4-based separation are retained and used in subsequent steps of the method, optionally followed by one or more further positive or negative selection steps.
[0273] In a particular example, a sample of PBMCs or other white blood cell sample is subjected to selection of CD4+ cells, where both the negative and positive fractions are retained, and the negative fraction is then subjected to negative selection based on expression of CD14 and CD45RA or CD19, and positive selection based on markers characteristic of central memory T cells, such as CD62L or CCR7, where the positive and negative selections are performed in either order.
[0274] CD4+ T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations with cell surface antigens. CD4+ lymphocytes can be obtained by standard methods. In some embodiments, naive CD4+ T lymphocytes are CD45RO-, CD45RA+, CD62L+, or CD4+ T cells. In some embodiments, central memory CD4+ cells are CD62L+ and CD45RO+. In some embodiments, effector CD4+ cells are CD62L- and CD45RO-.
[0275] In one example, to enrich for CD4+ cells by negative selection, the monoclonal antibody cocktail typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In some embodiments, the antibody or binding partner is bound to a solid support or matrix, such as magnetic or paramagnetic beads, to allow preparation of cells for positive and / or negative selection. For example, in some embodiments, cells and cell populations are separated or isolated using immunomagnetic (or affinity magnetic) separation techniques (reviewed in Methods in Molecular Medicine, vol. 58: Metastasis Research Protocols, Vol. 2: Cell Behavior In Vitro and In Vivo, p 17-25, edited by SA Brooks and U. Schumacher (Copyright) Humana Press Inc., Totowa, NJ).
[0276] In some aspects, the incubated cells or the composition of cells to be separated are incubated with a selection reagent that contains a small magnetizable or magnetically responsive material, such as magnetically responsive particles or microparticles of paramagnetic beads (e.g., Dynalbeads or MACS® beads, etc.). The magnetically responsive material (e.g., particles) is generally attached directly or indirectly to a binding partner (e.g., an antibody) that specifically binds to a molecule (e.g., a surface marker) present on a cell, a plurality of cells, or a population of cells that one wishes to separate (e.g., negatively or positively selected).
[0277] In some embodiments, magnetic particles or beads comprise magnetically responsive materials that are bound to specific binding members, such as antibodies or other binding partners.Many well-known magnetically responsive materials are known for use in magnetic separation methods, such as those described in U.S. Patent No. 4,452,773 to Molday and European Patent Specification No. EP 452342 B, which are hereby incorporated by reference.Colloidal-sized particles can also be used, such as those described in U.S. Patent No. 4,795,698 to Owen and U.S. Patent No. 5,200,084 to Liberti et al.
[0278] Incubation is generally carried out under conditions whereby the antibody or binding partner, or a molecule such as a secondary antibody or other reagent attached to a magnetic particle or bead that specifically binds to such an antibody or binding partner, specifically binds to a cell surface molecule if present on cells in the sample.
[0279] In certain embodiments, magnetically responsive particles are coated with a primary antibody or other binding partner, a secondary antibody, a lectin, an enzyme, or streptavidin. In certain embodiments, magnetic particles are attached to cells via coating with a primary antibody specific for one or more markers. In certain embodiments, cells, rather than beads, are labeled with a primary antibody or binding partner, and then magnetic particles coated with a cell type-specific secondary antibody or other binding partner (e.g., streptavidin) are added. In certain embodiments, streptavidin-coated magnetic particles are used in conjunction with biotinylated primary or secondary antibodies.
[0280] In some aspects, separation is achieved by placing the sample in a magnetic field, and those cells that are attached with magnetically responsive or magnetizable particles are attracted to the magnet and separated from unlabeled cells.For positive selection, the cells that are attracted to the magnet are retained; for negative selection, the cells that are not attracted (unlabeled cells) are retained.In some aspects, a combination of positive and negative selection is performed during the same selection step, in which case the positive and negative fractions are retained and further processed or subjected to further separation steps.
[0281] In some embodiments, affinity-based selection is by magnetic activated cell sorting (MACS) (Miltenyi Biotech, Auburn, CA). Magnetic activated cell sorting (MACS), such as the CliniMACS system, allows for high purity selection of cells attached to magnetized particles. In certain embodiments, MACS works in a manner that non-target and target species are eluted sequentially after application of an external magnetic field. That is, cells attached to magnetized particles are kept in place while non-attached species are eluted. Then, after this first elution step is completed, the species that are captured by the magnetic field and prevented from elution are released in a manner that they can be eluted and collected. In certain embodiments, non-target cells are labeled and depleted from the heterogeneous cell population.
[0282] In some embodiments, the processing step comprises expressing the cells incubated with one or more selection reagents from a centrifuge chamber. In some embodiments, the cells may be expressed after and / or continuously from one or more washing steps, which in some aspects may be performed within the centrifuge chamber.
[0283] In some embodiments, the magnetically responsive particles are left attached to the cells that are subsequently incubated, cultured, and / or genetically engineered; in some aspects, the particles are left attached to the cells for administration to a patient. In some embodiments, the magnetizable or magnetically responsive particles are removed from the cells. Methods for removing magnetizable particles from cells are known, including, for example, the use of competing unlabeled antibodies, magnetizable particles conjugated to cleavable linkers, or antibodies, and the like. In some embodiments, the magnetizable particles are biodegradable.
[0284] Freezing and cryopreservation In some embodiments, cells such as selected cells are suspended in freezing solution, for example after a washing step to remove plasma and platelets.Any of a variety of known freezing solutions and parameters can be used in some aspects.One example involves the use of PBS containing 20% DMSO and 8% human serum albumin (HSA), or other suitable cell freezing medium.Then, it is diluted 1:1 with medium, so that the final concentration of DMSO and HSA is 10% and 4%, respectively.
[0285] In some embodiments, cells, such as selected cells, may be transferred to a cryopreservation medium using a centrifuge chamber in conjunction with one or more systems associated with a cell processing system, such as those produced and sold by Biosafe SA, including for use with the Sepax® or Sepax 2® cell processing systems. In some embodiments, transfer to a cryopreservation medium is accompanied by one or more processing steps, which may include washing the sample (e.g., a selected cell sample) (e.g., to remove the selection medium) and / or replacing the cells in an appropriate cryopreservation buffer or medium for subsequent freezing.
[0286] In some embodiments, cells are frozen, e.g., cryopreserved, either before, during, or after the method for processing. In some embodiments, the freezing and subsequent thawing steps remove granulocytes and, to some extent, monocytes in the cell population. Then, cells are frozen to -80°C, typically at a rate of 1° per minute, and stored in the vapor phase of a liquid nitrogen storage tank.
[0287] Culture and stimulation In some embodiments, the processing step (e.g., performed in a chamber and / or closed system) includes culturing, stimulating, and / or activating the cells, such as by incubation and / or culturing the cells. For example, in some embodiments, methods are provided for stimulating isolated cells, such as selected cell populations. In some embodiments, the processing step includes incubation of a composition containing cells, such as selected cells, with at least a portion of the incubation being performed in a centrifuge chamber and / or other vessel, for example, under stimulation conditions. The incubation may be performed prior to or in conjunction with genetic manipulation (e.g., genetic manipulation performed according to embodiments of the transduction methods described above). In some embodiments, the stimulation results in activation and / or proliferation of the cells, for example, prior to transduction.
[0288] In some embodiments, the processing step includes incubation of cells, such as selected cells, and the incubation step can include culturing, culturing, stimulating, activating, and / or growing the cells. In some embodiments, the composition or cells are incubated under stimulatory conditions or in the presence of stimulants. Such conditions include those designed to induce proliferation, proliferation, activation, and / or survival of cells in the population, to mimic antigen exposure, and / or to prime cells for genetic manipulation, such as for the introduction of recombinant antigen receptors.
[0289] In some embodiments, conditions for stimulation and / or activation may include one or more of a particular medium, temperature, oxygen content, carbon dioxide content, time, agents such as nutrients, amino acids, antibiotics, ions, and / or stimulatory factors such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate cells.
[0290] In some embodiments, the stimulating condition or stimulating agent includes one or more agents, such as ligands, that can activate the intracellular signaling domain of the TCR complex. In some aspects, the agent turns on or initiates the TCR / CD3 intracellular signaling cascade in T cells, such as agents that are suitable for delivering primary signals, such as those specific for TCR components, for example, for initiating the activation of ITAM-induced signals, and / or agents that promote costimulatory signals, such as those specific for T cell costimulatory receptors, for example, anti-CD3, anti-CD28, or anti-41-BB, bound to solid supports, such as beads, and / or one or more cytokines. Among the stimulating agents are anti-CD3 / anti-CD28 beads (e.g., DYNABEADS® M-450 CD3 / CD28 T Cell Expander, and / or ExpACT® beads). Optionally, the expansion method can further include the step of adding anti-CD3 and / or anti-CD28 antibodies to the culture medium. In some embodiments, the stimulating agent includes IL-2 and / or IL-15, e.g., IL-2 at a concentration of at least about 10 units / mL. In some embodiments, the incubation is performed according to techniques such as those described in U.S. Patent No. 6,040,177 to Riddell et al., Klebanoff et al. (2012) J Immunother. 35(9):651-660, Terakura et al. (2012) Blood.1:72-82, and / or Wang et al. (2012) J Immunother. 35(9):689-701.
[0291] In some embodiments, the T cells are expanded by adding feeder cells, such as non-dividing peripheral blood mononuclear cells (PBMCs), to the composition (e.g., such that the resulting population of cells contains at least about 5, 10, 20, or 40 or more PBMC feeder cells for each T lymphocyte in the initial population to be expanded); and incubating the culture (e.g., for a time sufficient to expand the number of T cells). In some aspects, the non-dividing feeder cells can include PBMC feeder cells that have been gamma-irradiated. In some embodiments, PBMCs are irradiated with gamma rays in the range of about 3000-3600 rads to prevent cell division. In some aspects, the feeder cells are added to the culture medium prior to the addition of the population of T cells.
[0292] In some embodiments, the stimulatory conditions generally include a temperature suitable for the growth of human T lymphocytes, e.g., at least about 25°C, about at least about 30°C, and about or about 37°C. Optionally, the incubation can further include adding non-dividing EBV-transduced lymphoblastoid cells (LCL) as feeder cells. The LCL can be irradiated with gamma radiation in the range of about 6000-10,000 rads. The LCL feeder cells in some aspects are provided in any suitable amount, such as at a ratio of LCL feeder cells to primary T lymphocytes of at least about 10:1.
[0293] In some embodiments, antigen-specific T cells, such as antigen-specific CD4+ and / or CD8+ T cells, are obtained by stimulating naive or antigen-specific T lymphocytes with antigen.For example, antigen-specific T cell lines or clones can be generated against cytomegalovirus antigens by isolating T cells from infected subjects and stimulating the cells with the same antigen in vitro.
[0294] In some embodiments, at least a part of the incubation with one or more stimulating conditions or stimulating agents, such as any of the above, is carried out in the centrifuge chamber.In some embodiments, at least a part of the incubation carried out in the centrifuge chamber includes mixing with one or more reagents to induce stimulation and / or activation.In some embodiments, cells, such as selected cells, are mixed with stimulating conditions or stimulating agents in the centrifuge chamber.In some aspects of such a process, a volume of cells is mixed with one or more stimulating conditions or agents in a much smaller amount than is usually adopted when carrying out similar stimulation in cell culture plate or other systems.
[0295] In some embodiments, a substantially less amount (e.g., at most 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% of the amount) of stimulant is added to the cells in the cavity of the chamber compared to the amount of stimulant typically used or required to achieve the same or comparable efficiency for selection of the same number or volume of cells when selection is performed without mixing in a centrifuge chamber (e.g., in a tube or bag) with periodic shaking or rotation. In some embodiments, incubation is performed by addition of an incubation buffer to the cells and stimulant to provide, e.g., at least 10 mL or at least about 10 mL, at least 20 mL or at least about 20 mL, at least 30 mL or at least about 30 mL, at least 40 mL or at least about 40 mL, at least 50 mL or at least about 50 mL, at least 60 mL or at least about 60 mL, The target volume is achieved by incubation of 10-200 mL of reagent, such as at least 70 mL or at least about 70 mL, at least 80 mL or at least about 80 mL, at least 90 mL or at least about 90 mL, at least 100 mL or at least about 100 mL, at least 150 mL or at least about 150 mL, or at least 200 mL or at least about 200 mL. In some embodiments, the incubation buffer and the stimulant are premixed before addition to the cells. In some embodiments, the incubation buffer and the stimulant are added to the cells separately. In some embodiments, the stimulant incubation is performed using gentle periodic mixing conditions that may help promote energetically favorable interactions, thereby allowing for the overall use of less stimulant while still achieving stimulation and activation of the cells.
[0296] In some embodiments, the total duration of incubation with the stimulant is between 1 or about 1 hour and 72 or about 72 hours, between 1 or about 1 hour and 48 or about 48 hours, between 4 or about 4 hours and 36 or about 36 hours, between 8 or about 8 hours and 30 or about 30 hours, or between 12 or about 12 hours and 24 or about 24 hours, e.g., at least 6 or about 6 hours, 12 or about 12 hours, 18 or about 18 hours, 24 or about 24 hours, 36 or about 36 hours, or 72 or about 72 hours. In some cases, the total duration of incubation in the centrifuge chamber is between 5 minutes or about 5 minutes and 6 or about 6 hours, e.g., between 30 minutes and 3 hours, e.g., at least 30 minutes or about 30 minutes, 60 minutes or about 60 minutes, 120 minutes or about 120 minutes, or 180 minutes. In some cases, a further portion of the incubation may be carried out outside the centrifuge chamber.
[0297] In some embodiments, incubation generally occurs under mixing conditions, e.g., spinning at generally relatively low forces or speeds, e.g., spinning at speeds lower than those used to pellet the cells, e.g., from 600 or about 600 rpm to 1700 or about 1700 rpm (e.g., 600 rpm or about 600 rpm or at least 600 rpm, 1000 rpm or about 1000 rpm or at least 1000 rpm, or 1500 rpm or about 1500 rpm or at least 1500 rpm, or 170 0 rpm or about 1700 rpm or at least 1700 rpm), e.g., in the presence of a spin at an RCF of 80 g or about 80 g to 100 g or about 100 g (e.g., 80 g or about 80 g or at least 80 g, 85 g or about 85 g or at least 85 g, 90 g or about 90 g or at least 90 g, 95 g or about 95 g or at least 95 g, or 100 g or about 100 g or at least 100 g) on the sample or wall of the chamber or other container. In some embodiments, the spinning is performed by sequentially repeating such periods of spinning at low speeds followed by rest periods (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 seconds of spinning and / or resting, e.g., spinning for about 1 or 2 seconds followed by resting for about 5, 6, 7, or 8 seconds).
[0298] In some embodiments, the cells are incubated in the centrifuge chamber with one or more cell stimulants that can induce intracellular signaling and / or cell proliferation, and the cell stimulants are cell binding agents, such as antigen-binding reagents, such as antibodies. In some embodiments, the cells are incubated in the centrifuge chamber with anti-CD3 / anti-CD28 beads (including mixed with anti-CD3 / anti-CD28 beads) according to the process aspects of the provided methods.
[0299] In some embodiments, the processing step includes expressing cells that have been incubated with (e.g., mixed with) one or more stimulus conditions or agents from the centrifuge chamber. In some embodiments, one or more other additional processing steps, such as washing, can be performed in the chamber, which can be before, after, and / or consecutive to the stimulus incubation. In some embodiments, a washing step is performed before the stimulus, such as for selected or lysed cells, to remove the medium and replace it with a medium suitable for stimulating and culturing the cells.
[0300] In some embodiments, the cells that are squeezed out of the centrifuge chamber that has been incubated (e.g., mixed with) with one or more stimulating conditions or stimuli are further incubated outside the chamber.In some embodiments, the further incubation is carried out at a temperature above room temperature, for example, above or about 25°C, for example, about or about 32°C, about or about 35°C, or about or about 37°C.In some embodiments, the further incubation is carried out at a temperature of 37°C±2°C or about 37°C±2°C, for example, at or about 37°C. In some embodiments, the period of further incubation is from or about 12 hours to or about 96 hours, e.g., at least or at least about 12 hours, at least or at least about 24 hours, at least or at least about 36 hours, at least or at least about 48 hours, at least or at least about 72 hours, or at least or at least about 96 hours.
[0301] In some embodiments, further incubation is performed in a closed system. In some embodiments, the cells incubated with (e.g., mixed with) one or more stimuli conditions or stimuli are pressed from the centrifuge chamber into a container (e.g., bag) or the like, and the container containing the cells is incubated for an additional portion of time. In some embodiments, the container (e.g., bag) is incubated for 1 or about 1 hour to 48 or about 48 hours, 4 or about 4 hours to 36 or about 36 hours, 8 or about 8 hours to 30 or about 30 hours, or 12 or about 12 hours to 24 or about 24 hours (including limits) at a temperature of 37°C±2°C or about 37°C±2°C.
[0302] Formulation In some embodiments, the processing step (e.g., performed within a centrifuge chamber and / or closed system) can include formulation of cells, such as formulation of engineered cells resulting from a provided transduction processing step and / or one or more other processing steps described above. In some embodiments, provided methods related to formulation of cells include processing transduced cells, such as cells transduced and / or expanded using the processing steps described above, within a closed system, such as within or associated with a centrifuge chamber.
[0303] In some embodiments, the cells are formulated in a pharma- ceutically acceptable buffer, which may in some aspects contain a pharma- ceutically acceptable carrier or excipient. In some embodiments, processing involves exchanging the medium into a pharma- ceutically acceptable or desired medium or formulation buffer for administration to a subject. In some embodiments, the processing step may involve washing the transduced and / or expanded cells and replacing the cells in a pharma- ceutically acceptable buffer, which may contain one or more of any pharma- ceutically acceptable carriers or excipients. Exemplary such pharmaceutical forms, including pharma-ceutically acceptable carriers or excipients, may be any of the following, in combination with a form acceptable for administering the cells and compositions to a subject. The pharmaceutical composition in some embodiments contains an amount of cells that is effective for treating or preventing a disease or condition, such as a therapeutically or prophylactically effective amount.
[0304] In some embodiments, the formulation buffer contains a cryopreservative. In some embodiments, the cells are formulated with a cryopreservation solution containing 1.0%-30% DMSO solution, such as a 5%-20% or 5%-10% DMSO solution. In some embodiments, the cryopreservation solution is or contains, for example, PBS containing 20% DMSO and 8% human serum albumin (HSA), or other suitable cell freezing medium. In some embodiments, the cryopreservation solution is or contains, for example, at least 7.5% or at least about 7.5% DMSO. In some embodiments, the processing step may involve washing the transduced and / or expanded cells and replacing the cells in a cryopreservation solution.
[0305] In some embodiments, processing may include dilution or concentration of cells to a desired concentration or number (e.g., a unit dosage form composition containing that number of cells for administration at a given dose or fraction thereof). In some embodiments, the processing step may include volume reduction, thereby increasing the concentration of cells as desired. In some embodiments, the processing step may include volume addition, thereby decreasing the concentration of cells as desired.
[0306] In some embodiments, processing comprises adding a volume of formulation buffer to the transduced and / or expanded cells. In some embodiments, the volume of formulation buffer is at least or at least about 50 mL, at least or at least about 100 mL, at least or at least about 200 mL, at least or at least about 300 mL, at least or at least about 400 mL, at least or at least about 400 mL, at least or at least about 500 mL, or at least about 500 mL. or 500 mL, at least 600 or at least about 600 mL, at least 700 or at least about 700 mL, at least 800 or at least about 800 mL, at least 900 or at least about 900 mL, or at least 1000 or at least about 1000 mL, or about 1000 mL, such as 10 mL or about 10 mL to 1000 mL or about 1000 mL.
[0307] Exemplary such processing steps may be carried out using centrifuge chambers in conjunction with one or more systems or kits associated with a cell processing system, such as those produced and sold by Biosafe SA, including for use with the Sepax® or Sepax 2® cell processing systems.
[0308] In some embodiments, the method includes performing an expression of the formulated composition, which is the resultant composition of cells formulated in a formulation buffer, such as a pharma- ceutically acceptable buffer, from the internal cavity of the centrifuge chamber in any of the above described embodiments. In some embodiments, the expression of the formulated composition is an expression into a container (e.g., a bag) that is operably connected as part of a closed system with the centrifuge chamber. In some embodiments, the container (e.g., a bag) is connected to the system at an output line or output position as illustrated in the exemplary system illustrated in FIG. 5 or FIG. 7.
[0309] In some embodiments, a closed system (e.g., a centrifuge chamber) (e.g., associated with a cell processing system) includes a multi-port output kit that contains a multi-way piping manifold associated with a port (at each end of the piping line) to which one or more containers can be connected for the expression of the formulated composition. In some aspects, a desired number or a plurality of output containers (e.g., bags) can be aseptically connected to one or more, about two or more, such as at least 3, 4, 5, 6, 7, 8 or more of the ports of the multi-port output. For example, in some embodiments, one or more containers (e.g., bags) can be attached to the ports or to fewer than all of the ports. Thus, in some embodiments, the system can perform the expression of the output composition into multiple output bags.
[0310] In some aspects, cells can be expressed into one or more of the multiple output bags in an amount for dosage administration, such as for single unit dosage administration or multiple dosage administration.For example, in some embodiments, the output bags may each contain a number of cells for administration at a given dose or a portion thereof.Thus, each bag may in some aspects contain a single unit dose for administration, or may contain a portion of a desired dose, such that more than one of the multiple output bags (e.g., two or three of the output bags) together constitute a dose for administration.
[0311] Thus, the container (e.g., bag) generally contains the cells to be administered, for example, one or more unit doses thereof. A unit dose can be the amount or number of cells to be administered to a subject, or twice (or more than) the number of cells to be administered. It can be the lowest dose or the lowest possible dose of cells that will be administered to a subject.
[0312] In some embodiments, each container (e.g., bag) contains a unit dose of cells. Thus, in some embodiments, each container contains the same or approximately or substantially the same number of cells. In some embodiments, a unit dose is about 1×10 per kg of the subject to be treated and / or from which the cells are derived. 8 Less than 5 x 10 7 Less than 1 x 10 6 Less than 5 x 10 5 In some embodiments, each unit dose contains at least or about at least 1 x 10 cells. 6 , 2×10 6 , 5×10 6 , 1×10 7 , 5×10 7 , or 1 × 10 8In some embodiments, the volume of the formulated cell composition in each bag is at least 10 mL to 100 mL, such as at or about 20 mL, at or about 30 mL, at or about 40 mL, at or about 50 mL, at or about 60 mL, at or about 70 mL, at or about 80 mL, at or about 90 mL, or at or about 100 mL.
[0313] In some embodiments, one or more of the multiple output bags may be used to test, such as to evaluate transduction efficiency. For example, transduction efficiency in some aspects may be evaluated by measuring the level of expression of a recombinant protein, such as a heterologous protein, encoded by a nucleic acid contained in the genome of the viral vector particle after transduction using an embodiment of the method provided. Thus, in some embodiments, the expression level of the recombinant molecule may be evaluated by any of several well-known methods, such as, for example, by detection by affinity-based methods (e.g., immunoaffinity-based methods), such as flow cytometry, for cell surface proteins. In some aspects, cells contained in one or more of the multiple containers (e.g., bags) are tested for the expression level of the recombinant molecule by detection of a transduction marker and / or a reporter construct. In other embodiments, expression is evaluated using a nucleic acid encoding a truncated surface protein contained in the vector as a marker.
[0314] In some embodiments, all or substantially all of the plurality of vessels into which the cells are expressed contain the same number of cells and the same or substantially the same concentration. In some embodiments, the plumbing lines are primed prior to expressing the cells into one of the plurality of vessels.
[0315] IV. Cells and Compositions Among the cells used in the methods (eg, processing steps, such as introduction of viral nucleic acid, eg, transduction) are cells, cell populations, and compositions.
[0316] The cell is generally a mammalian cell, typically a human cell. In some embodiments, the cell is derived from blood, bone marrow, lymph, or lymphoid organs. In some aspects, the cell is a cell of the immune system, such as a cell of innate or adaptive immunity, e.g., a myeloid cell or a lymphoid cell, including lymphocytes, typically T cells and / or NK cells. Other exemplary cells include stem cells, such as multipotent and pluripotent stem cells, including induced pluripotent stem cells (iPSCs). The cell is typically a primary cell, such as one that is directly isolated from a subject and / or one that is isolated and frozen from a subject. In some embodiments, the cells include one or more subsets of T cells or other cell types, such as the total T cell population, CD4+ cells, CD8+ cells, and subpopulations thereof, such as those defined by function, activation state, maturity, differentiation potential, proliferation, recirculation, localization, and / or persistence, antigen specificity, type of antigen receptor, presence in a particular organ or compartment, marker or cytokine secretion profile, and / or degree of differentiation. With respect to the subject to be treated, the cells can be allogeneic and / or autologous. In some embodiments, the method includes steps of isolating cells from a subject, preparing, processing, culturing, and / or genetically manipulating them, and reintroducing them into the same subject before or after cryopreservation, which in some aspects can be accomplished in a closed system using one or more of the processing steps provided.
[0317] Among the subtypes and subpopulations of T cells and / or CD4+ and / or CD8+ T cells are stem cell memory T (T SCM ), Central Memory T(T CM ), Effector Memory T (T EM), or naive T (T), such as terminally differentiated effector memory T cells, tumor infiltrating lymphocytes (TILs), immature T cells, mature T cells, helper T cells, cytotoxic T cells, mucosal-associated invariant T (MAIT) cells, naturally occurring and adaptive regulatory T (Treg) cells, helper T cells such as TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9 cells, TH22 cells, follicular helper T cells, α / β T cells, and δ / γ T cells. N ) cells, effector T cells (T EFF ), memory T cells, and their subtypes.
[0318] In some embodiments, the cells are natural killer (NK) cells. In some embodiments, the cells are monocytes or granulocytes, such as myeloid cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, and / or basophils.
[0319] V. Viral Vector Particles, Viral Vectors, and Encoded Recombinant Products Transduction methods generally involve transduction with a viral vector (e.g., a vector encoding a recombinant product to be expressed in a cell). As used herein, the term "vector" refers to a nucleic acid molecule capable of amplifying another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors integrated into the genome of a host cell to which it is introduced. Certain vectors can induce expression of a nucleic acid to which they are operatively linked. Such vectors are referred to herein as "expression vectors." Vectors include viral vectors, e.g., retroviral vectors, e.g., lentiviral or gamma retroviral vectors, that have a genome that can be inserted into the host genome to carry and amplify another nucleic acid.
[0320] In some embodiments, the viral vector is introduced into the cell in a vehicle that is a viral vector particle, which comprises a virion that encapsulates and / or packages the viral vector genome. In some such embodiments, the genome of the viral vector typically includes sequences that allow the genome to be packaged into a viral particle in addition to the nucleic acid encoding the recombinant molecule.
[0321] In some embodiments, the viral vector contains a recombinant nucleic acid, such as a nucleic acid encoding a recombinant molecule, such as a recombinant protein or a heterologous protein, and / or a heterologous molecule. In some embodiments, such as in aspects of the methods provided, transduction with the viral vector produces an output composition, in which cells in the output composition are transduced and express the recombinant or engineered product of such nucleic acid. In some embodiments, the nucleic acid is a heterologous nucleic acid, i.e., not normally present in the cell or in a sample obtained from the cell, such as from another organism or cell, e.g., it is not normally found in the transduced cell and / or the organism from which such cell is derived. In some embodiments, the nucleic acid is not naturally occurring, e.g., a nucleic acid not found in nature, including a nucleic acid that includes a chimeric combination of nucleic acids encoding various domains from multiple different cell types.
[0322] In some embodiments, the recombinant nucleic acid is introduced into the cell using a recombinant virus or viral vector particle, such as a vector derived from Simian Virus 40 (SV40), adenovirus, or adeno-associated virus (AAV). In some embodiments, the recombinant nucleic acid is introduced into the cell, such as a T cell, using a recombinant lentiviral or retroviral vector, such as a gamma retroviral vector (see, e.g., Koste et al. (2014) Gene Therapy 2014 Apr 3. doi:10.1038 / gt.2014.25; Carlens et al. (2000) Exp Hematol 28(10):1137-46; Alonso-Camino et al. (2013) Mol Ther Nucl Acids 2, e93; Park et al., Trends Biotechnol. 2011 November 29(11):550-557).
[0323] In some embodiments, retroviral vectors, such as those derived from Moloney murine leukemia virus (MoMLV), myeloproliferative sarcoma virus (MPSV), mouse embryonic stem cell virus (MESV), murine stem cell virus (MSCV), spleen focus forming virus (SFFV), or adeno-associated virus (AAV), have long terminal repeats (LTRs). Many retroviral vectors are derived from murine retroviruses. In some embodiments, retroviruses include those derived from any avian or mammalian cell source. Retroviruses are typically amphotropic, meaning that they can infect host cells of several species, including humans. In one embodiment, the expressed gene replaces the gag, pol, and / or env sequences of the retrovirus. Several illustrative retroviral systems have been described (e.g., U.S. Pat. Nos. 5,219,740; 6,207,453; 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, AD (1990) Human Gene Therapy 1:5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037; and Boris-Lawrie and Temin (1993) Cur. Opin. Genet. Develop. 3:102-109).
[0324] Viral vector generally comprises recombinant nucleic acid such as transgene that encodes recombinant product that is expressed by cell.Recombinant product includes recombinant receptor, including functional non-TCR antigen receptor, for example antigen receptor such as chimeric antigen receptor (CAR), and other antigen-binding receptor such as transgenic T cell receptor (TCR).Some receptors are also chimeric receptors.
[0325] Exemplary antigen receptors, including CARs, and methods for engineering such receptors and introducing them into cells are described in, for example, International Patent Application Publication Nos. WO200014257, WO2013126726, WO2012 / 129514, WO2014031687, WO2013 / 166321, WO2013 / 071154, WO2013 / 123061, U.S. Patent Application Publication Nos. US2002131960, US2013287748, US2013 Nos. 6,451,995, 7,446,190, 8,252,592, 8,339,645, 8,398,282, 7,446,179, 6,410,319, 7,070,995, 7,265,209, 7,354,762, 7,446,191, 8,324,353, and 8,479,118, and European Patent Application EP 2537416, and / or those described in Sadelain et al., Cancer Discov. 2013 April; 3(4):388-398;Davila et al. (2013) PLoS ONE 8(4):e61338;Turtle et al., Curr. Opin. Immunol., 2012 October; 24(5):633-39;Wu et al., Cancer, 2012 March 18(2):160-75. In some aspects, antigen receptors include CARs described in U.S. Patent No. 7,446,190 and those described in International Patent Application Publication No. WO / 2014055668 A1.Examples of CARs include CARs disclosed in any of the above publications, such as WO2014031687, US 8,339,645, US 7,446,179, US 2013 / 0149337, U.S. Patent No. 7,446,190, U.S. Patent No. 8,389,282, Kochenderfer et al., 2013, Nature Reviews Clinical Oncology, 10, 267-276 (2013); Wang et al. (2012) J. Immunother. 35(9):689-701; and Brentjens et al., Sci Transl Med. 2013 5(177). See also WO2014031687, US 8,339,645, US 7,446,179, US 2013 / 0149337, U.S. Patent No. 7,446,190, and U.S. Patent No. 8,389,282. Chimeric receptors, such as CARs, generally comprise a portion of an antibody molecule, generally the variable heavy (V) domain of an antibody. H ) chain region and / or variable light (V L ) chain regions, e.g., scFv antibody fragments, which contain the extracellular antigen-binding domain.
[0326] In some embodiments, the recombinant receptor, e.g., antibody portion of the CAR, further comprises at least a portion of an immunoglobulin constant region, such as a hinge region, e.g., an IgG4 hinge region, and / or a CH1 / CL and / or Fc region. In some embodiments, the constant region and portion are of human IgG, such as IgG4 or IgG1. In some aspects, the portion of the constant region serves as a spacer region between the antigen recognition component, e.g., scFv, and the transmembrane domain. The spacer can be of a length that provides increased responsiveness of the cell after antigen binding compared to the absence of the spacer. Exemplary spacers, e.g., hinge regions, include those described in International Patent Application Publication No. WO2014031687. In some examples, the length of the spacer is 12 or about 12 or as long as 12 amino acids. Exemplary spacers include those having at least about 10 to about 229 amino acids, about 10 to about 200 amino acids, about 10 to about 175 amino acids, about 10 to about 150 amino acids, about 10 to about 125 amino acids, about 10 to about 100 amino acids, about 10 to about 75 amino acids, about 10 to about 50 amino acids, about 10 to about 40 amino acids, about 10 to about 30 amino acids, about 10 to about 20 amino acids, or about 10 to about 15 amino acids, and including any integer between any of the boundaries of the recited ranges. In some embodiments, they have about 12 or less, about 119 or less, or about 229 or less amino acids. Exemplary spacers include an IgG4 hinge alone, an IgG4 hinge linked to CH2 and CH3 domains, or an IgG4 hinge linked to a CH3 domain.
[0327] This antigen recognition domain is generally linked to one or more intracellular signaling components, such as signaling components that mimic activation through an antigen receptor complex, such as a TCR complex in the case of a CAR, and / or a signal through another cell surface receptor. Thus, in some embodiments, an antigen binding component (e.g., an antibody) is linked to one or more transmembrane domains and an intracellular signaling domain. In some embodiments, the transmembrane domain is fused to the extracellular domain. In one embodiment, a transmembrane domain that is naturally associated with one of the domains in a receptor, such as a CAR, is used. In some cases, the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domain to the transmembrane domain of the same or different surface membrane protein, minimizing interaction with other members of the receptor complex.
[0328] The transmembrane domain in some embodiments is derived from either natural or synthetic sources. When the source is natural, the domain in some aspects is derived from any membrane-bound or transmembrane protein. The transmembrane region includes those derived from the α, β, or ζ chain of the T-cell receptor, CD28, CD3ε, CD45, CD4, CD5, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154 (i.e., including at least the transmembrane region thereof). Alternatively, the transmembrane domain in some embodiments is synthetic. In some aspects, the synthetic transmembrane domain contains primarily hydrophobic residues, such as leucine and valine. In some aspects, a phenylalanine, tryptophan, and valine triplet is found at each end of the synthetic transmembrane domain. In some embodiments, the linkage is by a linker, spacer, and / or transmembrane domain.
[0329] Some intracellular signaling domains mimic or approximate signals through natural antigen receptors, signals through such receptors in combination with costimulatory receptors, and / or signals through costimulatory receptors alone. In some embodiments, a short oligo- or polypeptide linker, e.g., a linker of 2-10 amino acids in length, such as one containing glycine and serine, e.g., a glycine-serine duopolypeptide, is present and forms a link between the transmembrane domain and the cytoplasmic signaling domain of the CAR.
[0330] Receptors, e.g., CARs, generally comprise at least one or more intracellular signaling components. In some embodiments, receptors comprise intracellular components of the TCR complex, such as the TCR CD3 chain, e.g., the CD3ζ chain, which mediates T cell activation and cytotoxicity. Thus, in some aspects, the antigen-binding moiety is linked to one or more cell signaling modules. In some embodiments, the cell signaling module comprises a CD3 transmembrane domain, a CD3 intracellular signaling domain, and / or other CD transmembrane domains. In some embodiments, the receptor, e.g., CARs, further comprises one or more additional molecule portions, such as Fc receptor γ, CD8, CD4, CD25, or CD16. For example, in some aspects, CARs or other chimeric receptors comprise chimeric molecules between CD3-zeta (CD3-ζ) or Fc receptor γ and CD8, CD4, CD25, or CD16.
[0331] In some embodiments, upon ligation of the CAR or other chimeric receptor, the cytoplasmic domain or intracellular signaling domain of the receptor activates at least one of the normal effector functions or responses of an immune cell, such as a T cell engineered to express the CAR. For example, in some contexts, the CAR induces a function of the T cell, such as cytolytic activity or T helper activity, such as secretion of cytokines or other factors. In some embodiments, a truncated portion of the intracellular signaling domain of an antigen receptor component or a costimulatory molecule is used in place of an intact immunostimulatory chain, for example, when it transduces an effector function signal. In some embodiments, the one or more intracellular signaling domains also include the cytoplasmic sequence of a T cell receptor (TCR), and in some aspects, those of a co-receptor that acts in concert with such receptor to initiate signal transduction after antigen receptor engagement in a natural context.
[0332] In the context of natural TCR, sufficient activation generally requires not only signal transduction through TCR but also costimulatory signal.Thus, in some embodiments, CAR also includes components for generating secondary or costimulatory signal to promote sufficient activation.In other embodiments, CAR does not include components for generating costimulatory signal.In some aspects, additional CAR is expressed in the same cell and provides components for generating secondary or costimulatory signal.
[0333] T cell activation, in some aspects, has been described as being mediated by two classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signaling sequences), and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences). In some aspects, the CAR contains one or both of such signaling components.
[0334] In some aspects, CAR comprises a primary cytoplasmic signaling sequence that regulates the primary activation of TCR complex.The primary cytoplasmic signaling sequence that acts in a stimulatory manner can contain a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM.Examples of ITAM that contain a primary cytoplasmic signaling sequence include those derived from TCRzeta, FcRgamma, FcRbeta, CD3gamma, CD3delta, CD3epsilon, CDS, CD22, CD79a, CD79b and CD66d.In some embodiments, the cytoplasmic signaling molecule in CAR contains a cytoplasmic signaling domain, a part thereof, or a sequence derived from CD3zeta.
[0335] In some embodiments, the CAR comprises the signaling domain and / or transmembrane portion of a costimulatory receptor, such as CD28, 4-1BB, OX40, DAP10, and ICOS. In some aspects, the same CAR comprises both an activating component and a costimulatory component.
[0336] In some embodiments, the activation domain is included in one CAR, while the costimulatory component is provided by another CAR that recognizes another antigen. In some embodiments, the CAR includes an activating or stimulatory CAR, a costimulatory CAR, both expressed on the same cell (see WO2014 / 055668). In some aspects, the cell includes one or more stimulatory or activating CARs, and / or a costimulatory CAR. In some embodiments, the cell further includes an inhibitory CAR (iCAR, see Fedorov et al., Sci. Transl. Medicine, 5(215) (December 2013)), such as a CAR that recognizes an antigen other than that associated with and / or specific to a disease or condition, such that the activation signal delivered through the disease-targeting CAR is attenuated or inhibited by the binding of the inhibitory CAR to its ligand, for example, reducing off-target effects.
[0337] In certain embodiments, the intracellular signaling domain comprises a CD28 transmembrane and signaling domain linked to a CD3 (e.g., CD3-zeta) intracellular domain. In some embodiments, the intracellular signaling domain comprises a chimeric CD28 and CD137 (4-1BB, TNFRSF9) costimulatory domain linked to a CD3zeta intracellular domain.
[0338] In some embodiments, the CAR includes one or more (e.g., two or more) costimulatory domains and an activation domain (e.g., a primary activation domain) in the cytoplasmic portion. Exemplary CARs include the intracellular components CD3-zeta, CD28, and 4-1BB.
[0339] In some embodiments, the CAR or other antigen receptor further comprises a marker, such as a cell surface marker, which can be used to confirm the transduction or genetic engineering of cells expressing a receptor, such as a truncated version of a cell surface receptor, such as truncated EGFR (tEGFR). In some aspects, the marker comprises all or a portion (e.g., a truncated form) of CD34, NGFR, or epidermal growth factor receptor (e.g., tEGFR). In some embodiments, the nucleic acid encoding the marker is operably linked to a polynucleotide encoding a linker sequence, such as a cleavable linker sequence, e.g., T2A. See WO2014031687.
[0340] In some embodiments, the marker is a molecule that is not naturally found on or at the surface of T cells, e.g., a cell surface protein, or portion thereof.
[0341] In some aspects, the molecule is a non-self molecule, e.g., a non-self protein, ie, one that is not recognized as "self" by the immune system of the host into which the cells are adoptively transferred.
[0342] In some embodiments, the marker does not serve a therapeutic function and / or has no effect other than being used as a marker for genetic engineering, e.g., to select successfully engineered cells. In other embodiments, the marker may be a therapeutic molecule or a molecule that otherwise exerts a desired effect, e.g., a ligand that encounters the cells in vivo, e.g., a costimulatory molecule or immune checkpoint molecule that enhances and / or reduces the response of the cells upon adoptive transfer and encounter with the ligand.
[0343] In some cases, CARs are referred to as first, second, and / or third generation CARs. In some aspects, first generation CARs are those that simply provide a CD3 chain-inducible signal upon antigen binding; in some aspects, second generation CARs are those that provide such a signal and a costimulatory signal, such as those that include intracellular signaling domains from costimulatory receptors such as CD28 or CD137; in some aspects, third generation CARs are those that include multiple costimulatory domains from different costimulatory receptors.
[0344] In some embodiments, the chimeric antigen receptor comprises an extracellular portion containing an antibody or an antibody fragment. In some aspects, the chimeric antigen receptor comprises an extracellular portion containing an antibody or a fragment and an intracellular signaling domain. In some embodiments, the antibody or fragment comprises an scFv, and the intracellular domain comprises an ITAM. In some aspects, the intracellular signaling domain comprises the signaling domain of the zeta chain of the CD3-zeta (CD3ζ) chain. In some aspects, the chimeric antigen receptor comprises a transmembrane domain linking the extracellular domain and the intracellular signaling domain. In some aspects, the transmembrane domain comprises the transmembrane portion of CD28. In some aspects, the chimeric antigen receptor comprises an intracellular domain of a T cell costimulatory molecule. In some aspects, the T cell costimulatory molecule is CD28 or 41BB.
[0345] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues and are not limited to a minimum length. Polypeptides, including receptors and other polypeptides provided, such as linkers or peptides, can contain amino acid residues, including natural and / or non-natural amino acid residues. The term also includes post-expression modifications of polypeptides, such as glycosylation, sialylation, acetylation, and phosphorylation. In some aspects, polypeptides can contain modifications to native or natural sequences, so long as the protein maintains the desired activity. These modifications can be intentional, such as by site-directed mutagenesis, or can be accidental, such as by mutation of the host that produces the protein or by errors caused by PCR amplification.
[0346] The recombinant receptor such as CAR expressed by the cell administered to the subject generally recognizes or specifically binds to the molecule that is expressed and / or specific to the disease or disease state being treated or the cell.When specifically bound to the molecule, such as an antigen, the receptor generally delivers an immune stimulatory signal, such as ITAM transduction signal, to the cell, thereby promoting an immune response that targets the disease or disease state.For example, in some embodiments, the cell expresses a CAR that specifically binds to the antigen expressed by the cell or tissue of the disease or disease state or associated with the disease or disease state.
[0347] In some contexts, overexpression of stimulatory factors (e.g., lymphokines or cytokines) can be toxic to subjects. Thus, in some contexts, viral vectors introduce gene segments into cells that, when administered, such as in adoptive immunotherapy, make the cells susceptible to negative selection in vivo. For example, in some aspects, after transduction of cells with such gene segments, the cells are eliminated as a result of changes in the in vivo conditions of the subject to which they are administered. Negative selectable phenotypes can be generated by the insertion of genes that confer sensitivity to administered agents, such as compounds. Negatively selectable genes include the herpes simplex virus type I thymidine kinase (HSV-I TK) gene, which confers ganciclovir sensitivity (Wigler et al., Cell II :223, 1977); the cellular hypoxanthine phosphoribosyltransferase (HPRT) gene, the cellular adenine phosphoribosyltransferase (APRT) gene, and bacterial cytosine deaminase (Mullen et al., Proc. Natl. Acad. Sci. USA. 89:33 (1992)).
[0348] Among the additional nucleic acids that may be included in viral vectors for transduction and expression in cells are those that improve the efficacy of therapy, such as by promoting the viability and / or function of the transfected cells, as described by Lupton SD et al., Mol. and Cell Biol., 11:6 (1991) and Riddell et al., Human Gene Therapy 3:319-338 (1992); provide genetic markers for the selection and / or evaluation of cells, such as to assess in vivo survival or localization; and / or encode products that improve safety, for example, by making cells susceptible to negative selection in vivo; see also publications PCT / US91 / 08442 and PCT / US94 / 05601 by Lupton et al., which describe the use of bifunctional selectable fusion genes resulting from fusing dominant positive selectable markers with negative selectable markers. See, for example, columns 14-17 of U.S. Patent No. 6,040,177 to Riddell et al.
[0349] VI. Therapeutic Methods and Compositions In some aspects, the products of the method are used in a method of treatment, such as administering cells and compositions to a subject in adoptive cell therapy. Also provided are such methods, as well as uses of the cells processed and produced by the method, and pharmaceutical compositions and formulations for use therein. The provided methods generally involve administering cells or compositions, such as output compositions and / or formulated compositions, to a subject.
[0350] In some embodiments, the cells express recombinant receptors such as CARs, or other antigen receptors such as transgenic TCRs, such as those introduced in the transduction methods provided herein. Such cells are generally administered to subjects with a disease or condition that is specifically recognized by the receptor. In one embodiment, the cells express an antigen receptor, such as a recombinant or chimeric receptor, such as a CAR or TCR, that specifically binds to a ligand associated with the disease or condition or expressed by the cell or tissue. For example, in some embodiments, the receptor is an antigen receptor, and the ligand is an antigen that is specific and / or associated with the disease or condition. The administration generally results in the improvement of one or more symptoms of the disease or condition, and / or treats or prevents the disease or condition or its symptoms. Among the diseases, conditions, and disorders are tumors, including solid tumors, hematological malignancies, and melanomas, including localized and metastatic tumors, infectious diseases such as infections and parasitic diseases caused by viruses or other pathogens, such as HIV, HCV, HBV, CMV, and autoimmune and inflammatory diseases. In some embodiments, the disease or condition is a tumor, cancer, malignancy, neoplasm, or other proliferative disease or disorder. Such diseases include, but are not limited to, leukemia, lymphoma, such as chronic lymphocytic leukemia (CLL), ALL, non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, refractory follicular lymphoma, mantle cell lymphoma, indolent B-cell lymphoma, B-cell malignancies, colon, lung, liver, breast, prostate, ovarian, skin, melanoma, bone cancer, and brain tumor, ovarian cancer, epithelial cancer, renal cell carcinoma, pancreatic adenocarcinoma, Hodgkin's lymphoma, cervical carcinoma, colorectal cancer, glioblastoma, neuroblastoma, Ewing's sarcoma, medulloblastoma, osteosarcoma, synovial sarcoma, and / or mesothelioma.
[0351] In some embodiments, the disease or condition is an infectious disease or condition, such as, but not limited to, viral, retroviral, bacterial, and protozoal infections, immunodeficiencies, cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, BK polyomavirus, etc. In some embodiments, the disease or condition is an autoimmune or inflammatory disease or condition, such as arthritis, e.g., rheumatoid arthritis (RA), type I diabetes, systemic lupus erythematosus (SLE), inflammatory bowel disease, psoriasis, scleroderma, autoimmune thyroid disease, Graves' disease, Crohn's disease, multiple sclerosis, asthma, and / or a disease or condition associated with transplantation.
[0352] In some embodiments, the antigen associated with the disease or disorder targeted by the cell or composition is orphan tyrosine kinase receptor ROR1, tEGFR, Her2, L1-CAM, CD19, CD20, CD22, mesothelin, CEA, and hepatitis B surface antigen, antifolate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, 0EPHa2, ErbB2, 3, or 4, FBP, fetal acetylcholine e receptor, GD2, GD3, HMW-M AA, IL-22R-alpha, IL-13R-alpha2, kdr, kappa light chain, Lewis Y, L1-cell adhesion molecule, MAGE-A1, mesothelin, MUC1, MUC16, PSCA, NKG2D ligand, NY-ESO-1, MART-1, gp100, oncofetal antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, CS-1, c-Met, GD-2, and cyclins such as MAGE A3, CE7, Wilms' tumor 1 (WT-1), cyclin A1 (CCNA1), and / or biotinylated molecules, and / or molecules expressed by HIV, HCV, HBV, or other pathogens.
[0353] In some embodiments, the cells or compositions are administered in an amount that is effective for treating or preventing disease or condition, such as a therapeutically effective or prophylactically effective amount.Thus, in some embodiments, the method of administration comprises administering cells and compositions in an effective amount.The therapeutic or prophylactic effectiveness in some embodiments is monitored by periodic evaluation of the treated subject.For repeated administration over several days or longer, depending on the condition, treatment is repeated until the desired suppression of disease symptoms occurs.However, other dosing regimes may be useful and can be determined.
[0354] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to the complete or partial improvement or reduction of a disease or condition or disorder, or its associated symptoms, adverse effects or outcomes, or phenotype. Desirable effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, reduction of any direct or indirect pathological consequences of disease, prevention of metastasis, reduction of the rate of disease progression, improvement or mitigation of disease state, and remission or improvement of prognosis. The term does not imply complete cure of disease, or complete elimination of any symptoms, or effect on all symptoms or outcomes.
[0355] As used herein, "delaying the onset of disease" means to postpone, prevent, slow down, delay, stabilize, inhibit, and / or postpone the onset of disease (such as cancer). This delay can be of variable length of time, depending on the disease being treated and / or the medical history of the individual. As will be apparent to those skilled in the art, a sufficient or substantial delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, terminal cancer, such as the onset of metastasis, can be delayed.
[0356] As used herein, "preventing" includes providing prophylaxis against the occurrence or recurrence of a disease in a subject who may be susceptible to the disease but has not yet been diagnosed as having the disease. In some embodiments, the provided cells and compositions are used to delay the onset of the disease or slow the progression of the disease.
[0357] As used herein, "inhibiting" a function or activity refers to reducing a function or activity when compared to conditions that are otherwise the same except for the condition or parameter of interest, or alternatively, compared to another condition. For example, a cell that inhibits tumor growth reduces the rate of tumor growth compared to the rate of tumor growth in the absence of the cell.
[0358] An "effective amount" of an agent, e.g., a pharmaceutical formulation, cell, or composition, in the context of administration, refers to an amount effective, at dosages / amounts and for periods of time necessary, to achieve a desired result, such as a therapeutic or prophylactic result.
[0359] A "therapeutically effective amount" of an agent, e.g., a pharmaceutical formulation or cells, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic outcome, such as for the treatment of a disease, condition, or disorder, and / or the pharmacokinetic or pharmacodynamic effect of the treatment. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the subject, as well as the population of cells administered.
[0360] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic effect. Typically, but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
[0361] Methods of administering cells for adoptive cell therapy are known and can be used in connection with the provided methods and compositions.For example, methods of adoptive T cell therapy are described in, for example, U.S. Patent Application Publication No. 2003 / 0170238 to Gruenberg et al.; U.S. Patent No. 4,690,915 to Rosenberg; Rosenberg (2011) Nat Rev Clin Oncol. 8(10):577-85.See, for example, Themeli et al. (2013) Nat Biotechnol. 31(10):928-933; Tsukahara et al. (2013) Biochem Biophys Res Commun 438(1):84-9; Davila et al. (2013) PLoS ONE 8(4):e61338.
[0362] In some embodiments, cell therapy, such as adoptive cell therapy, such as adoptive T cell therapy, is carried out by autologous transfer, in which cells are isolated and / or otherwise prepared from the subject who should receive cell therapy or from a sample derived from such a subject.Thus, in some aspects, cells are derived from a subject, such as a patient, who needs treatment and cells, and after isolation and processing, the cells are administered to the same subject.
[0363] In some embodiments, cell therapy, such as adoptive cell therapy, such as adoptive T cell therapy, is carried out by allogeneic transfer, in which cells are isolated and / or otherwise prepared from a subject other than the subject that should or will eventually receive cell therapy, such as the first subject.In such embodiments, the cells are then administered to a different subject of the same species, such as the second subject.In some embodiments, the first and second subjects are genetically identical.In some embodiments, the first and second subjects are genetically similar.In some embodiments, the second subject expresses the same HLA class or supertype as the first subject.
[0364] The cells can be administered by any suitable means, for example, by bolus injection, injection, for example, intravenous or subcutaneous injection, intraocular injection, periocular injection, subretinal injection, intravitreal injection, transseptal injection, subscleral injection, intrachoroidal injection, intracameral injection, subconjectval injection, subconjuntival injection, subtenon injection, retrobulbar injection, peribulbar injection, or posterior juxtascleral delivery. In some aspects, they are administered parenterally, intrapulmonary, and intranasally, and, if desired for localized treatment, by intralesional administration. Parenteral injections include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some aspects, a predetermined dose is administered by a single bolus of cells, by multiple boluses of cells, or by continuous infusion of cells.
[0365] For prevention or treatment of disease, the appropriate dosage will depend on the type of disease being treated, the type of cells or recombinant receptor, the severity and course of the disease, whether the cells are administered for prophylactic or therapeutic purposes, previous therapy, the subject's medical history and response to the cells, and the discretion of the attending physician. The compositions and cells, in some embodiments, are suitably administered to the subject at one time or over a series of treatments.
[0366] In some embodiments, the cells are administered as part of a combination therapy, for example, simultaneously or sequentially in any order with another therapeutic intervention, such as an antibody or genetically engineered cell or receptor or agent (e.g., a cytotoxic or therapeutic agent). The cells in some embodiments are co-administered with or in association with one or more additional therapeutic agents, simultaneously or sequentially in any order. In some contexts, the cells are co-administered with another therapy close enough in time that the cell population enhances the effect of the one or more additional therapeutic agents, or vice versa. In some embodiments, the cells are administered before the one or more additional therapeutic agents. In some embodiments, the cells are administered after the one or more additional therapeutic agents. In some embodiments, the one or more additional agents include a cytokine, such as IL-2, for example, to enhance persistence.
[0367] Once the cells are administered to a subject (e.g., a human), the biological activity of the cell population in some aspects is measured by any of several known methods. Parameters to be evaluated include specific binding of the cells to antigens, for example, in vivo by imaging, or ex vivo by ELISA or flow cytometry. In certain embodiments, the ability of the cells to destroy target cells can be measured using any suitable method known in the art, such as cytotoxicity assays described in, for example, Kochenderfer et al., J. Immunotherapy, 32(7):689-702 (2009), and Herman et al. J. Immunological Methods, 285(1):25-40 (2004). In certain embodiments, the biological activity of the cells can also be measured by assaying the expression and / or secretion of certain cytokines, such as CD107a, IFNγ, IL-2, and TNF. In some aspects, the biological activity is measured by evaluating clinical outcomes, such as reduction in tumor burden or cell load. In some aspects, toxic outcomes, cellular persistence and / or proliferation, and / or the presence or absence of a host immune response are evaluated.
[0368] In certain embodiments, cells are modified in any number of ways to increase their therapeutic or prophylactic efficacy.For example, the engineered CAR or TCR expressed by the population can be directly or indirectly conjugated to targeting moiety through linker.The practice of conjugating a compound, such as a CAR or TCR, to targeting moiety is known in the art.See, for example, Wadwa et al., J. Drug Targeting 3:111 (1995) and U.S. Patent No. 5,087,616.
[0369] Pharmaceutical compositions or formulations for use in such methods are also provided, which in some embodiments are formulated in association with the processing methods provided, e.g., formulated in a closed system in which other processing steps are performed, e.g., in an automated or partially automated manner.
[0370] In some aspects, the cells and compositions are administered to a subject in the form of a pharmaceutical composition or formulation, such as a composition comprising a cell or cell population and a pharma- ceutically acceptable carrier or excipient.
[0371] The term "pharmaceutical formulation" refers to a preparation that is in a form that allows the biological activity of the active ingredients contained therein to be effective, and that does not contain additional components that are unacceptably toxic to the subject to which the formulation will be administered.
[0372] In some embodiments, the pharmaceutical composition additionally comprises other pharmacologic active agents or drugs, such as chemotherapeutic agents, for example, asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc. In some embodiments, the agent is administered in the form of a salt, for example, a pharmacologic acceptable salt. Suitable pharmacologic acceptable acid addition salts include those derived from mineral acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, and sulfuric acid, and organic acids, such as tartaric acid, acetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid, succinic acid, and arylsulfonic acid, for example, p-toluenesulfonic acid.
[0373] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0374] In some aspects, the choice of carrier is determined in part by the particular cells and / or by the method of administration. Thus, there are a variety of suitable formulations. For example, the pharmaceutical composition may contain a preservative. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives is used. The preservative or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition. Carriers are described, for example, by Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to, buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum. These include, but are not limited to, proteins such as albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG).
[0375] In some aspects, a buffering agent is included in the composition. Suitable buffering agents include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. In some aspects, a mixture of two or more buffering agents is used. The buffering agent or mixture is typically present in an amount of about 0.001% to about 4% by weight of the total composition. Methods for preparing administrable pharmaceutical compositions are known. Exemplary methods are described in more detail, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).
[0376] The formulation may comprise an aqueous solution.The formulation or composition may also contain more than one active ingredient, preferably one that has complementary activity with the cells, useful for the particular indication, disease or condition that is being treated with the cells, provided that the respective activities do not adversely affect each other.Such active ingredients are suitably present in combination in an amount that is effective for the intended purpose.Thus, in some embodiments, the pharmaceutical composition further comprises other pharmacologic active agents or drugs, such as chemotherapeutic agents, for example, asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, and / or vincristine.
[0377] In some embodiments, the pharmaceutical composition contains an amount of cells that is effective for treating or preventing a disease or condition, such as a therapeutically or prophylactically effective amount. The therapeutic or prophylactic effectiveness in some embodiments is monitored by periodic evaluation of the treated subject. The desired dosage can be delivered by a single bolus of cells, by multiple boluses of cells, or by continuous infusion of cells.
[0378] Cells and compositions can be administered using standard administration techniques, formulations, and / or devices. Administration of cells can be autologous or heterologous. For example, immunoresponsive cells or precursors can be obtained from one subject and administered to the same subject or different compatible subjects. Peripheral blood derived immunoresponsive cells or their progeny (e.g., in vivo, ex vivo, or in vitro derived) can be administered by catheter administration, systemic injection, local injection, intravenous injection, or local injection, including parenteral administration. When administering a therapeutic composition (e.g., a pharmaceutical composition containing genetically modified immunoresponsive cells), it is generally formulated in an injectable unit dosage form (solution, suspension, emulsion).
[0379] Formulations include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. In some embodiments, the cell population is administered parenterally. The term "parenteral" as used herein includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration. In some embodiments, the cells are administered to the subject using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection.
[0380] The composition in some embodiments is provided as a sterile liquid preparation, such as an isotonic aqueous solution, suspension, emulsion, dispersion, or viscous composition, which in some aspects can be buffered to a selected pH. Liquid preparations are usually easier to prepare than gels, other viscous compositions, and solid compositions. In addition, liquid compositions are somewhat more convenient to administer, especially by injection. On the other hand, viscous compositions can be formulated within a suitable viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can contain a carrier, which can be a solvent or dispersion medium, such as water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and suitable mixtures thereof.
[0381] Injectable sterile solutions can be prepared by incorporating the cells into a solvent, such as by mixing with a suitable carrier, diluent, or excipient, such as sterile water, physiological saline, glucose, dextrose, etc. The composition can contain auxiliary substances, such as wetting agents, dispersing agents, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, and / or coloring agents, depending on the route of administration and the preparation desired. Standard textbooks can be consulted in some aspects to prepare suitable preparations.
[0382] Various additives can be added to enhance the stability and sterility of the composition, including antimicrobial preservatives, antioxidants, chelating agents and buffers.Prevention of microbial action can be ensured by various antibacterial and antifungal agents, such as paraben, chlorobutanol, phenol and sorbic acid.Prolonged absorption of injectable pharmaceutical forms can be achieved by using agents that delay absorption, such as aluminum monostearate and gelatin.
[0383] Formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, for example, by filtration through sterile filtration membranes.
[0384] Processing steps may include formulating such compositions.
[0385] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, "a" or "an" means "at least one" or "one or more." Aspects and variations described herein are understood to include "consisting of" and / or "consisting essentially of" aspects and variations.
[0386] Throughout this disclosure, various aspects of the claimed subject matter are presented in range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the claimed subject matter. Thus, the description of a range should be considered to specifically disclose all possible subranges, as well as individual numerical values within that range. For example, when a range of values is provided, each intervening value between the upper and lower limits of the range, and any other stated or intervening value in the stated range, is understood to be included within the claimed subject matter. The upper and lower limits of these smaller ranges may be independently included within the smaller range, and are also included within the claimed subject matter, subject to any limits specifically excluded in the stated range. If a stated range includes one or both of the limits, then the range excluding either or both of those included limits is also included in the claimed subject matter. This applies regardless of the width of the range.
[0387] The term "about" as used herein refers to the normal error range for each value, which is readily known to those skilled in the art. Reference herein to a value or parameter of "about" includes (and describes) the embodiment directed to the value or parameter itself. For example, a description that refers to "about X" includes the description of "X".
[0388] As used herein, a composition refers to any mixture of two or more products, substances, or compounds, including cells, which may be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous, or any combination thereof.
[0389] As used herein, the statement that a cell or a group of cells is "positive" for a particular marker refers to the detectable presence of a particular marker, typically a surface marker, on or in the cell.When referring to a surface marker, the term refers to the presence of surface expression detected by flow cytometry, for example, by staining with an antibody that specifically binds to the marker and detecting the antibody, and the staining is detectable by flow cytometry at a level that is substantially higher than the staining detected by the same procedure using an isotype-matched control under otherwise identical conditions, and / or at a level that is substantially the same as that for cells known to be positive for the marker, and / or at a level that is substantially higher than that for cells known to be negative for the marker.
[0390] As used herein, the statement that a cell or a group of cells is "negative" for a particular marker refers to the substantial absence of detectable presence of a particular marker, typically a surface marker, on or in the cell.When referring to a surface marker, the term refers to the absence of surface expression detected by flow cytometry, for example, by staining with an antibody that specifically binds to the marker and detecting the antibody, and the staining is not detected by flow cytometry at a level substantially higher than the staining detected by the same procedure using an isotype-matched control under otherwise identical conditions, and / or at a level substantially lower than that for cells known to be positive for the marker, and / or at a level substantially similar to that for cells known to be negative for the marker.
[0391] VII. Exemplary Embodiments Among the aspects provided herein are the following. 1. A method of transduction comprising incubating an input composition comprising cells and viral particles containing a recombinant viral vector in an internal cavity of a centrifuge chamber; the centrifuge chamber is rotatable about an axis of rotation and includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of permitting the introduction of liquid into and the expulsion of liquid from the internal cavity; the centrifuge chamber is rotating about the axis of rotation during at least a portion of the incubation; and the method producing an output composition comprising a plurality of said cells transduced with said viral vector; The transduction method. 2. A method of transduction comprising incubating an input composition comprising cells and viral particles containing a recombinant viral vector in an internal cavity of a centrifuge chamber; the centrifuge chamber is rotatable about an axis of rotation and includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of permitting the introduction of liquid into and the expulsion of liquid from the internal cavity; the centrifuge chamber is rotating about the axis of rotation during at least a portion of the incubation; the total liquid volume of the input composition present in the cavity during rotation of the centrifuge chamber is at most about 5 mL per square inch of interior surface area of the cavity; and the method producing an output composition comprising a plurality of said cells transduced with said viral vector; The transduction method. 3. The rotation is Spinning at a relative centrifugal force (RCF) of greater than or about 200 g, greater than or about 300 g, or greater than or about 500 g on the inner surface of the side wall of the cavity and / or on the surface layer of the cells. 3. The method of embodiment 1 or 2, comprising: 4. The rotation is on the inner surface of the side wall of the cavity and / or on the surface layer of the cells, Spinning at a relative centrifugal force of at or about 600g, 800g, 1000g, 1100g, 1600g, 2000g, 2100g, 2200g, 2500g, or 3000g; or Spinning at a relative centrifugal force of at least 600g, 800g, 1000g, 1100g, 1600g, 2000g, 2100g, 2200g, 2500g, or 3000g; The method of any one of aspects 1 to 3, comprising: 5. The rotation Rotation at a relative centrifugal force of 500 or about 500 g to 2500 or about 2500 g, 500 or about 500 g to 2000 or about 2000 g, 500 or about 500 g to 1600 or about 1600 g, 500 or about 500 g to 1000 or about 1000 g, 600 or about 600 g to 1600 or about 1600 g, 600 or about 600 g to 1000 or about 1000 g, 1000 or about 1000 g to 2000 or about 2000 g, or 1000 or about 1000 g to 1600 or about 1600 g, each including the boundary values. The method of any one of aspects 1 to 4, comprising: 6. The at least a portion of the incubation, during which the chamber is rotating, about or greater than 5 minutes, about or greater than 10 minutes, about or greater than 15 minutes, about or greater than 20 minutes, about or greater than 30 minutes, about or greater than 45 minutes, about or greater than 60 minutes, about or greater than 90 minutes, or about or greater than 120 minutes; or 5 or about 5 minutes to 60 or about 60 minutes, 10 or about 10 minutes to 60 or about 60 minutes, 15 or about 15 minutes to 60 or about 60 minutes, 15 or about 15 minutes to 45 or about 45 minutes, 30 or about 30 minutes to 60 or about 60 minutes, or 45 or about 45 minutes to 60 or about 60 minutes, each inclusive; The method of any one of aspects 1 to 5, wherein the period is 7. The transduction method of any of aspects 1-6, wherein the centrifuge chamber further comprises a movable member, and the internal cavity is a variable volume cavity defined by the end wall, the substantially rigid side wall, and the movable member, and the movable member is movable within the chamber to vary the internal volume of the cavity. 8. The method of any of aspects 1-7, wherein the sidewall is curved. 9. The method of embodiment 8, wherein the side wall is generally cylindrical. 10. the movable member is a piston; and / or the movable member is movable axially within the chamber to vary the interior volume of the cavity; The method according to any one of aspects 7 to 9. 11. The at least one opening includes an inlet and an outlet capable of allowing the intake and expulsion, respectively; or said at least one opening includes a single port capable of permitting said intake and expulsion; The method of any one of aspects 1 to 10. 12. The method of any of the preceding aspects, wherein the at least one opening is coaxial with the chamber and located in the end wall. 13. The internal surface area of the cavity is at least 1×10 9 μm 2 Or at least about 1 × 10 9 μm 2 and; The cavity has an internal surface area of at least 1×10 10 μm 2 Or at least about 1 × 10 10 μm 2 and; the length of said rigid wall in a direction extending from said end wall is at least about 5 cm; the length of said rigid wall in a direction extending from said end wall is at least about 8 cm; and / or the cavity comprises a radius of at least about 2 cm in at least one cross section; The method of any one of aspects 1 to 12. 14. the average liquid volume of said input composition present in said cavity during said incubation is at most about 5 milliliters (mL) per square inch of interior surface area of said cavity during said incubation; the maximum liquid volume of said input composition present in said cavity at any one time during said incubation is at most about 5 mL per square inch of the maximum internal surface area of said cavity; the average liquid volume of said input composition present in said cavity during said incubation is at most about 2.5 milliliters (mL) per square inch of interior surface area of said cavity during said incubation; or the maximum liquid volume of said input composition present in said cavity at any one time during said incubation is at most about 2.5 mL per square inch of maximum internal surface area of said cavity; The method of any one of aspects 1 to 13. 15. The method of any of embodiments 1-14, wherein the liquid volume of the input composition present in the cavity during said rotation per square inch of internal surface area of the cavity (mL / sq.in.) is 0.5 or about 0.5 mL / sq.in. to 5 or about 5 mL / sq.in., 0.5 or about 0.5 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., 0.5 or about 0.5 mL / sq.in. to 1 or about 1 mL / sq.in., 1 or about 1 mL / sq.in. to 5 or about 5 mL / sq.in., 1 or about 1 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., or 2.5 or about 2.5 mL / sq.in. to 5 or about 5 mL / sq.in. 16. The number of cells in the input composition is sufficient or close to the number of cells sufficient to form a monolayer on the surface of the cavity during rotation of the centrifuge chamber at a force of at or about 1000 g or at or about 2000 g on the inner surface of the side wall and / or on a surface layer of the cells; and / or the number of said cells in said input composition is at most 1.5 or 2 times the number of said cells sufficient to form a monolayer on the surface of said cavity during rotation of said centrifuge chamber at a force of at or about 1000 g or at or about 2000 g on the inner surface of said side wall and / or on a surface layer of said cells; The method of any one of aspects 1 to 15. 17. The input composition in the cavity is at least 1×10 6 or at least about 1×10 6 comprises said cells; or The input composition in the cavity is at least 5×10 6 or at least about 5×10 6 comprises said cells; or The input composition in the cavity is at least 1×10 7 or at least about 1×10 7 comprises said cells; or The input composition in the cavity is at least 1×10 8 or at least about 1×10 8 comprising said cells; The method of any one of aspects 1 to 16. 18. The input composition in the cavity is at least 1×10 7 or at least about 1×10 7 Pieces, at least 2 x 10 7 or at least about 2×10 7 Pieces, at least 3 × 10 7 or at least about 3×10 7 Pieces, at least 4 × 10 7 or at least about 4×10 7 Pieces, at least 5 × 10 7 or at least about 5×10 7 Pieces, at least 6 × 10 7 or at least about 6×10 7 Pieces, at least 7 x 10 7 or at least about 7×10 7 Pieces, at least 8 x 10 7 or at least about 8×10 7 Pieces, at least 9 x 10 7 or at least about 9×10 7 Pieces, at least 1 × 10 8 or at least about 1×10 8 Pieces, at least 2 x 10 8 or at least about 2×10 8 Pieces, at least 3 × 10 8 or at least about 3×10 8 pieces, or at least 4 × 10 8 or at least about 4×10 8 18. The method of any of aspects 1 to 17, comprising said cells. 19. The input composition comprises at least 1 infectious unit (IU) or about 1 IU, at least 2 IU or at least about 2 IU, at least 3 IU or at least about 3 IU, at least 4 IU or at least about 4 IU, at least 5 IU or at least about 5 IU, at least 10 IU or at least about 10 IU, at least 20 IU or at least about 20 IU, at least 30 IU or at least about 30 IU, at least 40 IU or at least about 40 IU, at least 50 IU or at least about 50 IU, or at least 60 IU or at least about 60 IU of virus particles per cell; or the input composition comprises 1 infectious unit (IU) or about 1 IU, 2 IU or about 2IU, 3 IU or about 3IU, 4 IU or about 4IU, 5 IU or about 5IU, 10 IU or about 10 IU, 20 IU or about 20 IU, 30 IU or about 30 IU, 40 IU or about 40 IU, 50 IU or about 50 IU, or 60 IU or about 60 IU of viral particles per cell; The method of any one of aspects 1 to 18. 20. The method of any of aspects 1-19, wherein the maximum total liquid volume of said input composition present in said cavity at any one time during said incubation is at most 2 times, at most 10 times, or at most 100 times the total volume of said cells in said cavity, or the average volume of said input composition over the course of said incubation is at most 2, 10, or 100 times the total volume of cells in said cavity. 21. The method of any of embodiments 1-20, wherein the maximum volume of said input composition present in said cavity at any one time during said incubation or the average volume over the course of said incubation is at most 2-fold, 10-fold, 25-fold, 50-fold, 100-fold, 500-fold, or 1000-fold the volume of the monolayer of cells formed on the inner surface of the cavity during rotation of the chamber at a force of at or about 1000g or at or about 2000g on the inner surface of the side wall and / or on the surface layer of the cells. 22. The method of any of aspects 1-21, wherein the liquid volume of said input composition is at most 20 mL, at most 40 mL, at most 50 mL, at most 70 mL, at most 100 mL, at most 120 mL, at most 150 mL, or at most 200 mL. 23. The method of any of the preceding aspects, wherein said input composition occupies all or substantially all of the volume of said internal cavity during at least a portion of said incubation. 24. The method of any of aspects 1-23, wherein during at least a portion of said incubation in said chamber or during said rotation of said chamber, the liquid volume of said input composition occupies only a portion of the volume of said internal cavity of said chamber, and wherein the volume of said cavity during at least a portion of said incubation or during said rotation further comprises a gas, and wherein said gas is introduced into said cavity via said at least one opening before or during said incubation. 25. The method of embodiment 24, wherein the centrifuge chamber includes a movable member, and the introduction of gas into the centrifuge chamber causes the movable member to move to increase the volume of the internal cavity of the chamber, thereby decreasing the total liquid volume of the input composition present in the cavity during rotation of the centrifuge chamber per square inch of internal surface area of the cavity compared to when no gas is present in the chamber. 26. A method of transduction comprising the steps of: a) At least 1 × 10 9 μm 2 Or at least about 1 × 10 9 μm 2 , or at least 1 × 10 10 μm 2 Or at least about 1 × 10 10 μm 2 into an internal cavity of the centrifuge chamber having an internal surface area of i) an input composition comprising cells and viral particles comprising a recombinant viral vector, The number of cells in the input composition is at least 1×10 7 Individual and the viral particles are present in the input composition at at least 1 infectious unit (IU) or about 1 IU per cell; and the input composition comprising a liquid volume less than a maximum volume of the internal cavity of the centrifuge chamber; and ii) a volume of gas up to the remainder of the maximum volume of the internal cavity of the centrifuge chamber; providing b) incubating the input composition, at least a portion of the incubation being carried out within the internal cavity of the centrifuge chamber while rotating the centrifuge chamber. Including, The transduction method, wherein the method produces an output composition comprising a plurality of said cells transduced with said viral vector. 27. The number of cells is at least 50 x 10 6 Pieces or about 50 x 10 6 pieces, 100×10 6 Pieces or about 100 x 10 6 pcs, or 200 x 10 6 Pieces or about 200 x 10 6 and / or the viral particles are present at at least 1.6 IU / cell, 1.8 IU / cell, 2.0 IU / cell, 2.4 IU / cell, 2.8 IU / cell, 3.2 IU / cell, or 3.6 IU / cell, 4.0 IU / cell, 5.0 IU / cell, 6.0 IU / cell, 7.0 IU / cell, 8.0 IU / cell, 9.0 IU / cell, or 10.0 IU / cell; The method of embodiment 26. 28. The liquid volume of the input composition is 200 mL or less, 100 mL or less, 50 mL or less, or 20 mL or less; and / or the liquid volume of the input composition relative to the internal surface area of the cavity or the maximum internal surface area of the cavity during rotation is at most 50%, at most 40%, at most 30%, at most 20%, or at most 10%; The method of embodiment 26 or 27. 29. The method of any of aspects 26-28, wherein the volume of the gas is at most 200 mL, at most 180 mL, at most 140 mL, or at most 100 mL. 30. The rotation is Rotation at a relative centrifugal force of at least 600 g, 800 g, 1000 g, 1100 g, 1500 g, 1600 g, 2000 g, 2400 g, 2600 g, 2800 g, 3000 g, 3200 g, or 3600 g on the inner surface of the side wall of the cavity or on the surface layer of the cells. 30. The method of any one of embodiments 26 to 29, 31. A method of transduction comprising the steps of: incubating an input composition comprising cells and viral particles comprising the recombinant viral vector; at least a portion of the incubating step is performed under rotating conditions, thereby producing an output composition comprising a plurality of the cells transduced with the viral vector; The input composition comprises a volume that is about or greater than 20 mL, about or greater than 50 mL, at least 100 mL, or at least 150 mL, and / or the input composition comprises a volume of at least 1×10 8 contains cells; and the rotation conditions comprising a relative centrifugal force at a surface layer of the cells of greater than about 800 g, greater than about 1000 g, or greater than about 1500 g; The transduction method. 32. At least 25% or at least 50% of the cells in the output composition are transduced with the viral vector; and / or at least 25% or at least 50% of the cells in the output composition express the product of a heterologous nucleic acid contained within the viral vector; The method of embodiment 31. 33. The method of embodiment 31 or 32, wherein said incubation occurs in a cavity of a centrifuge chamber, and the number of said cells in said input composition is at or near the number of said cells sufficient to form a monolayer or bilayer on the interior surface of said cavity during said rotation. 34. The method of embodiment 33, wherein the centrifuge chamber includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of allowing the introduction of fluid into the internal cavity and the expulsion of fluid from the cavity. 35. The method of embodiment 34, wherein the centrifuge chamber further includes a movable member, and the internal cavity is a variable volume cavity defined by the end wall, the substantially rigid side wall, and the movable member, and the movable member is movable within the chamber to vary the internal volume of the cavity. 36. The input composition in the cavity has a liquid volume of at least 20 mL or at least 50 mL and an internal surface area of the cavity of at least 1 cm during at least a portion of the incubation. 236. The method of any of embodiments 1-30 or 33-35, comprising at or about 1 million cells per culture. 37. The method of any of the preceding aspects, wherein a further portion of the incubation is performed outside the centrifuge chamber and / or without rotation, said further portion being performed after said at least a portion performed within the chamber and / or with rotation. 38. The method of any of aspects 1-37, wherein the at least a portion of the incubation and / or the further portion of the incubation that takes place in the cavity of the centrifuge chamber is carried out at or about 37°C±2°C. 39. The method of embodiment 37 or 38, wherein said incubation further comprises the step of transferring at least a plurality of said cells to a container during said incubation, and wherein said further portion of said incubation is carried out in said container. 40. The method of embodiment 39, wherein the transferring step is performed in a closed system, and the centrifuge chamber and the container are integrated into the closed system. 41. The incubation is carried out for 1 or about 1 hour to 96 or about 96 hours, 4 or about 4 hours to 72 or about 72 hours, 8 or about 8 hours to 48 or about 48 hours, 12 or about 12 hours to 36 or about 36 hours, 6 or about 6 hours to 24 or about 24 hours, 36 or about 36 hours to 96 or about 96 hours, inclusive; or said further portion of said incubation is carried out for 1 or about 1 hour to 96 or about 96 hours, 4 or about 4 hours to 72 or about 72 hours, 8 or about 8 hours to 48 or about 48 hours, 12 or about 12 hours to 36 or about 36 hours, 6 or about 6 hours to 24 or about 24 hours, 36 or about 36 hours to 96 or about 96 hours, inclusive; The method of any one of aspects 37 to 40. 42. The incubation is for up to 48 hours, up to 36 hours, or up to 24 hours; or The further portion of the incubation is carried out for up to 48 hours, up to 36 hours, or up to 24 hours; The method of any one of embodiments 37 to 41. 43. The incubation is carried out in the presence of a stimulating agent; and / or said further portion of said incubation is carried out in the presence of a stimulant; The method of any one of embodiments 37 to 41. 44. The incubation is for up to 24 hours; The cells in the composition have not been subjected to temperatures above 30° C. for more than 24 hours; and / or The incubation is not carried out in the presence of a stimulating agent; The method of any one of embodiments 37 to 41. 45. The method of embodiment 43 or 44, wherein the stimulatory agent is an agent capable of inducing proliferation of T cells, CD4+ T cells, and / or CD8+ T cells. 46. The method of any of aspects 43-45, wherein the stimulatory agent is a cytokine selected from among IL-2, IL-15, and IL-7. 47. The output composition containing transduced cells comprises at least 1×10 7 or at least about 1×10 7 cells or at least 5 x 10 7 or at least about 5×10 7 The method of any of embodiments 1-46, comprising the cells. 48. The output composition containing transduced cells comprises at least 1×10 8 pcs or approx. 1×10 8 pieces, 2×10 8 pcs or approx. 2×10 8 pieces, 4×10 8 pcs or approx. 4 x 10 8 pieces, 6×10 8 pcs or approx. 6 x 10 8 pieces, 8×10 8 Pieces or about 8 x 10 8 pcs or 1×10 9 pcs or approx. 1×109 The method of embodiment 47, comprising the cells. 49. The method of embodiment 47 or 48, wherein the cell is a T cell. 50. The method of embodiment 49, wherein said T cells are unfractionated T cells, isolated CD4+ T cells, and / or isolated CD8+ T cells. 51. The method of any of aspects 1-50, wherein the method results in integration of said viral vector into the host genome of one or more of at least a plurality of said cells in said output composition, and / or into the host genome of at least or at least about 20%, or at least or at least about 30%, or at least or at least about 40% of the cells in said output composition. 52. At least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the input composition are transduced with the viral vector by the method; and / or at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition are transduced with the viral vector; and / or at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition express a product of a heterologous nucleic acid contained within the viral vector; The method of any one of embodiments 1 to 51. 53. The method of any of embodiments 1-52, wherein for an input composition comprising virus at a ratio of about 1 IU or about 2 IU per cell, the method is capable of producing an output composition wherein at least 10%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition generated by the method comprise t...
Claims
1. A method of transduction comprising the steps of incubating an input composition comprising cells and viral particles containing a recombinant viral vector in an internal cavity of a centrifuge chamber; the centrifuge chamber is rotatable about an axis of rotation and includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of permitting the introduction of liquid into and the expulsion of liquid from the internal cavity; the centrifuge chamber is rotating about the axis of rotation during at least a portion of the incubation; and the method produces an output composition comprising a plurality of said cells transduced with said viral vector; The transduction method.
2. A method of transduction comprising the steps of incubating an input composition comprising cells and viral particles containing a recombinant viral vector in an internal cavity of a centrifuge chamber; the centrifuge chamber is rotatable about an axis of rotation and includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of permitting the introduction of liquid into and the expulsion of liquid from the internal cavity; the centrifuge chamber is rotating about the axis of rotation during at least a portion of the incubation; the total liquid volume of the input composition present in the cavity during rotation of the centrifuge chamber is at most about 5 mL per square inch of interior surface area of the cavity; and the method produces an output composition comprising a plurality of said cells transduced with said viral vector; The transduction method.
3. The rotation is Spinning at a relative centrifugal force (RCF) of greater than or about 200 g, greater than or about 300 g, or greater than or about 500 g on the inner surface of the side wall of the cavity and / or on the surface layer of the cells.
3. The method of claim 1 or 2, comprising:
4. The rotation is on the inner surface of the side wall of the cavity and / or on the surface layer of the cells, Spinning at a relative centrifugal force of at or about 600g, 800g, 1000g, 1100g, 1600g, 2000g, 2100g, 2200g, 2500g, or 3000g; or Spinning at a relative centrifugal force of at least or about 600g, 800g, 1000g, 1100g, 1600g, 2000g, 2100g, 2200g, 2500g, or 3000g; The method of any one of claims 1 to 3, comprising:
5. The rotation is rotation at a relative centrifugal force of 500 or about 500 g to 2500 or about 2500 g, 500 or about 500 g to 2000 or about 2000 g, 500 or about 500 g to 1600 or about 1600 g, 500 or about 500 g to 1000 or about 1000 g, 600 or about 600 g to 1600 or about 1600 g, 600 or about 600 g to 1000 or about 1000 g, 1000 or about 1000 g to 2000 or about 2000 g, or 1000 or about 1000 g to 1600 or about 1600 g, inclusive of these limits, on the inner surface of the side walls of the cavity and / or on the surface layer of the cells; The method of any one of claims 1 to 4, comprising:
6. The at least a portion of the incubation, during which the chamber is rotating, or greater than about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 90 minutes, or about 120 minutes; or 5 or about 5 minutes to 60 or about 60 minutes, 10 or about 10 minutes to 60 or about 60 minutes, 15 or about 15 minutes to 60 or about 60 minutes, 15 or about 15 minutes to 45 or about 45 minutes, 30 or about 30 minutes to 60 or about 60 minutes, or 45 or about 45 minutes to 60 or about 60 minutes, each inclusive; The method of any one of claims 1 to 5, wherein the period is a period of time.
7. The transduction method of any one of claims 1 to 6, wherein the centrifuge chamber further comprises a movable member, and the internal cavity is a variable volume cavity defined by the end wall, the substantially rigid side wall, and the movable member, and the movable member is movable within the chamber to vary the internal volume of the cavity.
8. The method of any one of claims 1 to 7, wherein the sidewall is curved.
9. The method of claim 8 , wherein the side wall is generally cylindrical.
10. the movable member is a piston; and / or the movable member is movable axially within the chamber to vary the interior volume of the cavity; The method of any one of claims 7 to 9.
11. the at least one opening includes an inlet and an outlet capable of permitting the intake and expulsion, respectively; or said at least one opening includes a single port capable of permitting said intake and expulsion; The method of any one of claims 1 to 10.
12. The method of any one of claims 1 to 11, wherein the at least one opening is coaxial with the chamber and located in the end wall.
13. The cavity has an internal surface area of at least 1×10 9 μm 2 Or at least about 1 × 10 9 μm 2 and The cavity has an internal surface area of at least 1×10 10 μm 2 Or at least about 1 × 10 10 μm 2 and the length of said rigid wall in a direction extending from said end wall is at least about 5 cm; the length of said rigid wall in a direction extending from said end wall is at least about 8 cm; and / or the cavity comprises a radius of at least about 2 cm in at least one cross-section; The method of any one of claims 1 to 12.
14. an average liquid volume of said input composition present in said cavity during said incubation is at most about 5 milliliters (mL) per square inch of interior surface area of said cavity during said incubation; the maximum liquid volume of said input composition present in said cavity at any one time during said incubation is at most about 5 mL per square inch of the maximum internal surface area of said cavity; the average liquid volume of said input composition present in said cavity during said incubation is at most about 2.5 milliliters (mL) per square inch of interior surface area of said cavity during said incubation; or the maximum liquid volume of said input composition present in said cavity at any one time during said incubation is at most about 2.5 mL per square inch of maximum internal surface area of said cavity; The method of any one of claims 1 to 13.
15. 15. The method of any one of claims 1 to 14, wherein the liquid volume of the input composition present in the cavity during said rotation is from 0.5 or about 0.5 mL / sq.in. to 5 or about 5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 1 or about 1 mL / sq.in., from 1 or about 1 mL / sq.in. to 5 or about 5 mL / sq.in., from 1 or about 1 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., or from 2.5 or about 2.5 mL / sq.in. to 5 or about 5 mL / sq.in.
16. the number of cells in the input composition is at or near sufficient to form a monolayer on the surface of the cavity during rotation of the centrifuge chamber at a force of at or about 1000 g or at or about 2000 g on the inner surface of the side wall and / or a surface layer of the cells; and / or the number of said cells in said input composition is at most 1.5 or 2 times the number of said cells sufficient to form a monolayer on the surface of said cavity during rotation of said centrifuge chamber at a force of at or about 1000 g or at or about 2000 g on the inner surface of said side wall and / or on a surface layer of said cells; 16. The method of any one of claims 1 to 15.
17. The input composition in the cavity is at least 1×10 6 or at least about 1×10 6 or The input composition in the cavity is at least 5×10 6 or at least about 5×10 6 or The input composition in the cavity is at least 1×10 7 or at least about 1×10 7 or The input composition in the cavity is at least 1×10 8 or at least about 1×10 8 the cells; 17. The method of any one of claims 1 to 16.
18. The input composition in the cavity is at least 1×10 7 or at least about 1×10 7 Pieces, at least 2 x 10 7 or at least about 2×10 7 Pieces, at least 3 × 10 7 or at least about 3×10 7 Pieces, at least 4 × 10 7 or at least about 4×10 7 Pieces, at least 5 × 10 7 or at least about 5×10 7 Pieces, at least 6 x 10 7 or at least about 6×10 7 Pieces, at least 7 x 10 7 or at least about 7×10 7 Pieces, at least 8 x 10 7 or at least about 8×10 7 Pieces, at least 9 x 10 7 or at least about 9×10 7 Pieces, at least 1 × 10 8 or at least about 1×10 8 Pieces, at least 2 x 10 8 or at least about 2×10 8 Pieces, at least 3 × 10 8 or at least about 3×10 8 pieces, or at least 4 × 10 8 or at least about 4×10 8 The method of any one of claims 1 to 17, comprising said cells.
19. or the input composition comprises at least 1 infectious unit (IU) or about 1 IU, at least 2 IU or at least about 2 IU, at least 3 IU or at least about 3 IU, at least 4 IU or at least about 4 IU, at least 5 IU or at least about 5 IU, at least 10 IU or at least about 10 IU, at least 20 IU or at least about 20 IU, at least 30 IU or at least about 30 IU, at least 40 IU or at least about 40 IU, at least 50 IU or at least about 50 IU, or at least 60 IU or at least about 60 IU of virus particles per cell; or the input composition comprises 1 infectious unit (IU) or about 1 IU, 2 IU or about 2 IU, 3 IU or about 3 IU, 4 IU or about 4 IU, 5 IU or about 5 IU, 10 IU or about 10 IU, 20 IU or about 20 IU, 30 IU or about 30 IU, 40 IU or about 40 IU, 50 IU or about 50 IU, or 60 IU or about 60 IU of viral particles per cell; 19. The method of any one of claims 1 to 18.
20. 20. The method of any one of claims 1 to 19, wherein the maximum total liquid volume of the input composition present in the cavity at any one time during the incubation is at most 2 times, at most 10 times, or at most 100 times the total volume of the cells in the cavity, or wherein the average volume of the input composition over the course of the incubation is at most 2, 10, or 100 times the total volume of the cells in the cavity.
21. 21. The method of any one of claims 1 to 20, wherein the maximum volume of said input composition present in said cavity at any one time during said incubation or the average volume over the course of said incubation is at most 2 or about 2, 10 or about 10, 25 or about 25, 50 or about 50, 100 or about 100, 500 or about 500, or 1000 or about 1000 times the volume of the monolayer of cells formed on the inner surface of the cavity during rotation of the chamber at a force of at or about 1000g or at or about 2000g on the inner surface of the side wall and / or on the surface layer of the cells.
22. 22. The method of any one of claims 1 to 21, wherein the liquid volume of the input composition is at most 20mL, at most 40mL, at most 50mL, at most 70mL, at most 100mL, at most 120mL, at most 150mL, or at most 200mL.
23. 23. The method of any one of claims 1 to 22, wherein said input composition occupies all or substantially all of the volume of said internal cavity during at least a portion of said incubation.
24. 24. The method of any one of claims 1 to 23, wherein during at least a portion of said incubation in said chamber or during said rotation of said chamber, the liquid volume of said input composition occupies only a portion of the volume of said internal cavity of said chamber, and wherein the volume of said cavity during at least a portion of said incubation or during said rotation further comprises a gas, said gas being introduced into said cavity via said at least one opening before or during said incubation.
25. 25. The method of claim 24, wherein the centrifuge chamber includes a movable member, and the introduction of gas into the centrifuge chamber causes movement of the movable member to increase the volume of the interior cavity of the chamber, thereby reducing the total liquid volume of the input composition present in the cavity per square inch of interior surface area of the cavity during rotation of the centrifuge chamber compared to when no gas is present in the chamber.
26. 1. A method of transduction comprising the steps of: a) At least 1 × 10 9 μm 2 Or at least about 1 × 10 9 μm 2 , or at least 1 × 10 10 μm 2 Or at least about 1 × 10 10 μm 2 into an internal cavity of the centrifuge chamber having an internal surface area of i) an input composition comprising cells and viral particles comprising a recombinant viral vector, The number of cells in the input composition is at least 1×10 7 Individual and the viral particles are present in the input composition at at least 1 infectious unit (IU) or about 1 IU per cell; and the input composition comprising a liquid volume less than a maximum volume of the internal cavity of the centrifuge chamber; and ii) a volume of gas up to the remainder of the maximum volume of the internal cavity of the centrifuge chamber; providing b) incubating the input composition, at least a portion of the incubation being carried out within the internal cavity of the centrifuge chamber while rotating the centrifuge chamber. Including, The transduction method, wherein the method produces an output composition comprising a plurality of said cells transduced with said viral vector.
27. The number of cells is at least 50×10 6 Pieces or about 50 x 10 6 pieces, 100×10 6 Pieces or about 100 x 10 6 pcs, or 200 x 10 6 Pieces or about 200 x 10 6 and / or the viral particles are present at at least 1.6 IU / cell, 1.8 IU / cell, 2.0 IU / cell, 2.4 IU / cell, 2.8 IU / cell, 3.2 IU / cell, or 3.6 IU / cell, 4.0 IU / cell, 5.0 IU / cell, 6.0 IU / cell, 7.0 IU / cell, 8.0 IU / cell, 9.0 IU / cell, or 10.0 IU / cell; 27. The method of claim 26.
28. the liquid volume of the input composition is 200 mL or less, 100 mL or less, 50 mL or less, or 20 mL or less; and / or the liquid volume of the input composition relative to the internal surface area of the cavity or the maximum internal surface area of the cavity during rotation is at most 50%, at most 40%, at most 30%, at most 20%, or at most 10%; 28. The method of claim 26 or 27.
29. 29. The method of any one of claims 26 to 28, wherein the volume of gas is up to 200 mL, up to 180 mL, up to 140 mL, or up to 100 mL.
30. The rotation is Rotation at a relative centrifugal force of at least 600 g, 800 g, 1000 g, 1100 g, 1500 g, 1600 g, 2000 g, 2400 g, 2600 g, 2800 g, 3000 g, 3200 g, or 3600 g on the inner surface of the side wall of the cavity or on the surface layer of the cells. The method of any one of claims 26 to 29, wherein
31. 1. A method of transduction comprising the steps of: incubating an input composition comprising cells and viral particles comprising the recombinant viral vector; at least a portion of the incubating step is performed under rotating conditions, thereby producing an output composition comprising a plurality of the cells transduced with the viral vector; The input composition comprises a volume that is about or greater than 20 mL, about or greater than 50 mL, at least 100 mL, or at least 150 mL, and / or the input composition comprises a volume of at least 1×10 8 cells; and the rotation conditions comprising a relative centrifugal force at a surface layer of the cells of greater than about 800 g, greater than about 1000 g, or greater than about 1500 g; The transduction method.
32. at least 25% or at least 50% of the cells in the output composition are transduced with the viral vector; and / or at least 25% or at least 50% of the cells in the output composition express the product of a heterologous nucleic acid contained within the viral vector; 32. The method of claim 31.
33. 33. The method of claim 31 or 32, wherein the incubation occurs within a cavity of a centrifuge chamber and the number of cells in the input composition is at or near the number of cells sufficient to form a monolayer or bilayer on the inner surface of the cavity during rotation.
34. 34. The method of claim 33, wherein the centrifuge chamber includes an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of permitting the introduction of fluid into and the expulsion of fluid from the internal cavity.
35. 35. The method of claim 34, wherein the centrifuge chamber further comprises a movable member, and the internal cavity is a variable volume cavity defined by the end wall, the substantially rigid side wall, and the movable member, the movable member movable within the chamber to vary an internal volume of the cavity.
36. The input composition in the cavity has a liquid volume of at least 20 mL or at least 50 mL and an internal surface area of the cavity of at least 1 cm during at least a portion of the incubation. 2 36. The method of any one of claims 1-30 or 33-35, comprising at or about 1 million cells per culture.
37. 37. The method of any one of claims 1 to 36, wherein a further portion of incubation is performed outside the centrifuge chamber and / or without rotation, said further portion being performed after at least the portion performed within the chamber and / or with rotation.
38. 38. The method of any one of claims 1 to 37, wherein the at least a portion of the incubation and / or the further portion of the incubation that takes place in the cavity of the centrifuge chamber is carried out at or about 37°C±2°C.
39. 39. The method of claim 37 or 38, wherein said incubation further comprises transferring at least a plurality of said cells to a container during said incubation, and wherein said further portion of said incubation is performed within said container.
40. 40. The method of claim 39, wherein the transferring step is performed in a closed system, and the centrifuge chamber and the container are integrated into the closed system.
41. said incubation is for a period of time, inclusive, between 1 or about 1 hour and 96 or about 96 hours, between 4 or about 4 hours and 72 or about 72 hours, between 8 or about 8 hours and 48 or about 48 hours, between 12 or about 12 hours and 36 or about 36 hours, between 6 or about 6 hours and 24 or about 24 hours, between 36 or about 36 hours and 96 or about 96 hours; or said further portion of said incubation is carried out for 1 or about 1 hour to 96 or about 96 hours, 4 or about 4 hours to 72 or about 72 hours, 8 or about 8 hours to 48 or about 48 hours, 12 or about 12 hours to 36 or about 36 hours, 6 or about 6 hours to 24 or about 24 hours, 36 or about 36 hours to 96 or about 96 hours, inclusive; The method of any one of claims 37 to 40.
42. the incubation is for up to 48 hours, up to 36 hours, or up to 24 hours; or said further portion of said incubation is for up to 48 hours, up to 36 hours, or up to 24 hours; The method of any one of claims 37 to 41.
43. the incubation is carried out in the presence of a stimulant; and / or said further portion of said incubation is carried out in the presence of a stimulant; The method of any one of claims 37 to 41.
44. The incubation is for up to 24 hours; The cells in the composition have not been subjected to temperatures above 30° C. for more than 24 hours; and / or The incubation is not carried out in the presence of a stimulant; The method of any one of claims 37 to 41.
45. 45. The method of claim 43 or 44, wherein the stimulatory agent is an agent capable of inducing proliferation of T cells, CD4+ T cells, and / or CD8+ T cells.
46. The method of any one of claims 43 to 45, wherein the stimulatory agent is a cytokine selected from among IL-2, IL-15, and IL-7.
47. The output composition containing the transduced cells comprises at least 1×10 7 or at least about 1×10 7 cells or at least 5 x 10 7 or at least about 5×10 7 47. The method of any one of claims 1 to 46, comprising cells.
48. The output composition containing the transduced cells comprises at least 1×10 8 pcs or approx. 1×10 8 pieces, 2×10 8 pcs or approx. 2×10 8 pieces, 4×10 8 pcs or approx. 4 x 10 8 pieces, 6×10 8 pcs or approx. 6 x 10 8 pieces, 8×10 8 Pieces or about 8 x 10 8 pcs or 1×10 9 pcs or approx. 1×10 9 48. The method of claim 47, comprising cells.
49. 49. The method of claim 47 or 48, wherein the cell is a T cell.
50. 50. The method of claim 49, wherein the T cells are unfractionated T cells, isolated CD4+ T cells, and / or isolated CD8+ T cells.
51. 51. The method of any one of claims 1 to 50, wherein the method results in integration of the viral vector into the host genome of one or more of at least a plurality of said cells in the output composition, and / or into the host genome of at least or at least about 20%, or at least or at least about 30%, or at least or at least about 40% of the cells in the output composition.
52. at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the input composition are transduced with the viral vector by the method; and / or at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition are transduced with the viral vector; and / or at least 2.5%, at least 5%, at least 6%, at least 8%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition express a product of a heterologous nucleic acid contained within the viral vector; 52. The method of any one of claims 1 to 51.
53. 53. The method of any one of claims 1 to 52, wherein for an input composition comprising virus at a ratio of about 1 IU or about 2 IU per cell, the method is capable of producing an output composition wherein at least 10%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the cells in the output composition generated by the method comprise the recombinant viral vector and / or express a product of a recombinant nucleic acid contained within the vector.
54. the average copy number of the recombinant viral vector in all of the cells containing or incorporating the recombinant viral vector in the output composition is at most about 10, at most about 5, at most about 2.5, or at most about 1.5; or the average copy number of said vector in said cells in said output composition is at most about 2, at most about 1.5, or at most about 1; 54. The method of any one of claims 1 to 53.
55. The method of any one of claims 1 to 30 and 33 to 54, wherein the centrifuge chamber is incorporated into a closed system, the closed system comprising the chamber and at least one piping line operatively connected to the at least one opening via at least one connector, and in at least one configuration of the system, liquids and gases can be transferred between the cavity and the at least one piping line.
56. the at least one piping line comprises a series of piping lines; the at least one connector comprises a plurality of connectors; and the closed system further comprising at least one container operatively connected to the series of piping lines, the connection allowing liquid and / or gas to pass between the at least one container and the at least one opening via the series of piping lines; 56. The method of claim 55.
57. 57. The method of claim 55 or 56, wherein the at least one connector comprises a connector selected from the group consisting of a valve, a luer port, and a spike.
58. 58. The method of any one of claims 55 to 57, wherein the at least one connector comprises a rotary valve.
59. 59. The method of claim 58, wherein the rotary valve is a stopcock or a multi-rotary port.
60. The method of any one of claims 55 to 59, wherein the at least one connector comprises a sterile connector.
61. 61. The method of any one of claims 56-60, wherein the at least one container comprises a container selected from the group consisting of a bag, a vial, and a syringe.
62. 62. The method of any one of claims 56 to 61, wherein the at least one container comprises a diluent container, a waste container, a product collection container, and / or an input product container.
63. 63. The method of any one of claims 56 to 62, wherein said at least one container comprises at least one input container containing said viral vector particles and said cells, a waste container, a product container, and at least one diluent container, each connected to said cavity via said series of piping lines and said at least one opening.
64. 64. The method of claim 63, wherein the method further comprises a step of carrying out introduction of the input composition into the cavity before and / or during the incubation, the introduction comprising flowing liquid from the at least one input receptacle into the cavity through the at least one opening.
65. 65. The method of any one of claims 56 to 64, wherein at least one container further comprises a container containing a gas before and / or during at least a point during said incubation, and / or said closed system further comprises a microbial filter capable of introducing a gas into said internal cavity of said centrifuge chamber, and / or said closed system contains a syringe port for effecting the introduction of a gas.
66. 66. The method of claim 65, wherein the method comprises providing or performing an introduction of gas into the cavity under sterile conditions before and / or during the incubation, the introduction being performed by (a) inflow of gas from a container containing gas, (b) inflow of gas from the environment external to the closed system through a microbial filter, or (c) inflow of gas from a syringe connected to the system at the syringe port.
67. 67. The method of claim 66, wherein the step of effecting the introduction of a gas into the internal cavity of the centrifuge chamber is performed simultaneously or together with the step of effecting the introduction of the input composition into the internal cavity of the centrifuge chamber.
68. 68. The method of claim 66 or 67, wherein the input composition and gas are combined in a single container under sterile conditions outside the centrifuge chamber prior to said introduction of the input composition and gas into the internal cavity of the chamber.
69. 70. The method of claim 68, wherein the step of effecting the introduction of said gas is performed separately, either simultaneously or sequentially from the step of effecting the introduction of said input composition into said cavity.
70. 70. The method of any one of claims 66-69, wherein the introduction of gas is performed by allowing or causing gas to flow from a sterile sealed container containing the gas, from the external environment through a microbial filter, or from a syringe containing the gas.
71. The method of any one of claims 24 to 70, wherein the gas is air.
72. The incubation is part of a continuous process, and the method comprises: performing a continuous introduction of said input composition into said cavity during rotation of said chamber during at least a portion of said incubation; and performing a continuous expulsion of liquid from said cavity through said at least one opening while rotating said chamber during a portion of said incubation; The method of any one of claims 1 to 71, further comprising:
73. performing a continuous introduction of gas into the cavity during a portion of said incubation while rotating said chamber; and / or performing a continuous pumping of gas from said cavity during a portion of said incubation.
73. The method of claim 72, further comprising:
74. 74. The method of claim 73, wherein the method includes expressing the liquid and expressing the gas from the cavity, each simultaneously or sequentially into a different container.
75. 75. The method of any one of claims 72-74, wherein at least a portion of said continuous intake and said continuous expression are performed simultaneously.
76. The incubation is part of a semi-continuous process, the method comprising: prior to said incubation, introducing said input composition and optionally a gas into said cavity through said at least one opening; performing, after said incubation, the expulsion of liquid and / or optionally gas from said cavity; introducing into said internal cavity another input composition comprising cells and said viral particles containing a recombinant viral vector, and optionally a gas; and incubating said another input composition within said internal cavity; Further comprising: the method producing a further output composition comprising a plurality of cells of the further input composition transduced with the viral vector. The method of any one of claims 1 to 75.
77. Providing or introducing the input composition into the cavity comprises: introducing a single composition comprising said cells and said viral particles containing said recombinant viral vector; or incorporation of a composition comprising said cells and a separate composition comprising said viral particles containing said recombinant viral vector, said compositions being mixed to result in incorporation of said input composition; The method of any one of claims 64 to 76, comprising:
78. performing a rotation of said centrifuge chamber before and / or during said incubation; performing, after said incubation, an expression of liquid from said cavity into said waste container; forcing liquid from the at least one diluent container through the at least one opening into the cavity and mixing the contents of the cavity; and performing an expression of liquid from the cavity into the product vessel, whereby the viral vector-transduced cells are transferred into the product vessel. The method of any one of claims 64 to 77, further comprising:
79. (a) washing the biological sample containing the cells in the internal cavity of a centrifuge chamber prior to said incubation; and / or (b) isolating said cells from a biological sample, at least a portion of said isolating step being carried out within the internal cavity of a centrifuge chamber prior to said incubation; and / or (c) stimulating the cells before and / or during said incubation, said stimulating comprising exposing said cells to stimulatory conditions, thereby inducing proliferation of the cells of said input composition, at least a portion of said stimulating being carried out within the internal cavity of a centrifuge chamber; The method of any one of claims 1 to 78, further comprising:
80. 80. The method of claim 79, wherein said isolating comprises performing an immunoaffinity-based selection.
81. The method of claim 79 or 80, wherein the stimulatory conditions comprise the presence of an agent capable of activating one or more intracellular signaling domains of one or more components of the TCR complex.
82. 82. The method of claim 81, wherein the agents comprise a first agent that specifically binds to a member of the TCR complex and a second agent that specifically binds to a T cell costimulatory molecule.
83. the first agent specifically binds to CD3; and / or the costimulatory molecule is selected from the group consisting of CD28, CD137 (4-1-BB), OX40, or ICOS; 83. The method of claim 82.
84. 84. The method of claim 83, wherein the first and second agents comprise an antibody and / or are present on the surface of a solid support.
85. 85. The method of any one of claims 79-84, wherein the biological sample in (a) and / or (b) is or comprises a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukapheresis product.
86. 86. The method of any one of claims 1 to 85, further comprising formulating the cells transduced by said method in an internal cavity of the centrifuge chamber in a pharma- ceutically acceptable buffer, thereby producing a formulated composition.
87. 87. The method of claim 86, further comprising performing an expression of the formulated composition into one or more containers.
88. 88. The method of claim 87, wherein performing expression of the formulated composition comprises performing expression of a plurality of cells present in a single unit dose into one or each of the one or more containers.
89. The method of any one of claims 79 to 88, wherein each of said centrifuge chamber cavities is the same as or different from the centrifuge cavities employed in one or more of the other steps and / or in the process of incubation and / or rotation of the input composition containing cells and viral particles.
90. 90. The method of any one of claims 79 to 89, wherein each of the centrifuge chambers is incorporated into a closed system, the closed system comprising the chamber and at least one piping line operatively connected to the at least one opening via at least one connector, and wherein in at least one configuration of the system, liquids and gases can be transferred between the cavity and the at least one piping line.
91. 91. The method of any one of claims 1 to 90, wherein the cells in the input composition are primary cells.
92. the cells in the input composition comprise suspension cells; the cells in the input composition comprise white blood cells; and / or The cells in the input composition comprise T cells or NK cells.
92. The method of any one of claims 1 to 91.
93. The cells in the input composition may be unfractionated T cells, isolated CD8 + T cells, or isolated CD4 + The method of any one of claims 1 to 92, wherein the cell is a T cell.
94. 94. The method of any one of claims 1 to 93, wherein the cells in the input composition are human cells.
95. 95. The method of any one of claims 7 to 94, wherein the centrifuge chamber is further associated with a centrifuge, the centrifuge chamber being associated with a sensor and control circuitry during the incubation, the sensor being capable of monitoring the position of the movable member, the control circuitry being capable of receiving and transmitting information to and from the sensor and causing movement of the movable member, the control circuitry being capable of causing rotation of the chamber during the incubation.
96. 96. The method of any one of claims 7 to 95, wherein the chamber comprises the movable member and the centrifuge chamber is located within a centrifuge during the incubation and is associated with a sensor and control circuit, the sensor being capable of monitoring the position of the movable member and the control circuit being capable of receiving and transmitting information from the sensor and causing movement of the movable member, the intake and expulsion of liquids and / or gases into and out of the cavity via the one or more piping lines, and the rotation of the chamber by the centrifuge.
97. 97. The method of claim 95 or 96, wherein said chamber, said control circuitry, said centrifuge, and said sensor are housed within a cabinet during said incubation.
98. 98. The method of any one of claims 1-97, wherein said recombinant viral vector encodes a recombinant receptor, whereby said recombinant receptor is expressed by cells of said output composition.
99. 99. The method of claim 98, wherein the recombinant receptor is a recombinant antigen receptor.
100. The method of claim 99, wherein the recombinant antigen receptor is a functional non-T cell receptor.
101. The method of claim 100, wherein the functional non-T cell receptor is a chimeric antigen receptor (CAR).
102. 100. The method of claim 99, wherein the recombinant antigen receptor is a transgenic T cell receptor (TCR).
103. The method of claim 99, wherein the recombinant receptor is a chimeric receptor comprising an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain.
104. the cells comprise primary human T cells obtained from a human subject; and Prior to said incubation and / or prior to completion of said transduction, and / or prior to formulation, if said method includes formulation, the primary human T cells have not been present outside the subject at a temperature above 30° C. for more than 1 hour, more than 6 hours, more than 24 hours, or more than 48 hours; or prior to said incubation and / or completion of said transduction, and / or prior to formulation, if said method includes formulation, said primary human T cells have not been incubated in the presence of an antibody specific for CD3 and / or an antibody specific for CD28 and / or a cytokine for more than 1 hour, more than 6 hours, more than 24 hours, or more than 48 hours; The method of any one of claims 1 to 103.
105. (a) incubating a selection reagent and primary cells in an interior cavity of a centrifuge chamber under mixing conditions, whereby a plurality of the primary cells bind to the selection reagent; and (b) separating the plurality of primary cells from one or more of the other primary cells based on binding to the selection reagent, thereby enriching the primary cells based on binding to the selection reagent; A method for selection comprising: The centrifuge chamber is rotatable about an axis of rotation, and the internal cavity has a maximum volume of at least 50, at least 100, or at least 200 mL. A method for said selection.
106. 1. A method for stimulating cells comprising incubating a stimulatory agent with primary cells under conditions in which the stimulatory agent binds to a molecule expressed by a plurality of the primary cells and the plurality of cells are activated or stimulated, at least a portion of said incubation takes place in an internal cavity of a centrifuge chamber under mixing conditions; The centrifuge chamber is rotatable about an axis of rotation; and the internal cavity having a maximum volume of at least 50, at least 100, or at least 200 mL; A method for stimulating said cells.
107. 107. The method of claim 105 or 106, wherein the chamber further comprises an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of allowing liquid to be introduced into and expelled from the internal cavity.
108. 18. A composition comprising a transduced cell produced by the method of any one of claims 1 to 107.
109. The composition of claim 108, wherein the cells are primary cells; and / or human cells; and / or comprise leukocytes; and / or comprise T cells; and / or comprise NK cells.
110. At least 5 x 10 7 Pieces or about 5 x 10 7 pieces, 1×10 8 pcs or approx. 1×10 8 pieces, 2×10 8 pcs or approx. 2×10 8 pieces, 4×10 8 pcs or approx. 4 x 10 8 pieces, 6×10 8 pcs or approx. 6 x 10 8 pieces, 8×10 8 Pieces or about 8 x 10 8 pcs or 1×10 9 pcs or approx. 1×10 9 110. The composition of claim 108 or 109, comprising cells.
111. The composition of any one of claims 106-110, comprising a therapeutically effective number of cells for use in adoptive T cell therapy.
112. the cell is a T cell; and After transduction, the cells in the composition are not subjected to cell proliferation in the presence of a stimulating agent and / or the cells are not incubated at a temperature above 30° C. for more than 24 hours, or the composition does not contain a cytokine, or the composition does not contain a stimulating agent that specifically binds to the CD3 or TCR complex. The composition of any one of claims 106 to 111.
113. At least 1×10 7 or at least 5 × 10 7 A composition comprising T cells, at least a plurality of the cells are transduced with a recombinant viral vector or express a recombinant or engineered antigen receptor; After transduction, the cells in the composition have not been subjected to cell proliferation in the presence of a stimulant; and / or After transduction, the cells have not been incubated at temperatures above 30° C. for more than 24 hours; The composition.
114. At least 1×10 7 or at least 5 × 10 7 1. A composition comprising primary human T cells, at least a plurality of the cells being transduced with a recombinant viral vector or expressing a recombinant or engineered antigen receptor, and at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the T cells in the composition comprise high expression of CD69 and / or TGF-β-II.
115. The composition of claim 114, wherein said at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of said T cells in said composition do not comprise surface expression of CD62L and / or comprise high expression of CD25, ICAM, GM-CSF, IL-8, and / or IL-2.
116. At least 1×10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8 pieces, 8×10 8 pcs or 1×10 9 The composition of any one of claims 113-115, comprising the cells.
117. The composition of any one of claims 109-116, wherein the T cells are unfractionated T cells, isolated CD8+ T cells, or isolated CD4+ T cells.
118. The composition of any one of claims 108-117, wherein at least 2.5%, 5%, 6%, 8%, 10%, 20%, 25%, 30%, 40%, 50%, or 75% of said cells in said composition are transduced with said viral vector.
119. the viral vector encodes a recombinant receptor; and transduced cells in said composition express said recombinant receptor; The composition of any one of claims 108 to 118.
120. The composition of claim 119, wherein the recombinant receptor is a recombinant antigen receptor.
121. The composition of claim 120, wherein the recombinant antigen receptor is a functional non-T cell receptor.
122. The composition of claim 121, wherein the functional non-T cell receptor is a chimeric antigen receptor (CAR).
123. The composition of any one of claims 119-122, wherein said recombinant receptor is a chimeric receptor comprising an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain.
124. The composition of claim 120, wherein the recombinant antigen receptor is a transgenic T cell receptor (TCR).
125. the average copy number of the recombinant viral vector in all cells in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2; or The average copy number of the recombinant viral vector in cells transduced with the vector in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2. The composition of any one of claims 110 to 124.
126. The composition of any one of claims 110 to 125, comprising a pharma- ceutically acceptable excipient.
127. 127. An article of manufacture comprising one or more containers, said one or more containers collectively containing the composition of any one of claims 113-126.
128. 128. The article of manufacture of claim 127, wherein the one or more containers comprise two or more or three or more bags, and the composition further comprises a pharma- ceutically acceptable excipient.
129. 127. A method of treatment comprising administering to a subject having a disease or condition a composition of any one of claims 110-126.
130. The method of claim 129, wherein in said subject, the transduced T cells in said composition exhibit greater or longer proliferation and / or persistence than transduced T cells in a composition that has been subjected to cell expansion in the presence of a stimulant after transduction and / or incubated at a temperature above 30° C. for more than 24 hours.
131. The method of claim 129 or 130, wherein the recombinant receptor, chimeric antigen receptor, or transgenic TCR specifically binds to an antigen associated with the disease or condition.
132. The method of any one of claims 129-131, wherein the disease or condition is cancer, an autoimmune disease or disorder, or an infectious disease.
133. At least 1×10 7 cells; and at least 1 infectious unit (IU) or at least about 1 IU of viral particles comprising the recombinant viral vector per cell; A composition comprising:
134. The cells are at least 50×10 6 Pieces or about 50 x 10 6 pieces, 100×10 6 Pieces or about 100 x 10 6 pcs, or 200 x 10 6 Pieces or about 200 x 10 6 and / or the viral particles are present in the composition in an amount of at least 1.6 IU / cell, 1.8 IU / cell, 2.0 IU / cell, 2.4 IU / cell, 2.8 IU / cell, 3.2 IU / cell, 3.6 IU / cell, 4.0 IU / cell, 5.0 IU / cell, 6.0 IU / cell, 7.0 IU / cell, 8.0 IU / cell, 9.0 IU / cell, or 10.0 IU / cell; The composition of claim 133.
135. 135. The composition of claim 133 or 134, wherein the liquid volume of the composition is 220 mL or less, 200 mL or less, 100 mL or less, 50 mL or less, or 20 mL or less.
136. The composition of any one of claims 133-135, wherein the cells are primary cells.
137. The composition of any one of claims 133 to 136, wherein the cell is a human cell.
138. the cells comprise suspension cells; the cells comprise white blood cells; and / or the cells comprise T cells or NK cells; The composition of any one of claims 133-137.
139. The composition of claim 138, wherein the cell is a T cell, and the T cell is an unfractionated T cell, an isolated CD8+ T cell, or an isolated CD4+ T cell.
140. The composition of any one of claims 133-139, wherein said viral vector encodes a recombinant receptor.
141. The composition of claim 140, wherein the recombinant receptor is a recombinant antigen receptor.
142. The composition of claim 141, wherein the recombinant antigen receptor is a functional non-T cell receptor.
143. The composition of claim 142, wherein the functional non-T cell receptor is a chimeric antigen receptor (CAR).
144. The composition of any one of claims 140-143, wherein said recombinant receptor is a chimeric receptor comprising an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain.
145. The composition of claim 141, wherein the recombinant antigen receptor is a transgenic T cell receptor (TCR).
146. 127. A centrifuge chamber rotatable about an axis of rotation, the centrifuge chamber comprising an internal cavity comprising the composition of any one of claims 110-126.
147. A centrifuge chamber rotatable about an axis of rotation, the centrifuge chamber comprising: (a) at least 5×10 7 and / or (b) a composition containing at least 5×10 primary T cells; 7 the centrifuge chamber comprising an internal cavity containing: a composition comprising a number of primary T cells and a viral particle containing a recombinant viral vector.
148. 148. A centrifuge chamber as described in claim 146 or 147, wherein the chamber further comprises an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of allowing liquid to be introduced into the internal cavity and expelled from the cavity.
149. The composition in the cavity is at least 1×10 8 pieces, 2×10 8 pieces, 4×10 8 pieces, 6×10 8 pieces, 8×10 8 pcs or 1×10 9 149. The centrifuge chamber of claim 147 or 148, comprising cells.
150. The centrifuge chamber of claim 147 or 148, wherein the T cells are unfractionated T cells, isolated CD8+ T cells, or isolated CD4+ T cells.
151. The centrifuge chamber of any one of claims 147 to 150, wherein at least 2.5%, 5%, 6%, 8%, 10%, 20%, 25%, 30%, 40%, 50%, or 75% of the cells in the composition are transduced with a viral vector.
152. the viral vector encodes a recombinant receptor; and the cells in the composition express the recombinant receptor; The centrifuge chamber of any one of claims 147 to 151.
153. 152. The centrifuge chamber of claim 151, wherein the recombinant receptor is a recombinant antigen receptor.
154. The centrifuge chamber of claim 153, wherein said recombinant antigen receptor is a functional non-T cell receptor.
155. The centrifuge chamber of claim 154, wherein the functional non-T cell receptor is a chimeric antigen receptor (CAR).
156. The centrifuge chamber of any one of claims 151 to 155, wherein the recombinant receptor is a chimeric receptor comprising an extracellular portion that specifically binds to a ligand and an intracellular signaling portion that contains an activation domain and a costimulatory domain.
157. 154. The centrifuge chamber of claim 153, wherein said recombinant antigen receptor is a transgenic T cell receptor (TCR).
158. the average copy number of the recombinant viral vector in all cells in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2; or The centrifuge chamber of any one of claims 147 to 157, wherein the average copy number of the recombinant viral vector in cells transduced with the vector in the composition is at most about 10, at most 8, at most 6, at most 4, or at most about 2.
159. 146. A centrifuge chamber rotatable about an axis of rotation, the centrifuge chamber comprising an internal cavity comprising the composition of any one of claims 133-145.
160. 160. The centrifuge chamber of claim 159, further comprising a volume of gas up to a maximum volume of said internal cavity of said chamber.
161. 161. The centrifuge chamber of claim 160, wherein the gas is air.
162. 162. The centrifuge chamber of any one of claims 146 to 161, wherein the chamber is rotatable about an axis of rotation and comprises an end wall, a substantially rigid side wall extending from the end wall, and at least one opening, at least a portion of the side wall surrounding the internal cavity, and the at least one opening capable of allowing liquid to be introduced into and expelled from the internal cavity.
163. The centrifuge chamber of any one of claims 146 to 162, wherein the side wall is curved.
164. 164. The centrifuge chamber of claim 163, wherein the side wall is generally cylindrical.
165. the at least one opening includes an inlet and an outlet capable of permitting the intake and the expulsion, respectively; or said at least one opening includes a single port capable of permitting said intake and said expulsion; A centrifuge chamber as described in any one of claims 162 to 164.
166. 166. A centrifuge chamber as described in any one of claims 162 to 165, wherein the at least one opening is coaxial with the chamber and located in the end wall.
167. The centrifuge chamber of any one of claims 162 to 166, wherein the centrifuge chamber further includes a movable member, and the internal cavity is a variable volume cavity defined by the end wall, the substantially rigid side wall, and the movable member, and the movable member is movable within the chamber to vary the internal volume of the cavity.
168. the movable member is a piston; and / or The movable member is movable axially within the chamber to vary the interior volume of the cavity. The centrifuge chamber of claim 167.
169. The cavity has an internal surface area of at least 1×10 9 μm 2 Or at least about 1 × 10 9 μm 2 and The cavity has an internal surface area of at least 1×10 10 μm 2 Or at least about 1 × 10 10 μm 2 and the length of said rigid wall in a direction extending from said end wall is at least about 5 cm; the length of said rigid wall in a direction extending from said end wall is at least about 8 cm; and / or the cavity comprises a radius of at least about 2 cm in at least one cross-section; The centrifuge chamber of any one of claims 162 to 168.
170. The centrifuge chamber of any one of claims 159 to 169, wherein the liquid volume of the composition present in the cavity per square inch of internal surface area of the cavity (mL / sq.in.) is from 0.5 or about 0.5 mL / sq.in. to 5 or about 5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., from 0.5 or about 0.5 mL / sq.in. to 1 or about 1 mL / sq.in., from 1 or about 1 mL / sq.in. to 5 or about 5 mL / sq.in., from 1 or about 1 mL / sq.in. to 2.5 or about 2.5 mL / sq.in., or from 2.5 or about 2.5 mL / sq.in. to 5 or about 5 mL / sq.in.
171. The centrifuge chamber of any one of claims 159 to 169, wherein the liquid volume of the composition present in the cavity is at least 0.5 mL / sq.in., 1 mL / sq.in., 2.5 mL / sq.in., or 5 mL / sq.in.
172. A closed system comprising a centrifuge chamber according to any one of claims 147-158 and 162-171.
173. 173. The closed system of claim 172, further comprising a multi-way manifold operatively connected to the one or more containers.
174. A closed system comprising a centrifuge chamber according to any one of claims 159 to 171.
175. 175. The closed system of claim 174, further comprising a sterile filter.
176. 176. The closed system of any one of claims 172-175, wherein the centrifuge chamber can rotate at a speed of up to 8000 g and can withstand forces of up to 500 g, up to 600 g, up to 1000 g, up to 1100 g, up to 1200 g, up to 1400 g, up to 1500 g, up to 1600 g, up to 2000 g, up to 2500 g, up to 3000 g, or up to 3200 g without substantially denting, bending, breaking, or otherwise damaging the chamber, and / or while substantially maintaining a generally cylindrical shape under such forces.
177. 50. The method of claim 49, wherein at least or at least about 30%, at least or at least about 40%, at least or at least about 50%, at least or at least about 60%, at least or at least about 70%, at least or at least about 80%, or at least or at least about 80% of the T cells in the output composition comprise high expression of CD69 and / or TGF-β-II.
178. The method of claim 177, wherein at least 30, 40, 50, 60, 70, 80, or 80% of said T cells in said composition do not contain surface expression of CD62L and / or contain high expression of CD25, ICAM, GM-CSF, IL-8, and / or IL-2.
179. (a) washing the primary human cells; and (b) incubating the cells with a selection reagent under agitation conditions, wherein at least a plurality of the human cells are specifically bound by the selection reagent. A method comprising: The method, wherein the washing and incubating steps are performed within a closed, sterile system and at least partially within the internal cavity of a centrifuge chamber incorporated within the closed, sterile system.
180. 180. The method of claim 179, wherein the method steps are performed in an automated manner based on input from a user to initiate the method, resulting in the completion of the method steps.
